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Introduction and aim of the study 
Mitochondrial creatine kinase (Mi-CK; EC 2.7.3.2) is localized at the outer 
surface of the inner mitochondrial membrane. The enzyme catalyzes the 
transfer of they-phosphate group of adenosine triphosphate (ATP) to creatine 
(Cr), thereby producing phosphocreatine (PCr) plus adenosine diphosphate 
(ADP). Mi-CK plays an essential role in the shuttling of high-energy phos-
phates produced by the intramitochondrially situated energy-generating 
system in organs with a high and fluctuating energy demand like skeletal 
muscle, heart and brain. 
A reduction in the activity of Mi-CK may cause severe problems with 
respect to energy-consuming processes. Saks and co-workers showed that 
inhibition of Mi-CK by a specific antibody resulted in a decreased total ATP 
production by mitoplasts [1 ]. The physiological role of the enzyme has hardly 
been investigated in human pathology. 
It may be assumed that a deficiency of Mi-CK leads to a high intra-
mitochondrial ATP/ADP ratio and a decreased amount of PCr (Figure 1). 
The ATP/ADP ratio has its influence on several metabolic steps. In the first 
place, the activity of the pyruvate dehydrogenase complex (PDHc) is inacti-
vated by a high ATP/ADP ratio mediated by a phosphorylation of the El 
subunit of PDHc [2]. Furthermore, in the presence of a physiological, intact 
coupling state of the oxidative phosphorylation, an increased ATP/ADP 
ratio causes inhibition of the electron flow through the respiratory chain. The 
resulting increase of the NADH/NAD+ ratio also produces a feedback 
inhibition of the PDHc, leading to accumulation of pyruvate and lactate. As 
a result of the increased intrami tochondrial NADH /N AD+ ratio the cy tosolic 
NADH/NAD+ ratio is shifted likewise through the action of the malate-
aspartate shuttle. The final result is an increased lactate/pyruvate (L/P) ratio 
in body fluids. Both lactic acidosis and an increased L/P ratio is frequently 
found in body fluids of patients with mitochondrial myopathy. 
A mitochondrial myopathy can be defined as a muscle disease 
characterized by structurally or numerically abnormal mitochondria and / or 
abnormal functioning of mitochondria. Such a disease may be expected in 
patients with muscle weakness and exercise intolerance. In most of the 
laboratories involved in the diagnosis of mitochondrial disorders the follow-
ing biochemical measurements are performed in skeletal muscle biopsies of 
such patients: substrate oxidation rates, ATP production rates and activities 
of PDHc and respiratory chain complexes [e.g. 3]. However, despite these 
intensive studies, no specific enzyme deficiency could be detected in 
approximately 30% of the muscle samples with a disturbed pyruvate and 
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malate oxidation rate. Therefore, extension of the diagnostic program includ-
ing determination of Mi-CK activity is warranted. 
The aim of this study was to develop a method to measure Mi-CK activity 
in human skeletal muscle and to study its applicability with respect to 
mitochondrial myopathies. 
Outline of the study 
In this study the results of investigations of Mi-CK activity in human skeletal 
muscle are described. A critical study of the literature concerning Mi-CK is 
presented in Chapter 2. The first objective of this study was to develop a 
method to determine Mi-CK activity in a small amount of human skeletal 
muscle and to collect reference values for Mi-CK activity. Method and 
reference values are presented in Chapter 3. From scarce literature data and 
the experience from oui group it appears that the activity of enzymes 
involved in the energy metabolism of muscle mitochondria inaeases with 
age during development and reaches adult levels approximately a few 
months post partum [4,5]. 
Knowledge about the existence of age-dependency is important to the 
interpretation of the biochemical studies performed in the very young age 
group with the suspicion of a mitochondrial disorder. Chapter 4 contains data 
concerning the development of Mi-CK and other CK isoenzymes in preterm 
born infants. Reference values for this specific age group are given. Sub-
sequently Mi-CK activity in patients with a disturbed pyruvate and malate 
oxidation rate, in which no specific defect of the pyruvate dehydrogenase 
complex and the respiratory chain could be established, was studied. Results 
of this investigation are presented in Chapter 5. A striking structural ab-
normality regularly observed in the intermembrane space of mitochondria of 
patients suffering from mitochondrial myopathies is the occurrence of 
crystals. Recently it was shown that these crystals contain Mi-CK protein 
[6,7]. We studied the relationship between Mi-CK containing crystals and the 
muscle aeatine content. This is presented in Chapter 6. Finally, considera-
tions about the work performed in this study and recommendations for 
future investigation are given in Chapter 7. 
Introduction 5 
Lactate 
Glucose 
. LDH \ C r ^ / ^ 
f -^ *- Pyruvate · j j 
PCr | 
Cytosol 
Fig. 1. Hypothetical biochemical consequences of a Mi-CK deficiency. 
LDH = Lactate dehydrogenase; PDHc = Pyruvate dehydrogenase complex; 
OM = Outer mitochondrial membrane; IM = Inner mitochondrial membrane. 
= porm 
= adenine nucleotide translocator 
= pyruvate translocator 
= long chain fatty acids are, in contrast to medium and short chain fatty 
acids, transported via a carnitine dependent transport system 
= respiratory chain 
•• F^-ATPase 
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I. Introduction 
The primary source of energy for many crucial processes in living cells is 
ATP. However, even though cellular pools of ATP are rather small, no 
significant decrease in [ATP] is detected during cell activation (e.g., muscle 
contraction, brain stimulation, phototransduction in retina or initiation of 
sperm motility) [for reviews see Refs. 318,417]. In all these tissues or cells with 
high and fluctuating energy requirements, ATP is continuously replenished 
from phosphocreatine (PCr) by the action of the creatine kinase (CK, EC 
2.7.3.2) system. The CK isoenzymes catalyze the transphosphorylation reac­
tion between PCr and ADP: 
PCr2" + MgADP' +(χ)·Η+ « » MgATP2 + Cr 
The indicated charges are approached above pH 6.5 where χ approximates 1. 
When the pH is lowered below 6.5, the charges considerably change and χ 
decreases. 
Five CK isoenzymes are currently known in avian and mammalian 
tissues. Three of them are found within the cytoplasm and two are strictly 
mitochondrial. The cytosolic CK isoenzymes form only dimeric molecules, 
namely MM-CK, MB-CK and BB-CK, composed of two types of subunits, the 
M or muscle type subunit and the В or brain type subunit [95,115]. MM-CK 
is predominantly found in mature skeletal muscle and mammalian 
myocardium; BB-CK in mammalian brain and neural tissues, embryonic 
skeletal and cardiac muscle, and avian myocardium; and MB-CK in adult 
mammalian heart as well as in striated muscles during the developmental 
transition from BB- to MM-CK [115,227,530]. Subcellular fractionation, e.g. 
isolation of myofibrils, sarcoplasmic reticulum, plasma membranes, etc., as 
well as direct in situ immunolocalization studies revealed a cellular and 
subcellular compartmentation of the cytoplasmic CK isoenzymes [for re­
views see Refs. 38379,491,492]. In muscle, for example, a small but significant 
fraction of MM-CK is specifically associated with the myofibrillar M-band 
where it directly rephosphorylates ADP generated by the actin-activated 
myosin ATPase. 
The two mitochondrial CK (Mi-CK) isoenzymes, due to their tissue-
specificity of expression on one hand and their relative isoelectric points on 
the other hand, were called either ubiquitous and sarcomeric Mi-CK 
[162,163,244,344] or Mi
a
- and Mib-CK (only for chicken) [397,516], respec­
tively. Both Mi-CK isoenzymes are located within the mitochondrial 
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intermembrane space and form, in contrast to the cytosolic CK isoenzymes, 
octameric as well as dimeric molecules. 
In recent years, the obvious importance of the CK isoenzymes for cellular 
energetics has attracted considerable attention, and three main functions 
were assigned to the CK/PCr system [491,492]: (i) In many tissues, the 
concentrations of Cr and PCr are much higher than those of ADP and ATP, 
thus enabling efficient buffering oí the ADP and ATP concentrations within 
these cells, (ii) The higher concentrations together with the higher diffusion 
coefficients of Cr and PCr relative to ADP and ATP [524,525] ensure a 
significantly enhanced maximal rate of delivery of "high-energy phos-
phates" to sites within the cells where energy is consumed and where ATP 
has to be locally regenerated (transport function of the CK system), (iii) Since 
the CK system is only involved in one particular reaction pathway, and since 
the CK isoenzymes are subcellularly compartmentalized, the CK system 
offers an attractive opportunity to specifically regulate local ATP / ADP ratios 
as well as cellular energy metabolism in general. 
For reviews on the physiology of the CK isoenzyme system and on the 
biochemistry and evolution of the cytoplasmic CK isoenzymes, the reader is 
referred to Refs. 37,38,209,218,230,240,261,311,379,416,488,491-494. 
The purpose of this review is to summarize the important findings on 
Mi-CK since its discovery in 1964 and to convey our current ideas on the 
physiological significance and on the structure-function relationships of this 
enzyme important for the bioenergetics of cells with high and fluctuating 
energy turnover. 
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IL Biochemical studies of Mi-CK 
Д-А. Purification of Mi-CK isoenzymes 
In order to obtain homogeneous starting material for biochemical and 
biophysical experiments as well as for the production of polyclonal and 
monoclonal antibodies, Mi-CK has been purified from a variety of animal and 
human tissues, namely bovine heart [123,166,167,280], chicken heart [63,396], 
dog heart [363-365], human heart [49,50,156,231,457], pig heart [355], rabbit 
heart [132], rat heart [81,82,387], chicken brain [516], human liver [231], 
pigeon pectoralis muscle [281], and sea urchin spermatozoa [464]. Most of the 
purification procedures described take advantage of the intracellular locali­
zation of Mi-CKwhichis attached to theoutersurfaceof the inner mitochondrial 
membrane [213,411 ]. In a first step, mitochondria are enriched by differential 
centrifugation. Then, Mi-CK is released from the mitochondrial inner mem­
brane ("extraction"), and finally, it is separated from contaminating proteins 
by ethanol or ammonium sulphate fractionation, chromatofocussing, affinity, 
ion exchange, hydrophobic interaction, or gel permeation chromatography. 
Some aspects of the purification procedures will now be discussed in more 
detail. 
Simply rupturing the outer mitochondrial membrane, followed by 
extraction of the enzyme under iso-osmotic conditions, does not give satisfac­
tory yields of Mi-CK. Instead, swelling of the mitochondria by incubation in 
a hypotonic medium or in an isotonic phosphate solution prior to extraction 
is a prerequisite for an optimal release of Mi-CK from the inner mitochondrial 
membrane [122,130]. Upon incubation with sodium phosphate, mitochondria 
swell because of a passive uptake of sodium as well as phosphate ions. 
Swelling with potassium phosphate is only observed in respiring 
mitochondria, since the uptake of potassium ions is an active process. 
Accordingly, respiratory inhibitors block potassium-induced swelling of the 
mitochondria [122,130]. 
Release of Mi-CK from swollen mitochondria can be achieved by a 
variety of conditions. In most studies, 10-100 mM phosphate was used at pH 
values of 6.5-9.0 [31,63,81,82,101,123,130,132,156,166,167,210,213,231, 
243,296,324,363-365,374,377,396,401,409,434,457,481,482,487,498,502, 
504,516]. Extraction of Mi-CK by phosphate was shown to be strongly pH-
dependent, being more efficient at pH values higher than 7.0 [481]. Besides 
phosphate ions, adenine nucleotides [265,296,385,482], negatively charged 
organic mercurials [81,82,130,131,324,482,498], and 100-250 mM KCl 
[265,280,481,482,498] were also used to release Mi-CK from the inner 
mitochondrial membrane. Organic mercurials like parahydroxymercuri-
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benzoate and mersalyl at concentrations as low as 10 μΜ seem to be the most 
potent releasing agents resulting in more than 80 % solubilization of Mi-CK 
[482]. Since mersalyl blocks the uptake of phosphate ions into mitochondria, 
however, it should not be used in combination with phosphate. Organic 
mercurials have the additional disadvantage that they inhibit the enzymatic 
activity of Mi-CK, probably by reacting with the "essential" sulphydryl 
group of the enzyme, but enzymatic activity can easily be recovered by 
incubation with excess amounts of reducing agents (2-mercaptoethanol or 
dithiothreitol). Because KCl extracts Mi-CK, the binding of the latter to 
mitochondrial membranes was believed to depend on ionic interactions and 
therefore to be sensitive to the ionic strength of the medium [281,498]. Instead, 
Saks et al. [385] suggested that the decisive factor is not the ionic strength of 
the medium by itself but rather the ion composition. Whereas in their 
experiments 125 mM KCl released more than 50 % of Mi-CK, a "physiological 
salt solution" containing only 10 mM chloride, but with higher ionic strength 
and osmolarity, released only 12 %. Chloride (and other anions) therefore 
seem to have a special effect on the release of Mi-CK, probably by binding to 
the active site of the enzyme [316,494]. 
Three types of affinity matrices have been used up to now for Mi-CK 
purification, namely Cibachrome-Blue-based matrices [50,132,396,487,516], 
ADP-hexane-agarose [63,132], and ATP-hexane-agarose [167]. Whereas only 
2-5 ml columns of the latter two matrices were used. Blue Sepharose CL-6B 
columns of up to 250 ml were routinely employed for the purification of the 
chicken Mi-CK isoenzymes [140,396,516], thus allowing the application of 
large amounts of protein. Nevertheless, the most powerful affinity chroma­
tography technique is probably the transition state-analogue affinity chro­
matography procedure developed by Brooks et al. [63]. In this method, the 
interaction of Mi-CK with the ADP-hexane-agarose matrix is selectively 
strengthened by the addition to the application buffer of magnesium ions, 
creatine and nitrate, thus inducing a transition state-analogue complex of the 
enzyme. The nitrate ion mimics the phosphate group to be transferred during 
catalysis [316], which is thought to be planar in the transition state of the 
reaction. 
A considerable problem in the purification of Mi-CK is its separation 
from the cytosolic CK isoenzymes, because in many tissues, Mi-CK makes up 
only a few percent of the total CK activity. A large part of the contaminating 
cytosolic CK can be eliminated by differential centrifugation. In this respect, 
brain is more delicate, because synaptosomes formed during homogeniza-
tion of the tissue contain cytosolic CK [136,504] and co-sediment with 
mitochondria. In chicken and rat, however, swelling of the mitochondrial 
(and synaptosomal) suspension breaks up the synaptosomes, and a first 
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separation of the mitochondrial and cytosolic CK isoenzymes can be achieved 
by an additional centrifugation step [516,518]. Mi-CK can also be separated 
from the cytosolic CK isoenzymes by ethanol fractionation [166,503] or, 
because Mi-CK isoenzymes of most species have much higher isoelectric 
points (IEP > 8; see II-D.) than the cytosolic CK isoenzymes (IEP < 7) 
[185,483,526], by ion exchange chromatography. In addition, mitochondrial 
and cytosolic CK isoenzymes can be separated by hydrophobic interaction 
chromatography [9,49,50,401,499], indicating that Mi-CK is more hydropho-
bic than cytosolic CK. Finally, both a complete separation of the isoenzymes 
as well as an additional purification of Mi-CK itself were achieved by affinity 
chromatography [167,396,487,516]. A second serious problem during puri-
fication emerges from the "oligomeric heterogeneity" of Mi-CK. It is well 
established now that Mi-CK isoenzymes form octameric as well as dimeric 
molecules which are - depending on protein concentration, substrate concen-
trations, pH, etc. - readily interconvertible (see III-D.). Mi-CK octamers and 
dimers behave quite differently in most of the purification methods men-
tioned above so that one oligomeric form has to be strongly favoured by 
appropriate experimental conditions in order to obtain maximal yields 
(Schlegel, J., Wyss, M. and Wallimann, T., unpublished data). 
The purification procedures for two Mi-CK isoenzymes differ from the 
"general scheme" described above. The purification of human heart Mi-CK 
by Blum et al. [50] includes three chromatography steps, but no enrichment 
of mitochondria by differential centrifugation. The low specific activity of 
their Mi-CK preparation may be explained by the rather harsh and lengthy 
procedure used. A purification scheme based on differential centrifugation 
may turn out to be superior if one takes into account the fact that an optimal 
release of human sarcomeric Mi-CK from the mitochondrial membranes can 
only be achieved by addition of 0.05 % Triton X-100 to the extraction buffer 
[434]. Because differential centrifugation of spermatozoa is almost impossi-
ble, this step was also omitted from the purification scheme of sea urchin 
sperm Mi-CK [464]. Furthermore, phosphate failed to release significant 
amounts of Mi-CK from the sperm membranes, and instead, 5% of the 
non-ionic detergent Nonidet P-40 was used [463,464]. Additional purifica-
tion of sperm Mi-CK was achieved by selective precipitation in a buffer of low 
ionic strength [464]. 
The specific activities of the purified Mi-CK isoenzymes shall not be 
listed here, since they strongly depend on the reaction direction and on the 
experimental conditions used. The most reasonable range in the direction of 
ATP synthesis at 30CC and pH near neutrality seems to be 100-200 
^o l /min /mg protein [26,63,281,287]. 
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II-B. Molecular size 
Whereas it is generally accepted that cytosolic CK isoenzymes exclusively 
form dimeric molecules (MM-, MB- and BB-CK) [95,115,494], the naturally 
occurring oligomeric forms of Mi-CK were a matter of debate for quite a long 
time. Some research groups presented evidence that Mi-CK, like the cytosolic 
CK isoenzymes, is also exclusively a dimeric molecule with a M
r
 of 80 500-
84 000 [23,49,50,63,156,364,365,439] and even claimed that the higher M
r 
aggregates reported by others represent "induced artifacts" [156,365]. 
Nevertheless, an increasing body of evidence, starting with the pioneering 
studies of Farrell et al. [122], Saks et al. [374] and Jacobs [211], demonstrated 
that Mi-CK, at least in vitro, forms stable dimeric and octameric molecules. 
Dimeric and octameric Mi-CK are readily interconvertible (see Ш-D.) and 
have molecular masses of 75-91 kDa and 306-380 kDa, Stokes radii of 36-38 
Â and 59-65 Â, and sedimentation coefficients of 4.9-5.4 S and 11.6-13.5 S, 
respectively (Table 1). 
The most thorough analysis concerning the molecular mass was per-
formed on the Mi-CK isoenzymes from chicken, namely ubiquitous Mia-CK 
from brain and sarcomeric Mib-CK from heart. Gel permeation 
chromatography and analytical ultracentrifugation of the purified isoenzymes 
revealed two oligomeric forms each with M/s of 83 000-86 000 and 306 000-
364 000, respectively, with no indication for the existence of an intermediate 
form [396,397,403,516]. Considering the protomeric Mr of -43 000 (Table 1), 
the cDNA sequences (see II-F.) and hybridization experiments [516], the 
lower Mr form in all likelihood corresponds to dimeric Mi-CK molecules. In 
contrast, the higher Mr value, which in addition was confirmed by direct mass 
measurements of single Mi-CK molecules by scanning transmission electron 
microscopy [403,516], is strongly indicative for an octameric molecule. This 
view is also supported by electron microscopical examination of Mi-CK 
molecules (see II-C), which suggests that four ellipsoid Mi-CK dimers are 
arranged in parallel to each other to form an octamer. 
In several studies [26,27,82,100,122,156,167,278,464,504], the higher Mr 
value of Mi-CK was underestimated to be in the range 180 000-250 000. The 
reasons for these underestimations seem to be manifold: (i) already in 1972, 
Farrell et al. [122] published a Stokes radius of 65 Â for beef heart Mi-CK 
which is fully in line with the available data for octameric Mi-CK (Table 1). 
However, probably due to inappropriate Mr standards, the molecular mass 
was calculated by the same authors to be only 250 kDa; (ii) due to its 
recommended Mr fractionation range of 5 000-250 000, Sephacryl S-200 
clearly represents a bad choice for the estimation of the higher Mr value of 
Mi-CK [100,156,167]. In addition, dimeric Mi-CK revealed a Mr of only 65 000 
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Table L Molecular masses, sedimentation coefficients and Stokes radii ofMi-CK isoenzymes 
Species - Tissue 
bovine heart 
chicken heart 
chicken brain 
dog heart 
human heart 
pig heart 
pigeon pectoralis 
rabbit heart 
rat heart 
sea urchin sperm 
Molecular 
protomer 
41^4 
42^3 
42 
41^4 
41-42 
-
44 
40-45 
42^3 
44-50 
masses [kDa] 
dimer 
80-89 
78-87 
85 
82-84 
80-85 
75 
87-91 
81 
82-87» 
-
oc ta mer 
317-355 
321-378 
306-352 
-
350 
342 
331-380 
332-377 
340-345* 
353 
Sedimentation 
coefficients [S] 
dimer 
5 3-5 4 
5 0 
4 9-5 3 
-
5 0 
-
5 4 
-
-
-
oc tamer 
118-12 4 
12 8-13 5 
116-12 0 
-
-
(117) 
12 0 
-
-
12 4 
Stokes radu [A] 
dimer 
37 
38 3* 
36 3* 
-
-
-
374 
36-39* 
37 7* 
-
octamer 
59-65 
62.4* 
60 3» 
-
. 
-
59 3 
56" 
611* 
62 8 
Ref 
a 
b 
с 
d 
e 
f 
В 
h 
1 
1 
References a) 26-29,122,123,211,212,280,282,283,286, b) 63,396,397,403, с) 397,516, d) 23,347,348,363-365, 
e) 49,50,156,231,243, f) 242,296,483, g) 281,283, h) 132,296,353,439,482,483, ι) 81,82,266,344,382,387,396, 
))463,464^17/*)Wyss,M,Schlegel,] and Wallimann,T,unpublished data^ViaLC,unpublished data. 
on Sephacryl S-200, but one of 80 000 on Sephadex, indicating that the choice 
of the gel filtration matrix is crucial for molecular mass determination of 
Mi-CK [156]; (iii) using a FPLC Superose-12 column from Pharmacia, Tombes 
and Shapiro [464] determined a Stokes radius of only 45 Â for sperm Mi-CK 
of the sea urchin Strongylocentrotus purpurei us, whereas we [517] obtained a 
Stokes radius of 62 8 Â and a Mr of 353 000 for the same protein from the sea 
urchin Psammechmus miliaris (Table 1) Since Tombes and Shapiro for their 
ultracentrifugation experiments used a calculation method where the Mr is 
a function of the Stokes radius whereas the sedimentation coefficient is not, 
they underestimated the Mr as 235 000, but obtained a "correct" sedimenta-
tion coefficient of 12 4 S Correction for a Stokes radius of 62 8 Â gives a Mr 
of 328 000 instead of 235 000; (iv) the Mr of 240 000 reported for rat heart 
Mi-CK [82] can be explained by partial dissociation of the Mi-CK octamers 
during the gel filtration run. First, in the very same experiments, a 
Mr > 100 000 was obtamed for dimeric Mi-CK [81], second, faster gel 
permeation chromatography on a FPLC Superose-12 column revealed a M 
of 340 000 [396], and third, purified rat heart Mi-CK octamers proved to 
readily dissociate [398]; (v) the observations on bovine heart Mi-CK made by 
Belousova and co-workers [26-29,123] are an exception, since these authors 
are the only ones who provided experimental evidence for two different high 
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Mr forms, namely "hexameric" (Mr 240 000) as well as "octameric" Mi-CK 
(Mr 340 000). In their most recent article, however, "hexameric" and 
"octameric" Mi-CK both were shown to have a sedimentation coefficient of 
12.3-12.4 S and to display a four-fold symmetry on electron micrographs. 
Since a hexamer would be highly inconsistent with a four-fold symmetry, one 
is now tempted to suggest that the two forms represent different conforma-
tions of octameric Mi-CK [28,29]. 
In vitro translation of Mi-CK mRNA [162,348] as well as determination 
of the cDNA sequences of the two human and rat Mi-CK isoenzymes 
[162,163344] revealed that Mi-CK is synthesized as a precursor protein of Mr 
47 000-48 000 containing anN-terminal mitochondrial target sequence which 
is proteolytically removed after the import into the mitochondria to yield 
mature Mi-CK subunits with a Mr of approximately 42 000. A Mr of 42 000 was 
also reported for Mi-CK protomers from rooster spermatozoa [489] and 
chicken retina [490,496]. Gel filtration experiments performed by Yasui et al. 
[523] revealed two oligomeric forms of Mi-CK from human skeletal muscle, 
heart and stomach having Mr's of 80 000 and 370 000, but only one form of Mr 
370 000 for human brain Mi-CK. Similarly, two different oligomeric forms 
with M/s of 80 000 and 350 000 were described for human liver Mi-CK [231]. 
However, since liver only contains minute amounts of CK [40,518], the 
assumption that this Mi-CK in fact originated from liver cells is unlikely. 
Instead, the extracted Mi-CK may be derived from blood vessels because 
vascular and intestinal smooth muscle cells have recently been shown to 
contain appreciable amounts of octameric Mi-CK [207]. As a last point it 
seems worth mentioning that already in 1968, Keto and Doherty [242] 
enriched a CK form with a sedimentation coefficient of 11.73 S from a 
particulate fraction of pig heart. Even though the authors claimed that this 
form was not of mitochondrial origin, they were, in hindsight, probably the 
first to describe octameric Mi-CK. 
JJ-C. Three-dimensional structure: Electron microscopy and protein 
crystallography 
By electron microscopy, the octameric forms of Mi-CK isoenzymes from all 
species investigated so far reveal a very similar structure. Bovine heart 
[28,29,122,286], rat heart [82], chicken heart [396,397,403-407,507], chicken 
brain [397,404] as well as sea urchin sperm Mi-CK [517] seem to be cube-like 
molecules with a side-length of 10 nm, displaying a four-fold symmetry and 
a central stain-filled indentation or cavity. The fact that not only the oligomeric 
state but also the overall three-dimensional structure of Mi-CK has been 
conserved throughout evolution from sea urchins to mammals points to an 
important physiological role of this structure. 
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At least two different projections have to be assumed for an octameric, cube-
like molecule. However, negative staining (Fig. 1A,B) [396,397,403,404,507] 
and rotary shadowing (Fig. 1C,D) [403,407,507] of single molecules of 
chicken sarcomeric Mib-CK revealed only one single view of the molecule, 
indicating that the top and bottom faces of the octamer are identical and have 
a distinctly higher affinity for a variety of support films used for electron 
microscopy than the side faces [407]. Since the cross-like surface depression 
of Mib-CK visualized by rotary shadowing (Fig. 1C,D) is slightly twisted in 
dock-wise direction relative to the side faces of the octamer [407,507], and 
since computer averaging of the structure of negatively stained and rotary 
shadowed Mib-CK octamers revealed a four-fold symmetry [507], a single 
view for all four side faces has to be assumed. This side view of the octamer 
has only recently been obtained under one set of particular conditions. 
Overnight incubation of chicken Mib-CK with neutral uranyl acetate, fol-
lowed by dialysis against distilled water, resulted in the formation of linear 
unbranched Mi-CK filaments, in which Mi-CK octamers were stacked by 
their top and bottom faces on top of each other (Fig. IE) [407]. The side view 
of the filaments, therefore, also displays the side face of the Mi-CK octamers. 
One possibility for the overall three-dimensional structure of Mi-CK 
octamers is that a central cavity is present inside the octamer (Fig. IF) and is 
connected with the exterior of the molecule by two smaller channels, 
protruding from the midst of the top and bottom faces right into the middle 
of the octamer. This possibility is favoured by the facts that negative staining, 
visualizing a projected view of the entire volume of the molecule, reveals a 
central accumulation of stain with a diameter of about 2.5 nm (Fig. 1 A,B), and 
that rotary shadowing, reflecting the surface structure of Mib-CK, gives rise 
to a small orifice only (Fig. 1C,D). Alternatively, the side view displayed by 
the linear Mi-CK filaments (Fig. IE), as well as the recent observation of a 
second projection of single Mi-CK octamers (Kaldis, P., Schnyder, T. and 
Wallimann, T., unpublished data), favour the notion that the banana-shaped 
dimers are arranged in such a way that they form funnel-like indentations in 
the middle of the top and bottom faces (Fig. IF). Further insight into the 
structural organization within the octamer was gained from experiments on 
the formation of heterooctameric molecules of chicken ubiquitous Mia- and 
sarcomeric Mib-CK [516]. MiaMib-CK heterooctamers were formed out of a 
mixture of Mia- and Mib-CK homodimers and subsequently stored for three 
months at 4°C. Upon re-dissociation of the octamers, cellulose polyacetate 
electrophoresis only revealed Mia- and Mib-CK homodimers, but no 
MiaMib-CK heterodimers, thereby proving that within the octamer, discrete 
dimers are the stable building blocks, with no subunit exchange between 
them. 
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Fig. 1. The three-dimensional structure of chicken sarcomeric Mi-CK octamers deduced from 
electron micrographs. 
A) Negative staining of Mi-CK octamers; B) contour representation of A) after 
circular harmonic averaging [507]; C) Mi-CK octamers rotary-shadowed with Ta/ 
W at low temperature and ultra-high vacuum [407]; D) contour representation of 
Mi-CK octamers rotary-shadowed with Pt/lr/C after circular harmonic averaging 
[507]; E) linear filaments of positively stained Mi-CK octamers. The inset on the right 
side displays an averaged stretch of the filaments. The side view of one octamer is 
outlined by dots [407]; F) model representations of the structure of an octamer. 
Above: top or bottom view; below: the two possible side views displayed as sections 
through the center of an octamer (see text). 
Though crys tallization of cy tosolic CK isoenzymes has already been reported 
by several groups [69,151,185,304], and though these crystals diffracted to up 
to 2.0 À resolution, no three-dimensional structure has been solved up to 
now. One reason for this probably is the microheterogeneity of purified MM-
and BB-CK preparations [185356] which is primarily due toposttranslational 
modifications. This problem may be overcome by crystallizing chicken 
sarcomeric Mib-CK [404,405,408] for which no posttranslational modifica-
tions are currently known. Precipitation of Mib-CK with polyethylene glycol 
1000, either in the presence or absence of ATP, yielded two different types of 
tetragonal crystals with the space groups P4212 and P422, containing one 
octamer and one dimer per asymmetric unit, respectively. The former crystal 
type diffracts to at least 3 Â resolution [405]. A change in the crystal form in 
the presenceof ATP might be indicative for a conformational change induced 
by substrate binding, a phenomenon that has attracted much interest in the 
study of the cy tosolic CK isoenzymes [39]. As far as Mi-CK is concerned, 
conformational changes induced by substrates were assumed to influence the 
dimer to octamer ratio [280,281,296], since in a variety of studies, formation 
of a "transition state-analogue complex" of Mi-CK with MgADP, Cr and 
nitrate resulted in the complete dissociation of the octamers into dimers (see 
Ш-D.). Conformational differences of octameric Mi-CK were also thought to 
be the basis for the apparent "hexameric" and "octameric" forms of bovine 
heart Mi-CK described by Belousova and co-workers [28,29,123] (see Π-Β.). 
Thefinding that the modification of Mi-CK dimers, "hexamers" and octamers 
with SH group reagents is biphasic, with the first half of the subunits being 
more readily modified than the second half, was taken as an argument for an 
asymmetric association of the subunits within the dimer [26,27,123], but 
might be explained as well by a conformational change of discrete dimers 
induced by modification of only one of their subunits. Surprisingly, however, 
only half of the active sites within the octamer bound MgADP in the presence 
of Cr and nitrate [124]. 
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II-D. Isoelectric point 
With the exception of sea urchin sperm Mi-CK [464], all Mi-CK isoenzymes 
currently investigated have higher isoelectric points than the cytosolic CK 
isoenzymes of the respective species. Whereas pi's of 8.2-9.7 were reported 
for most Mi-CK isoenzymes (Table 2), pi's of 6.2 and 7.0 were obtained for sea 
urchin sperm [464] and frog heart Mi-CK [273]. The results on the human 
Mi-CK isoenzymes are somewhat contradictory. From the cDNA sequences 
of cardiac and placental Mi-CK [162,163], pi's of 7.42 and 7.49 can be 
calculated for the mature subunits. These values agree quite well with those 
determined for native human heart and brain Mi-CK (6.8-7.0) [50,502,504], 
but are distinctly lower than the value of 9.35 reported for human heart 
Mi-CK by Khuchua et al. [243]. Besides the differences between particular 
Mi-CK isoenzymes, distinct isoelectric points were also observed for dimeric 
and octameric Mi-CK. Whereas a higher pi for the octamer than for the dimer 
was reported for Mi-CK from rabbit heart, chicken heart and chicken brain, 
an inverse relationship was found for the isoenzymes from bovine heart and 
pigeon pectoralis (see Table 2). However, these latter results have to be 
questioned since in cellulose acetate electrophoresis experiments, octameric 
bovine heart Mi-CK migrated further towards the cathode than dimeric 
[100,167] (see also HI-D.), thus suggesting that the octamer is also more 
positively charged in bovine heart. 
Mi-CK can be released from the inner mitochondrial membrane by high 
salt concentrations (see II-A.) and is therefore thought to be bound via ionic 
interactions [82,369,395,498]. In fact, the basic pi of Mi-CK indicates that, 
within the mitochondrial intermembrane space, positively charged Mi-CK 
may bind to negatively charged membrane phospholipids. Accordingly, 
octameric Mi-CK from chicken heart, probably due to i ts higher pi, was found 
to interact more strongly with mitoplast and model membranes than dimeric 
Mi-CK [369399]. Even though ionic interactions of Mi-CK with mitochondrial 
membranes are important, hydrophobic interactions can not be excluded, 
especially in the case of sea urchin sperm Mi-CK which can only be detached 
from the membranes by relatively high concentrations of detergents, but not 
by any other treatment known to release Mi-CK isoenzymes [464]. This may 
be due to its acidic pi of 6.2, indicating that ionic interaction with the 
mitochondrial membranes is reduced, but compensated for by increased 
hydrophobic interaction. 
Because of the higher pi, Mi-CK isoenzymes can be nicely separated 
from the cytosolic CK isoenzymes under native conditions by electrophoresis 
on cellulose polyacetate strips as well as starch or agar gels, with Mi-CK 
migrating more cathodically than cytosolic CK [13,50,208,222,326,338, 
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Table II. Isoelectric 
Species - Tissue 
bovine heart 
chicken heart 
chicken brain 
frog heart 
human heart 
human brain 
pig heart 
pigeon pectoralis 
rabbit heart 
rat heart 
rat brain 
sea urchin sperm 
points of Mi-CK 
dimeric 
Mi-CK 
9.67 
9.3 
8.4-8.5 
-
6.94 
7.01 
8.20 
9.56 
8.24 
-
-
-
octameric 
Mi-CK 
8.93 
9.4 - 9.5 
8.7 - 9.0 
-
-
-
-
8.91 
8.83 
-
-
-
other forms1 
9.2 - 9.6 
8.25' 
7.94» 
7.0 
6.8; 9.35; 7.42» 
7.49» 
-
10.25 
-
9.4; 7.88» 
7.73» 
6.2 
refs. 
a 
b 
с 
d 
e 
f 
g 
h 
i 
i 
к 
1 
'Included in this column are values determined for Mi-CK which was either monomeric or 
for which the oligomeric form was not determined. Values marked with a * were calculated 
from the cDNA sequence. References: a) 26,27,208,211,282; b) 196,399,516; c) 399,508,516; 
d) 273; c) 50,163,243,502; 0 162,504; g) 354; h) 282; i) 354,483; j) 266,344,387; k) 344; 1) 464. 
374,390,410,441,516,518]. The only exceptions known are human and frog 
heart Mi-CK. Human heart Mi-CK, because its pi is very similar to that of 
MM-CK, may be obscured by the latter isoenzyme [173]. Frog (Rana esculenta) 
heart Mi-CK, though having a pi which is distinctly higher than those of its 
cytosolic counterparts (7.0 vs. 5.5-5.8), migrated in between the cytosolic CK 
isoenzymes on cellulose polyacetate strips [273], as did the isoenzyme termed 
CK-V of Xenopus frogs which is expressed in lung and heart [511]. Since 
CK-I of Xenopus is supposed to be of mitochondrial origin as well, but is 
expressed in eye, brain and stomach, these results may indicate that frog, like 
chicken, rat and man, also contains two different Mi-CK isoenzymes. Inter­
estingly, the fact that the mitochondrial isoenzymes have a higher isoelectric 
point than the cytosolic ones is not restricted to CK, but seems to be a rather 
general phenomenon [175]. Therefore, the hypothesis has been raised that the 
increased pi is either a prerequisite for an efficient import of the precursor 
proteins into the mitochondria or an adaptation to the metabolic conditions 
within these organelles. 
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II-E. Kinetic constants 
Since the kinetic constants of the Mi-CK isoenzymes strongly depend on the 
calculation method used, on the species investigated, on the purity of the 
enzyme preparation, as well as on buffer composition, temperature and pH, 
it is beyond the scope of this review to mention all of the available data [for 
discussion see Ref. 419]. Instead, those studies are selectively picked out 
which compared different purified CK isoenzymes under exactly the same 
conditions, in which a variety of kinetic constants were determined for a 
single isoenzyme, or which allow interesting conclusions. 
As already mentioned, the CK isoenzymes catalyze the trans-
phosphorylation reaction between PCr and ADP (see I.). Most studies on the 
reaction mechanism were performed on the cytosolic CK isoenzymes [for a 
review see Ref. 240]. For Mi-CK, it was only shown that at pH 7.4 the reaction 
mechanism is of the "rapid-equilibrium random" type [287,375], that one 
cysteine [27,123] as well as two arginine residues per subunit [323,420] are 
"essential" for catalytic activity, and that probably Asp-335 is involved in 
substrate binding [223] (see also II-F.). 
The pH optima of the reaction catalyzed by Mi-CK from bovine heart 
[100,167], chicken heart [516], human heart [49,50], rabbit heart [439], guinea 
pig heart [338], rat heart [213], chicken brain [516], guinea-pig brain [456] and 
sea urchin spermatozoa [464] all range from 6.0-7.0 in the direction of ATP 
synthesis and from 7.5-9.0 in the direction of PCr synthesis, therefore being 
in about the same range, or slightly lower than the respective values of the 
cytosolic CK isoenzymes [338,341,439,464,494] as well as of all other known 
Phosphagen kinases [for a review see Ref. 322]. These findings are fully in line 
with pH studies on rabbit MM-CK which revealed that a single group with 
a pK
a
 near 7, probably a histidine residue, acts as an acid-base catalyst and 
must be unpro tonated in the direction of PCr formation and protonated in the 
direction of ATP formation [90]. 
All purified Mi-CK isoenzymes investigated so far have a lower K
m
 value 
for MgADP than for MgATP, and a lower K
m
 value for PCr compared to Cr 
[23,26,50,63,100,167,231,287,397,401,410,448,464,523]. The same relationships 
have been described for the cytosolic CK isoenzymes [for a review see Ref. 
48]. The K
m
 values of the Mi-CK isoenzymes were reported to be: 42 μΜ-1.7 
mM for MgATP, 15-150 μΜ for MgADP, 3.4-62 mM for Cr, and 0.23-4.1 mM 
for PCr. Human and chicken ubiquitous Mi-CK display a 2-fold and 4-fold 
lower K
m
 value for PCr than the respective sarcomeric Mi-CK isoenzymes 
[397,523], possibly reflecting a metabolic adaptation to the lower PCr concen­
trations in brain compared to cardiac and skeletal muscle. Furthermore, the 
fact that in intact mitochondria, Mi-CK has a lower K
m
 for ATP produced in 
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the matrix compartment and presented by the adenine nucleotide translocator 
(ANT) than for exogeneously added ATP was taken as an argument that 
Mi-CK has privileged access to intr amitochondrially synthesized ATP due to 
a direct interaction of Mi-CK with ANT [169,266,267,382,38537]. However, 
the differences in K
m
 values could also be explained by restricted diffusion 
of adenine nucleotides across the outer mitochondrial membrane, signifying 
that especially at high velocities of the Mi-CK reaction, the substrate concen­
trations within the intermembrane space would not correspond to the 
extramitochondrial ones [146-148,257]. This controversy between "direct 
interaction of Mi-CK with ANT" and "restricted diffusion of adenine 
nucleotides" will be discussed in more detail in chapter Ш-С. The indications 
that the ANT has a much lower K
m
 for ADPand a higher one for ATP than 
Mi-CK were thought to explain why PCr is the high-energy phosphate 
compound leaving the mitochondria as the net product of oxidative 
phosphorylation [167]. However, on the basis that the K
m
 values of Mi-CK 
and ANT should not be compared since Mg ADP and MgATP are the effective 
substrates of Mi-CK, whereas only the uncomplexed adenine nucleo tides are 
transported by ANT, this interpretation has to be seriously questioned. 
Different cooperativities of substratebindingbetween individual subunits 
might be a distinguishing feature of dimeric and octameric Mi-CK and 
thereby represent an effective means of regulating the enzymatic activity of 
the Mi-CK isoenzymes. However, the Hill coefficients of sarcomeric and 
ubiquitous Mi-CK octamers for the binding of PCr in the presence of excess 
MgADP are only 1.2 and 1.0, respectively [397], meaning that almost no 
communication between the subunits in the binding of this substrate occurs. 
Cooperativity in the binding of the adenine nucleotides is more likely to 
occur, since ATP and ADP are not only more tightly bound to Mi-CK, but are 
also more potent in inducing conformational changes of CK isoenzymes 
[238]. 
Arrhenius plots of the temperature dependence of the enzymatic activity 
were used to calculate the activation energies of the CK reaction in the 
direction of ATP formation. For the human isoenzymes, significantly higher 
activation energies of 101-142 kj/mol were found for ubiquitous and 
sarcomeric Mi-CK than for MM-, MB- and BB-CK (49-76 kj/mol) 
[164,340,448,449,523], indicating that the substrates PCr and ADP are more 
strongly bound by the mi tochondrial than by the cy toplasmic CK isoenzymes 
[231,401,448,503]. Whether this 2-fold difference in activation energies is of 
physiological importance, for example reflecting an adaptation to lower PCr 
or ADP concentrations in the intermembrane space compared to the cytosol, 
remains to be elucidated. Yet, a higher activation energy by all means causes 
a lowered maximal reaction velocity (V ). Accordingly, lower V
max
 values 
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in the direction of ATP formation were reported for the chicken mitochondrial 
than for the cytosolic CK isoenzymes [518]. 
JÍ-F. Nucleic and amino acid sequences 
Compared to the cytosolic CK isoenzymes [for references see Ref. 223], 
Mi-CK sequence data are rather sparse. Besides several partial protein 
sequences [50,82,137,196,223,464,516], six cDNA sequences [162,163,196, 
344,508] and two genomic sequences [162,244] were published up to now. 
Originally, determination of the aminoterminal sequences of chicken heart 
and brain Mi-CK proved that these tissues contain two different Mi-CK 
isoenzymes [196], as had been suggested earlier for the rat from agarose gel 
electrophoresis experiments [391]. In the meantime, communication of two 
different Mi-CK cDNA sequences each for chicken [196,508], man [162,163] 
and rat [344] confirmed these findings and further demonstrated that they are 
due to two different nuclear genes rather than differential splicing of a single 
gene. Since on RNA blots, specific probes for the sarcomeric and ubiquitous 
human Mi-CK isoenzymes only detected minute amounts of Mi-CK RNA in 
uterus and testis, tissues known to contain significant CK activities including 
Mi-CK, Payne et al. [344] assumed that a third Mi-CK isoenzyme is expressed 
in these tissues. This might indicate, together with the finding that in rainbow 
trout a CK isoenzyme termed TCK1 is expressed mainly in testis but only 
faintly in other tissues displaying CK activity [142], that testis has its own 
particular set of CK isoenzymes. 
Since in a few instances contradictory results were published for Mi-CK 
sequences, the respective references shall be shortly mentioned to avoid 
confusion in case the original literature is studied. In the cDNA sequence for 
human ubiquitous Mi-CK presented in Fig. 3 of the article written by Haas 
et al. [162], the 11 aminoterminal residues were erroneously replaced by the 
10 corresponding residues of human sarcomeric Mi-CK, which the authors 
already knew at that time [162]. Furthermore, 4 of the 11 aminoterminal 
amino acids determined for human heart Mi-CK [50], 5 of the 120 amino adds 
specified for chicken ubiquitous Mi-CK [516] and 7 of the 40 aminoterminal 
amino acids determined for rat sarcomeric Mi-CK [82] by protein chemical 
methods do not agree with the respective cDNA sequences [163,344,508]. 
Finally, Benfield et al. [30] published a partial sequence of a rat CK gene 
differing from M- and B-CK which probably corresponds, in spite of a variety 
of differences, to rat ubiquitous Mi-CK [344]. 
The gene structures of human ubiquitous [162] and sarcomeric Mi-CK 
[244] differ considerably from those of the cytosolic CK isoenzymes. The 
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former genes span 5.5 and 37 kb, are located on chromosomes 15 [447] and 
5 [244] and contain 9 and 11 exons, respectively. The lengths of the coding 
region exons as well as the locations of the exon junctions are absolutely 
identical between the two human Mi-CK isoenzymes, but differ considerably 
from those of the cytosolic CK isoenzymes, indicating that from an evolutio­
nary point of view, a first duplication even t of a common primordial CK gene 
resulted in ancestral mitochondrial and cytosolic CK genes. Only at a later 
stage, further gene duplications gave rise to the four different CK isoforms 
known for avian and mammalian species [244]. Very interestingly, exons 1 
and 2 of the human sarcomeric Mi-CK are untranslated and followed by an 
11 and 7 kb-intron, respectively [244]. Since sarcomeric contractile proteins 
were found to share a similar 5' organization, with an untranslated first exon 
followed by a relatively large intron [250], it has been hypothesized that this 
common feature is responsible for the coordinate transcriptional activation 
of sarcomeric Mi-CK and contractile proteins [244]. 
In contrast to M- and B-CK mRNA, Mi-CK mRNAs code, in addition to 
the native protein, for an aminoterminal mitochondrial target peptide which 
is proteolytically removed after import into the mitochondria [162,163, 
196,344,347]. This target peptide is 39 amino acids long, rich in serine, 
threonine and basic amino acid residues, and has a characteristic tripartite 
structure [174]. Its amino terminus (residues 1-16) is positively charged and 
hydrophilic, and likely represents a mitochondrial matrix-targeting signal. 
Residues 17-32 constitute a stretch of uncharged amino acids which might act 
as a stop-transfer signal, therefore directing the protein into the intermembrane 
space. And finally, residues 33-39 are again positively charged and hydrophilic 
and are probably responsible for proper cleavage to yield the native enzyme. 
Sequence comparisons show that within the native protein, within the 
mitochondrial targeting peptide, as well as within the 3' and 5' untranslated 
regions, the sarcomeric Mi-CK isoenzymes on one hand and the ubiquitous 
Mi-CK isoenzymes on the other hand of chicken, man and rat are more closely 
related to each other than the sarcomeric and ubiquitous Mi-CK isoenzymes 
of one particular species, indicating that two different Mi-CK isoenzymes 
already appeared before divergent evolution of birds and mammals oc­
curred. This is in line with the likely presence of two different Mi-CK 
isoenzymes in frog tissues (see Π-D.). By the Needleman-Wunsch method, 
the native sarcomeric Mi-CK isoenzymes display 89-96 % amino acid se­
quence identity and the ubiquitous isoenzymes 91-96 %, whereas within the 
same species, the two Mi-CK isoenzymes have only an identity of 82-84 %. 
The fact that in rat and man the mitochondrial targeting peptides are much 
more conserved between the sarcomeric (87 %) and the ubiquitous Mi-CK 
isoenzymes (92 %), respectively, as compared to both Mi-CK isoenzymes of 
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the same species (37 % in rat, 38 % in man), was taken as an argument for 
tissue-specific mitochondrial import receptors [344]. Furthermore, the marked 
isoenzyme-specific rather than species-specific conservation of the 3' 
untranslated regions indicates an important function of these stretches of 
DNA for Mi-CK gene expression. 
The mitochondrial and cytosolic CK isoenzymes represent a class of 
highly conserved proteins. When the sequences of the known isoenzymes are 
compared, one finds six blocks of very high homology separated by seven 
regions which are less conserved [196]. Among the latter are the amino- and 
the carboxy terminus. The highly conserved regions are likely to be involved 
in essential functions of the enzyme like catalytic activity and dimer forma­
tion. For example, affinity labelling of chicken sarcomeric Mib-CK with the 
ATP analogue T^-OJ^-chloroethyl-N-methylamino)] benzylamide ATP 
(C1RATP) led to the selective modification of Asp-335, a residue which is 
conserved in all Mi-CK and the great majority of the cytosolic CK sequences 
[223]. Since in C1RATP, the reactive label is attached to the γ-phospha te group 
of ATP, and on the basis of structural comparisons with adenylate kinase, 
Asp-335 was suggested to be involved in the binding of Mg2+ ions 
coordinated to the phosphate groups of ATP. The findings (i) of a partial loss 
of enzymatic activity of chicken sarcomeric Mib-CK when Asp-335 is changed 
to a Thr, Asn, Ala or Lys residue by site-directed mutagenesis (Furter, R., 
unpublished data), and (ii) of a complete loss of enzymatic activity upon 
selective cleavage by proteinase К of M-CK between Ala-328 and Ala-329 
[271,321] as well as of chicken sarcomeric Mi-CK between Ala-324 and 
Val-325 (Wyss, M., Schlegel, J. and Wallimann, T., unpublished data) further 
substantiate that besides the region around the "essential" Cys-278, stretches 
around Asp-335 are also important for substrate binding and catalysis. 
In contrast, the regions less conserved between the CK isoenzymes might 
be responsible for isoenzyme-specific properties like octamer formation, 
binding to cellular membranes, or binding to the myofibrillar M-band. In 
experiments with purified Mi-CK peptides, for example, Cheneval and 
Carafoli [82] found only one peptide, corresponding to the 25 amino terminal 
residues, which bound to cardiolipin-containing liposomes. Accordingly, 
the positively charged residues Arg-19, Lys-20 and His-21 have been impli­
cated to mediate the binding of Mi-CK to the negatively charged phospholipids 
of the mitochondrial membranes [82]. As a matter of fact, these three amino 
add residues are absolutely conserved among all amino termini known for 
the sarcomeric and ubiquitous Mi-CK isoenzymes from chicken [196,508,516], 
man [162,163], and rat [82,344], as well as for mouse brain Mi-CK [344], but 
not among the cytosolic CK isoenzymes. 
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III. Functional studies of Mi-CK 
Ш-А. Species and tissue distribution 
Highest enzymatic activities and mRNA levels of Mi-CK are present in 
tissues with high and fluctuating energy demands like heart 
[13,50,82,156,167,210,213,338,344,363,377,396,410,411, 441], skeletal muscle 
[31,34,173,196,210,281,293,326,344,377,410], brain [53,210,213,268,344, 
397,456,504,512,516], retina [41,268,490,496] and spermatozoa [463-465,489]. 
Smaller amounts of Mi-CK and Mi-CK mRNA are found in smooth muscle-
containing tissues like uterus [163,344], placenta [344], intestine [41,63,162, 
206,207,213,239,344], vas deferens as well as aorta [207]. In contrast, no 
Mi-CK activity was detected in chicken gizzard in spite of its high cytosolic 
BB-CK activity [396]. It has been hypothesized that this difference in Mi-CK 
content between distinct smooth muscle types is due to the different 
physiological functions of these muscles [207,492]; whereas most smooth 
muscles respond to stimulation with very long tonic contractions, carbachol 
and electric field stimulation in chicken gizzard elicited only phasic con­
tractions without a tonic component. Maximal force was developed within 
10-15 s, and almost complete relaxation was accomplished in less than a 
minute [126]. Therefore, the CK/PCr system in chicken gizzard has to 
"buffer" [ATP] which can easily be accomplished by the extraordinarily large 
amounts of BB-CK present, with no need for an additional mitochondrial 
isoenzyme. In contrast, "transport" of PCr and Cr between Mi-CK and 
cytosolic CK isoenzymes may be a prerequisite for the proper functioning of 
tonic smooth muscles (see also IV-B.). 
In contrast to earlier studies [210,213], significant amounts of Mi-CK 
activity and mRNA were also observed in rat kidney [1,41,137,344], where 
Mi-CK, together with BB-CK, was found in cortex and outer medulla, 
probably supporting sodium transport in the distal nephron [137]. Liver was 
reported to contain either no or only minute amounts of Mi-CK activity and 
mRNA [41,163,210, 213,344,518]. Nevertheless, Kanemitsu et al. [231] suc­
ceeded in purifying Mi-CK from human liver and provided some, albeit 
weak evidence indicating that this isoenzyme differs from human heart 
Mi-CK. Finally, Mi-CK might become increasingly important as a valuable 
diagnostic tool since it was also found in certain tumor cells as well as in 
serum (see ΠΙ-G.). These data show that Mi-CK expression is regulated ¿и α 
físswe- and cell type-specific fashion. In all instances, however, Mi-CK is 
coexpressed with at least one of the cytosolic CK isoenzymes MM-, MB- or 
BB-CK. As discussed in Π-R, it is now clear that at least two different Mi-CK 
isoenzymes exist and are products of distinct genes. Northern blot analysis 
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revealed that mRNA for the isoenzyme termed sarcomeric Mi-CK is almost 
exclusively expressed in heart and skeletal muscle [163,196,244,344]. In 
contrast, mRNA for ubiquitous Mi-CK was mainly found in kidney, placenta, 
intestine and brain. Seemingly, sarcomeric Mi-CK is the counterpart of M-CK 
and ubiquitous Mi-CK that of B-CK. 
The relative proportions of Mi-CK vary considerably between different 
tissues and species. Mi-CK amounts to 0.5-15 % of total CK activity in brain 
[48,245,335,391,423] and to 10-15 % in kidney [137]. Since in fast-twitch 
skeletal muscle, the percentage of Mi-CK is rather low [48,173, 
294,326,410,434,520], while it is considerably higher in slow-twitch skeletal 
muscle [210,520], the proportion of Mi-CK can be increased within a particu-
lar muscle by endurance training [9] or chronic stimulation [400]. The highest 
proportions of Mi-CK are found in the heart, where Mi-CK was reported to 
constitu te<l-59%of total CKactivity [4,13,40,43,47,48,103,133,202,204,210,245, 
273,327,335,338,350,374,377,378,390,391,410,439,441,459,460,480]. Both the 
upper and lower limit clearly represent over- and underestimations due, for 
example, to incomplete release of Mi-CK from the mitochondrial mem-
branes. The real range may be -10-35 %, with the actual value depending on 
the spedes and the direction of the CK reaction under consideration. Very 
likely, the proportion of Mi-CK correlates very well with the relative impor-
tance of the "transport function" of the CK/PCr system expected for a given 
tissue (for discussion see IV-B.). In absolute terms, highest total CK activities 
are present in skeletal muscle, 2-4-times less in heart and about 10-times less 
in brain [391]. However, in terms of lU/mg mitochondrial protein, the 
specific activity of Mi-CK was found to be equal for all Mi-CK-containing 
tissues of a given species, with a ratio of Mi-CK to ANT molecules of exactly 
one [265,266]. If these findings were true, changes in the absolute amount of 
Mi-CK would directly reflect changes in the percentage of whole cellular 
protein made up by mitochondria. However, a Mi-CK to ANT ratio of 1:1 is 
unlikely since other researchers de termined the concentration of Mi-CK to be 
much lower than that of ANT. ANT was reported to make up about 10 % of 
total mitochondrial protein [for a review see Ref. 248], whereas the relative 
proportion of Mi-CK is < 1 % [355,396,482], maximally 2.5 % [265,384]. 
As far as the evolutionary aspect is concerned, Mi-CK was found in 
echinoderms [359,463-465], fish [50], amphibians [273,511], birds 
[34,210,281,396,397,489,490,516] and mammals [see for example Refs. 
50,167,210,213,268,296,363,374]. Since the CK/PCr system seems to be most 
advantageous for energy metabolism of spermatozoa of the primitive type 
(see IV-B.), and since Cr was detected in sperm of invertebrate species [493], 
these highly specialized cells appear to be most promising for a search for 
Mi-CK in phyla "below" the echinoderms. Mitochondrial arginine kinase 
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(Mi-AK) has been described for crustacean and crab muscles [78,105,106,113] 
as well as for Drosophila [325], whereas most of the molluscs, insects and 
annelids lack Mi-AK [for a review see Ref. 113]. 
Ш-В. Intracellular localization of Mi-CK: Binding to mitochondrial 
inner and outer membranes 
In most studies, Mi-CK was found to be enriched in the mitochondrial 
fraction [103,210,326,338, 410,441], and immunohistochemistry with anti­
bodies directed against Mi-CK also revealed an accumulation of this isoenzyme 
exclusively within mitochondria [396,489,490,496]. Nevertheless, CK of 
cathodic mobili ty resembling Mi-CK was found in the nuclear fractions of rat, 
human and pig heart and skeletal muscle [117,228]. 
Since some mitochondrial subf ractionation experiments were performed 
in phosphate- [246, 350,509] or KCl-containing solutions [278,498], these 
conditions being known to release Mi-CK from the mitochondrial mem­
branes (see II-A.), it is not surprising that Mi-CK was suggested to be soluble 
in the mitochondrial intermembrane space. However, in a number of subse­
quent studies it was proven, instead, that Mi-CK is bound to the outer surface 
of the inner mitochondrial membrane. Rotenone, a strong inhibitor of the 
respiratory chain, inhibited the solubilization of Mi-CK from mitochondrial 
membranes by phosphate [122]. Subfractionation studies in hypotonic tris/ 
phosphate, hypotonic tris/hydrochloride or isotonic sucrose solutions as 
well as with digitonin revealed that most of the Mi-CK remains associated 
with the inner membrane/matrix fraction [3,64,104,208,213,409, 411]. Fur­
thermore, the facts thatMi-CK activity couldnotbe inhibited by atractyloside, 
a competitive inhibitor of adenine nucleotide transport across the inner 
membrane [213,480], and that Mi-CK can be released by phosphate only from 
mitoplasts, but not from intact mitochondria [130] both demonstrate that 
Mi-CK is located inside the outer membrane, but on the "cytoplasmic" side 
of the ANT. Finally, electron microscopical cytochemistry and immunohisto­
chemistry revealed an accumulation of Mi-CK protein along the inner 
mitochondrial membrane [13,380,396,421,496]. 
Recent evidence suggests that Mi-CK is not distributed at random over 
the inner membrane, but may be accumulated in contact sites (CS) between 
the inner and outer mitochondrial membrane. CS are thought to play an 
important role in the mitochondrial production of high-energy phosphates, 
because they were found to increase in extent and number during oxidative 
phosphorylation [40,58,68,249]. In subfractionation experiments of rat brain 
and kidney mitochondrial membranes, Mi-CK was predominantly found, in 
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association with hexokinase I, in a fraction enriched for CS [1,59,256,257]. It 
is likely that Mi-CK in that fraction binds simultaneously to both membranes 
and is functionally coupled to the ANT in the inner and to porin in the outer 
membrane [61] (see ПІ-С). These conclusions are corroborated by the 
following facts:(i) 40-50 % of the total Mi-CK in rat brain mitochondria was 
not readily accessible to external substrates and could only be released from 
the membranes by rather high concentrations of digitonin [1,33,257]. (ii) After 
selective disruption of the ou ter membrane by digitonin, or in isolated contact 
site fractions, König's polyanion, known to inhibit the transport of adenine 
nucleotides through porin [32], inhibited Mi-CK activity by 50 % [1,257]. 
(iii) In inhibition experiments on intact or digitonin-treated mitochondria, 50 
% of the Mi-CK was not accessible to externally added PCr and iodoacetate, 
the latter substance being known efficiently to inhibit purified Mi-CK. A 
reasonable explanation for these findings is that about half of the total Mi-CK 
is buried between the two mitochondrial membranes in the CS, where porin 
is thought to be in its cation-selective s tate, thus creating a microcompartment 
that is fairly inaccessible to externally added anions [257]. 
The localization of Mi-CK within the CS of intact mitochondria in situ 
was further corroborated by electron microscopical immunohistochemistry 
showing an accumulation of gold particles at places where inner and outer 
membranes approach each other [396,496], and by electron microscopical 
cytochemistry displaying a CK-dependent trapping of stain within CS of rat 
heart, brain, retina photoreceptor cells, skeletal muscle and kidney [40,41]. 
Dinitrophenol and amytal, known to reduce the number of CS [58], also 
diminished the proportion of Mi-CK-derived stain within CS [40,41]. 
The ability of Mi-CK to simultaneously interact with two different 
membranes was directly investigated in an in vitro system generated (i) by 
a monolayer of outer membrane lipids or spread outer membranes, and (ii) 
by addition to the subphase of radioactively labelled large unilamellar 
vesicles (LU V's) of inner membrane lipids or inner membranes, respectively. 
Mi-CK proved to be highly efficient in inducing close contacts between the 
monolayer and the vesicles, the octameric form being more potent than the 
dimeric one [333,370]. In contrast to Mi-CK, polylysines not only mediated 
contacts between LUV's and monolayer, but in addition caused membrane 
fusion between them, suggesting that the rather large side-length of the 
Mi-CK octamer is an essential prerequisite to avoid fusion between two 
opposing membranes. These results, however, do not imply that Mi-CK is an 
essential prerequisite for the formation of membrane contacts, since CS were 
also found in rat liver mitochondria known to be devoid of Mi-CK [68,249]. 
Instead, they clearly indicate that the Mi-CK octamer is a structure ideally 
suited for a contact site localization and possibly also for a stabilization of 
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such contacts. Electron micrographs of Mi-CK are fully in line with this 
interpretation, displaying two identical top and bottom faces for the octameric 
molecule and therefore suggesting that both faces have the same potential to 
interact with membranes (see П-С). 
Once it was established that Mi-CK interacts with mitochondrial mem­
branes, the biochemical nature of the "receptor" for Mi-CK binding was 
investigated. Because most Mi-CK isoenzymes can be released from the 
mitochondrial membranes by a variety of different salts in a ionic strength-
dependent manner (see also П-А.), a mainly electrostatic interaction of 
positively charged Mi-CK with negatively charged phospholipids of the 
membranes was assumed [64,278]. Cardiolipin seems to be the most likely 
candidate, since (i) experiments on artificial liposomes composed of defined 
mixtures of phospholipids demonstrated that Mi-CK preferentially binds to 
cardiolipin [324,369], (ii) the binding of Mi-CK to cardiolipin-containing 
liposomes, aqueous dispersions of cardiolipin, as well as to heart and liver 
mitoplasts was inhibited by adriamycin [64,83,324,331], a clinically useful 
anticancer drug which was suggested to specifically interact with cardiolipin 
[80], (iii) treatment of rat heart mi tochondria with phospholipase A2, but not 
with phospholipase С led to the release of Mi-CK, therefore also indicating 
that the interaction is critically dependent on cardiolipin [395], (iv) both inner 
and outer mitochondrial membranes, but not other cellular membranes, 
contain cardiolipin [197], and (v) Mi-CK (see above) as well as cardiolipin [10] 
are highly accumulated in CS. In experiments with cyanogen bromide-
digested rat heart Mi-CK, only one peptide representing the 25 aminoterminal 
residues bound to cardiolipin-containing liposomes, whereby this interac­
tion was also inhibited by adriamycin [82]. In addition, chemical modifica­
tion of arginine and lysine residues of Mi-CK drastically reduced the binding 
of the enzyme to the liposomes. Therefore, it was suggested that the positively 
charged residues Arg-19, Lys-20 and His-21 are responsible for the specific 
binding of Mi-CK to cardiolipin [82,344]. In fact, these three residues are 
absolutely conserved among all known Mi-CK sequences (see Π-F.). How­
ever, it should be kept in mind that the interaction of Mi-CK with cardiolipin 
might not be as specific as originally thought. First, Mi-CK proved to bind 
also to other negatively charged phospholipids like phosphatidyl serine or 
phosphatidyl inositol [81369] as well as to monolayers of spread microsomal 
membranes [369] known to be virtually devoid of cardiolipin [94]. Further­
more, two different classes of Mi-CK binding sites were found on mitoplasts, 
one with high and the other with low affinity [285,395]. The number of high-
affinity binding sites approximately equalled the amount of Mi-CK in heart 
mitochondria [395], but in total, two to fourteen times this amount could be 
rebound to heart and liver mitoplasts [64,131,168,324,395]. Therefore, 
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cardiolipin may constitute the low-affinity binding si tes. The isoelectric point 
of octameric and dimeric Mi-CK may be a last argument for a ionic interaction 
of this isoenzyme with the mitochondrial membranes [354]. Mi-CK octamers 
have a higher isoelectric point than the corresponding dimers (see Π-D.), and, 
as a matter of fact, octameric Mi-CK was found to be the exclusive or 
predominant oligomeric form being bound to the mitochondrial membranes 
(see ni-D.). 
Whereas Cheneval et al. [83] obtained no evidence for penetration of 
Mi-CK into a membrane bilayer, monolayer experiments with spread 
mitochondrial membranes or membrane lipids clearly showed an increase in 
surface pressure upon binding of chicken sarcomeric Mib-CK, suggesting 
that Mi-CK penetrates into the hydrophobic domain, at least under the 
experimental conditions used [369,370]. This phenomenon can be ascribed to 
the hydrophobic nature of Mi-CK (see II-A.) and is also in agreement with 
experiments on the extraction of Mi-CK from chicken heart mitoplasts which 
were indicative for a small nonpolar effect [64]. Furthermore, detergents had 
to be used for an optimal release of Mi-CK from rat heart [395], human skeletal 
muscle [434] and sea urchin sperm mitochondria [463,464317]. 
As an alternative to cardiolipin, ANT may be suggested to act as a 
"receptor" protein for Mi-CK [376,380], since a variety of studies revealed a 
functional coupling between Mi-CK and ANT of the inner membrane (see Ш-
C). However, incubation of Mi-CK with ANT-containing liposomes [324] as 
well as crosslinking experiments [406] failed so far to demonstrate such a 
relationship. In addition, electrostatic repulsion of the two very basic proteins 
was taken as an argument against a direct interaction between Mi-CK and 
ANT [278]. However, a specific interaction of certain domains of both 
proteins can not be ruled out by the mere fact that both proteins have an 
overall positive charge. 
In conclusion, Mi-CK is primarily attached to the outer surface of the 
inner mitochondrial membrane, but, within CS, additionally interacts with 
the outer membrane as well. Binding of Mi-CK molecules exclusively to the 
outer membrane was never observed in situ. The interaction of Mi-CK 
octamers with the mitochondrial membranes seems to be mostly due to an 
electrostatic interaction of positively charged Mi-CK with negatively charged 
phospholipids like cardiolipin, but hydrophobic interactions as well as the 
existence of a specific receptor (protein) can not yet be ruled out. The question 
of whether the release of Mi-CK from the membranes into the intermembrane 
space by phosphate ions or other effector molecules is of physiological 
importance remains to be elucidated. Rojo et al. [370] recently showed that 
Mi-CK octamers and, to a much lesser extent, Mi-CK dimers are able to 
mediate contact formation between two mitochondrial membranes. This 
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data, together with the finding of functional coupling between Mi-CK and 
ANT of the inner as well as porin of the outer mitochondrial membrane 
provoked alternative ideas about the functional involvement of Mi-CK in CS, 
as will be discussed in the next chapter. 
Ш-С. Functional coupling 
Besides the still existing controversy in assigning an exclusive "buffer" or 
"transport function" to the CK/PCr system (see IV-B.), the question of how 
PCr production is coupled to mitochondrial oxidative phosphorylation is 
also heavily disputed. Therefore, this topic will be discussed here in more 
detail. Already in 1911, Thunberg [461] realized that addition of Cr to a 
respiring muscle homogenate results in increased oxygen uptake. In isolated 
respiring mitochondria from cardiac and skeletal muscle as well as brain, Cr 
together with catalytic amounts of ADP or ATP also stimulates oxygen 
consumption [34,122,153,213,319,377,381,439,480,521]. This is due to Mi-CK 
continuously regenerating ADP from ATP, produced by oxidative 
phosphorylation, and Cr. The ADP, in turn, further stimulates oxygen 
consumption. The stimulatory effect is dependent on the concentration of Cr, 
with Cr-stimulated respiration approaching the state-3 rate [34,213]. Under 
the conditions described, PCr is the net product of oxidative phosphorylation 
[54,213,319,374,377]. Most importantly, the Mi-CK content of heart 
mitochondria is sufficient to transphosphorylate all of the ATP produced by 
oxidative phosphorylation to PCr at all rates of respiration [213,374,381,480]. 
A large number of subsequent studies demonstrated that on one hand, 
Mi-CK has "privileged access" to ATP, produced in the mitochondrial matrix 
by oxidative phosphorylation, over externally added (extramitochondrial) 
ATP, and that on the other hand, the ANT preferentially transports ADP 
liberated by Mi-CK over externally added ADP. In other words, Mi-CK and 
oxidative phosphorylation seem to be functionally coupled in some way or 
another. The major evidence supporting this view shall now be summarized: 
(a) For PCr production, the K
m
 value for ATP of intact mitochondria 
[119,120,216,380,381] ormitoplasts [384] is significantly lower when ATP 
is produced within the matrix by oxidative phosphorylation, than when 
ATP is added externally. Due to this decreased K
m
 value for ATP, PCr 
synthesis by intact, respiring mitochondria, compared to rotenone- plus 
oligomycin-inhibited mitochondria with externally added ATP, is less 
susceptible to product inhibition by PCr [216,381]. In other words, at 
identical ATP and Cr concen trations in the surrounding medium, the rate 
of PCr production is much higher when oxidative phosphorylation is 
34 CHAPTER 2 
activated compared to when it is inhibited [375,376,381] and therefore is 
also much higher than calculated from the substrate concentrations in the 
medium and the kinetic constants of Mi-CK [375]. 
(b) Similarly, ADP produced in the intermembrane space by Mi-CK proved 
to be much more potent (lower K
m
 value) in stimulating oxidative 
phosphorylation than ADP which was externally added or produced by 
hexokinase [65,218,220,320]. Accordingly, much less atractyloside/mg 
mitochondrial protein was needed to suppress respiratory stimulation by 
externally added ADP than for stimulation by ADP produced by Mi-CK 
[320,384]. Furthermore, the uptake of [3H]-labelled ADP or ATP into 
respiring mitochondria was found to be high in the absence, but much 
lower in the presence of Cr or PCr, respectively, thus suggesting as well 
that ADP or ATP produced by Mi-CK has preferential access to the ANT 
over externally added ADP or ATP [20,266,385]. 
(c) Externally added phosphoenolpyruvate (PEP) plus pyruvate kinase (PK) 
fully suppressed respiratory stimulation when ADP was produced in the 
extramitochondrial compartment by hexokinase, but only partially di­
minished the stimulatory effect of ADP produced in the intermembrane 
compartment by Mi-CK [145,147,148,257,384,386]. 
(d) After short incubations of respiring rabbit heart mitochondria with 
γ-[32Ρ]-ΑΤΡ and Cr, the specific radioactivity of PCr was only 36 % of that 
of ATP [522]. However, if mitochondrial respiration was uncoupled by 
carbonylcyanide m-chlorophenyl hydrazone or inhibited by atractyloside, 
the specific radioactivi ties of PCr and ATP were the same. These findings 
indicate that intra- and extramitochondrial ATP do not readily equili­
brate and that Mi-CK has preferential access to intramitochondrial ATP. 
The same conclusions were drawn from similar labelling experiments 
with γ-[32Ρ]-ΑΤΡ or [33P]-phosphate [118-120]. 
(e) Under identical experimental conditions, intact rat heart mitochondria 
produced 2.3 times the amount of PCr as rat liver mitochondria contain­
ing no Mi-CK themselves, but to which the same quantity of Mi-CK had 
been added externally [380]. 
(f) Whereas all experiments described so far deal with kinetic effects, a 
thermodynamic approach was chosen by DeFuria et al. [98] and Saks et 
al. [384,386] to shed more light on Mi-CK function. Normally, the mass 
action ratio of the CK substrates,r= [Mg ADP"] [PCr2"] [H+] / [Mg ATP2"] [Cr], 
relative to the equilibrium constant K, determines in which direction the 
reaction will proceed. An approximation to the equilibrium state of the 
reaction is reflected by a diminuition of the difference between Γ and K. 
Whereas partially purified Mi-CK or Mi-CK in inhibited, non-respiring 
mitochondria obeyed this thermodynamic law, PCr production in re­
spiring mitochondria or mitoplasts still proceeded even when Γ > К. 
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Although some experiments described above have been criticized and 
conflicting reports have been presented [4,5,54,55,279], it is now generally 
accepted that a functional coupling between Mi-CK and oxidative 
phosphorylation indeed exists. Two alternative explanations have mainly 
been proposed as basis for this coupling. On one hand, Mi-CK may be bound 
to the inner membrane in close proximity to or directly associated with the 
ANT, thus creating a microenvironment enabling efficient metabolic chan­
nelling of substrates between the catalytic sites of both enzymes [20,145,218, 
220,266,267,320,375,376,380-382,384-387]. On the other hand, the outer 
mitochondrial membrane might act as a diffusion barrier for adenine 
nucleotides, leading to concentration gradients over the outer membrane 
[38,65,98,118,119,147,148,218,220]. In this latter case, substrate concentra­
tions in the surrounding medium would not reflect those experienced in the 
intermembrane space. 
Whereas most of the arguments mentioned above (a-f) are compatible 
with both ideas, several experiments favour a direct interaction between 
Mi-CK and ANT. Phosphate and high concentrations of chloride ions are 
known to release Mi-CK from mitoplasts (see Π-Α.) and can therefore also be 
assumed to detach Mi-CK from the membranes in intact mitochondria. 
Incubation of intact mitochondria in phosphate- or chloride-containing 
media significantly raised the K
m
 values of Mi-CK for ADP and ATP [474] and 
drastically reduced the functional coupling between Mi-CK and oxidative 
phosphorylation [169,170,267,387], suggesting that the binding of Mi-CK to 
the membranes and possibly to ANT is mainly responsible for the kinetic 
coupling. The observation of functional coupling not only in intact 
mitochondria, but also in mitoplasts, supports this view [384,386]. Further­
more, in rat heart mitoplasts, rabbit anti-rat Mi-CK antibodies affected 
neither Mi-CK nor ANT activity, whereas chicken anti-rat Mi-CK antibodies 
inhibited Mi-CK and ANT activity as well as the rate of oxidative 
phosphorylation approximately to the same extent [266,382,385]. Removal of 
Mi-CK from the mitoplast membranes by 150 mM KCl plus 20 mM ADP 
completely abolished these inhibitory effects, thus suggesting an intimate 
functional and structural interaction of Mi-CK and ANT, with the catalytic 
sites of both enzymes lying side by side. 
In contrast, the ANT inhibitors atractyloside and carboxyatractyloside 
hadnoeffectonthekineticpropertiesofMi-CK-innon-respiringmitochondria, 
arguing that the active sites of Mi-CK and ANT do not simply overlap 
[146,474]. Instead, the outer mitochondrial membrane as a diffusion barrier 
for adenine nucleotides was suggested to be responsible for the functional 
coupling on the basis of the following experiments: 
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(a) Labelling studies with pPj-phosphate demonstrated that selective da-
mage or removal of the outer mitochondrial membrane by digitonin 
abolishes the functional coupling between Mi-CK and oxidative 
phosphorylation [119]. Furthermore, approximately equal Km values of 
Mi-CK for ATP were found for respiring, digitonin-treated mitochondria, 
for atractyloside-inhibited, digitonin-treated mitochondria, as well as for 
respiring intact mitochondria, whereas the corresponding value for 
atractyloside-inhibited, intact mitochondria was significantly higher. 
(b) Under conditions where 70 % of Mi-CK was membrane-bound, the Km 
value of Mi-CK for ATP in respiring as well as in oligomycin-inhibited 
mitoplasts was indistinguishable from the corresponding value of the 
soluble enzyme, while it was significantly lower in respiring and much 
higher in oligomycin-treated intact mitochondria [65]. 
(c) As already mentioned above, externally added pyruvate kinase (PK) plus 
phosphoenolpyruvate (PEP) fully suppressed the respiratory stimulation 
of ADP produced by hexokinase [145,147,148,386]. However, if ADP was 
liberated either by membrane-bound Mi-CK or by the intermembrane 
space protein adenylate kinase, PK/PEP in both cases inhibited the 
respiratory stimulation by ADP only partially and approximately to the 
same extent, indicating that diffusion limitation by the outer membrane 
is more likely to be responsible for the functional coupling of Mi-CK and 
ANT than interaction of Mi-CK with the inner membrane [148]. 
Finally, membrane energization, alkalinization near the mitochondrial mem-
branes as well as unstirred layer effects were also taken into consideration to 
explain the functional coupling, but most of these possibilities have been 
dismissed as sole explanation for the observed phenomena, although in 
combination with each other they may play an important role 
[147,169,218,220,320,381,474]. To conclude, the experiments performed sofar 
do not allow a definite answer to be given on the true basis for the functional 
coupling between Mi-CK and oxidative phosphorylation. In fact, depending 
on the metabolic state, one, two or all of the mechanisms mentioned above 
may be operational at the same time. 
However, many recent experiments argue for a third explanation of the 
functional coupling, thatofmicrocompartmen ta tion and metabolite channel-
ling within the CS. Four new aspects have opened the door to this fascinating, 
alternative explanation (Fig. 2; page 38). First, porin of the outer mitochondrial 
membrane was recognized as a voltage-dependent channel for polar 
metabolites and is therefore also known as voltage-dependent anion-selec-
tive channel (VDAC) [87]. Below a membrane potential of 30 mV, porin is 
anion-selective, whereas above 30 mV, it adopts a different state which is 
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characterized by a lower conductance and cation-selectivity [125,135,291,371]. 
In this latter state, ADP and ATP are excluded from transport by porin 
[32,33,59,61]. It was assumed that within the CS between the mitochondrial 
inner and outer membranes, the cation-selective state of porin is induced by 
"capacitive coupling" to the membrane potential of the inner membrane. 
Beyond the CS, where the distance between inner and outer membrane 
would be too large to allow capacitive coupling, porin is thought to be in its 
anion-selective state [33,61]. Second, Mi-CK was found to be enriched in 
mitochondrial CS where its activity is "latent" [1,59,257] (see also ΠΙ-Β.). In 
other words, Mi-CK within the CS is not readily accessible to externally 
added substrates. Furthermore, König's polyanion, known to block porin, 
reversibly inhibited the activity of Mi-CK within the CS by cessation of the 
adenine nucleotide diffusion through the outer membrane [257]. And finally, 
Mi-CK within the CS was neither accessible to product inhibition by the 
negatively charged substrate PCr nor to irreversible inhibition by negatively 
charged iodoacetate [257]. Third, structural analysis of Mi-CK revealed an 
intriguing octameric structure with two identical top and bottom faces and 
either central indentations in these two faces or a channel through the 
molecule (see П-С). And fourth, Mi-CK was found to be able to interact 
simultaneously with two different membranes probably due to its identical 
top and bottom faces [370]. 
In the two alternative models depicted in Fig. 2, all of these findings were 
taken into account. Within the CS, Mi-CK is buried between the two 
mitochondrial membranes where it is functionally (and structurally?) cou­
pled to ANT of the inner and porin of the outer mitochondrial membrane. It 
may even be hypothesized that octameric Mi-CK, tetrameric ANT [484], 
oligomeric (tetrameric?) porin [259,276] and possibly also tetrameric 
hexokinase [519] form a highly ordered multi-enzyme complex allowing 
efficient substrate channelling. In the CS, Mi-CK has preferential access to 
ATP produced by oxidative phosphorylation within the mitochondrial 
matrix. According to the first model [61,492] (Fig. 2A), Cr is "presented" to 
Mi-CK by porin in its cation-selective state. Mi-CK activity liberates ADP, 
which is preferentially and directly re-taken up into the matrix, as well as PCr, 
which as the net product of oxidative phosphorylation leaves the mitochondria 
beyond the CS through porin in its anion-selective state. This model has the 
disadvantage that newly synthesized PCr would equilibrate with the substrate 
pools in the remaining intermembrane space before its export out of the 
mitochondrion. Accordingly, it seems unlikely that the cytosolic 
phosphorylation potential in this case could be sensed by the mitochondria, 
either within or beyond the CS. 
This problem is circumvented by the second model (Fig. 2B). ANT, Mi-CK 
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Fig. 2. Structure and function of Mi-CK mthin the mitochondrial intermembrane space with 
special reference to the contact sites. 
Within CS (surrounded by a dashed line), exclusively octameric Mi-CK interacts 
with both the inner (IM) and the outer mitochondrial membrane (OM) and is 
thought to be functionally coupled to ANT of the inner and porin (P) of the outer 
membrane. Below the contacts, Mi-CK may be dimeric or octameric, and it may be 
either bound to the inner membrane or free in the intermembrane space. In contrast 
to Mi-CK, adenylate kinase (AdK) is not firmly bound to the membranes. In both 
models, it is schematically indicated that two different microcompartments for CK 
substrates exist within and beyond the CS. Due to this microcompartmentation, 
PCr production by Mi-CK may still proceed even at a high cytosolic ATP/ADP 
ratio. Note that by the schematic representation it is not intended to suggest that 
Mi-CK is only active within the CS. Furthermore, it should not be inferred that 
below the CS, the two mitochondrial membranes are far from each other. In fact, 
electron microscopic analysis of insitu mitochondria revealed that the mitochondrial 
inner and outer membrane form a 5-layered structure with a width of only 12 nm, 
whereas a 7-layered structure would be expected for two separated membranes 
[295]. (A) Within CS, porin is in its cation-selective state and therefore only 
permeable to Cr. Porin beyond the CS is in i ts anion-selective state and thus allows 
diffusion of ATP, ADP and PCr through the outer membrane. (B) Tetrameric ANT, 
octameric Mi-CK and (tetrameric) porin form a highly organized multienzyme 
complex and thereby create a microcompartment allowing efficient substrate 
channelling between the three enzymes. PCr is produced within the central channel 
of the octameric Mi-CK molecule and is directly pulled out of the mitochondria by 
electrostatic repulsion through the superimposed porin molecule. For simplicity, 
the subunit "boundaries" were orni tted in the Mi-CK octamer localized within the 
CS. For further details see the text. 
and porin form a contiguous channel spanning both mitochondrial mem-
branes. PCr is produced within the channel and is directly exported to the 
cytosol where it rapidly equilibrates with the cytosolic PCr/Cr and 
ATP/ADP pools through the action of the cytosolic CK isoenzymes which are 
thought to be in a near-equilibrium state [205,262,298,310]. PCr production 
even at a high cytosolic phosphorylation potential may be accomplished by 
"active" expulsion of PCr from the channel possibly due to electrostatic 
repulsion. On the other hand, the cytosolic phosphorylation potential could 
be sensed by the mitochondria in regions beyond the CS. Clearly, elucidation 
of the structural and functional involvement of octameric Mi-CK in the CS 
will be an exciting task for future studies and may establish the existence of 
a multi-enzyme complex suited for metabolic channelling [442,443]. 
Independently of both models, Mi-CK is not restricted to the CS, as was 
shown by in situ localization studies [396,496] and biochemical experiments. 
In rat brain mitochondria, only 50 % of the total Mi-CK activity was "latent" 
and not susceptible to inhibition by PCr or iodoacetate [1,257]. Furthermore, 
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since CS are dynamic structures changing in number and extent depending 
on the metabolic state of the mitochondria (see Ш-В.), the proportion of 
Mi-CK within the CS is also supposed to correlate with the respiratory rate. 
Accordingly, dpher 1 in Fig. 2 indicates the dynamic equilibrium between 
the two Mi-CK localizations "in" and beyond" the CS. Whereas it is highly 
likely that exclusively octameric Mi-CK is present in the CS [257,370], 
reversible changes in the dimer to octamer ratio (ciphers 2 and 4) as well as 
dissociation and reassociation of Mi-CK from and to the inner membrane 
(ciphers 3 and 5) may be important regulatory parameters beyond the CS 
[399] (see also III-D.). Usually, dissociation of Mi-CK octamers into dimers is 
accompanied by the release of Mi-CK from the membranes, and vice versa 
[296,399]. In turn, release of Mi-CK from the inner membrane may abolish the 
functional coupling between Mi-CK and ANT, thus potentially diminishing 
the overall Mi-CK reaction rate. Finally, Mi-CK dimers, when bound to the 
inner membrane, reassociate to octamers, a process which is probably 
facilitated by lateral diffusion of the dimers on the membrane [399]. 
The involvement of Mi-CK in a specialized structure like the CS is highly 
indicative for a metabolic advantage of this location. The facts that Mi-CK 
within the CS is "buried", that it is protected from inhibition by PCr and 
iodoacetate, and that its activity is "latent" strongly suggest that CS represent 
a special microcompartment with substrate concentrations differing from 
those in the remaining intermembrane space as well as in the 
extramitochondrial compartment(s), an assumption that has been corrobo­
rated by experiments on hexokinase and glycerol kinase bound to 
mitochondrial CS [36,58,155,161; for reviews see Refs. 1,60,61]. In liver 
mitochondria, for example, hexokinase and adenylate kinase usually share 
the same adenine nucleotide pool. However, 5 μΜ Ca2+, known to increase 
the number of CS, resulted in metabolic separation of the two enzymes [58]. 
Interestingly, in intact respiring rabbit heart mitochondria containing both 
hexokinase, bound within the CS at the outer surface of the outer membrane 
to porin, as well as Mi-CK, the formation of glucose-6-phosphate was 
depressed by creatine at a low ATP/ADP ratio. However, glucose had no 
effect on PCr production, indicating that Mi-CK has preferential access over 
mitochondrial hexokinase to ATP produced in the matrix [55]. Accordingly, 
even within the CS, rapid equilibration of substrate concentrations does not 
occur. 
The assumption of a separate microcompartment for adenine nucleotides 
within the CS (see also IV-C.) has dramatic consequences for total cellular 
energy metabolism. First, it may explain why the cytosolic ATP/ADP ratio 
is considerably lower in liver than in muscle [179,247,440]. In liver lacking 
Mi-CK, the inner membrane potential seems to be the primary determinant 
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of the cytosolic ATP/ADP ratio. In muscle, however, the functional coupling 
of Mi-CK and ANT within the CS, the particular substrate concentrations 
experienced in this microcompar tment, and the vectorial export of PCr out of 
the mitochondria before equilibration with the substrate concentrations 
beyond the CS may allow the build-up of a higher ATP/ADP ratio and 
therefore also of a higher phosphorylation potential in the cytosol. Second, 
the localization of Mi-CK, hexokinase, glycerol kinase and nucleoside 
diphosphate kinase within the CS [1,2,59] seems to be especially relevant, 
since all of them, due to their involvement in the regulation of the energy 
metabolism and/or in the export of high-energy phosphates out of the 
mitochondria, influence the cytosolic phosphorylation potential. In contrast, 
adenylate kinase, thought to protect the cell from an accumulation of ADP 
[492], is not found within the CS and is not or only partially bound to 
mitochondrial membranes. And third, microcompartmentation within the 
CS may account for the finding that mitochondrial PCr production still 
proceeds even if, on the basis of total (intra- and extramitochondrial) 
substrate concentrations, the opposite CK reaction direction is favoured 
[98,384,386]. 
To conclude, it is now largely accepted that functional compartmen tation 
of Mi-CK within the mitochondrial intermembrane space is an essential 
prerequisite for efficient mitochondrial PCr production. However, it is not 
yet completely clear whether this compartmentation is due only to an 
interaction of Mi-CK with ANT, to diffusion limitations by the outer 
mitochondrial membrane, to both of these effects, or to microcompartmentation 
and metabolic channelling within the CS. A variety of recent studies favour 
the latter hypothesis. Consequently, in any description or mathematical 
modelling of mitochondrial PCr production in particular and of total cellular 
energy metabolism in general, the particular substrate concentrations expe-
rienced in the CS, together with the fact that the substrate concentrations 
within the CS are no t in equilibrium with those of the cy tosol, have to be taken 
into account. The same holds true for the interpretation of in vivo 31P-NMR 
measurements. 
III-D. Dynamic regulation of the octamer to dinter ratio 
Before anything was known about the molecular size of Mi-CK, two distinct 
cathodically migrating bands with Mi-CK activity were often observed using 
cellulose acetate, agarose and acrylamide gel electrophoresis at pH 8.0-8.8 
[166,222,268,374,502]. These two bands were readily interconvertible, there-
fore indicating that they were not due to different Mi-CK isoenzymes [166]. 
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Instead, they could be assigned to two distinct oligomeric forms of the same 
isoenzyme [100,167,504]. The band moving faster to the cathode corresponds 
to octameric Mi-CK with a M
r
 of approximately 350 000, and the more slowly 
migrating band represents dimeric Mi-CK with a M
r
 of approximately 85 000 
[231,296,516]. The existence of two different, readily interconvertible 
oligomeric forms was subsequently corroborated by several techniques (see 
Π-Β.). In only two experiments, acrylamide gel electrophoresis [100] and 
isoelectric focussing of bovine heart Mi-CK [282], additional Mi-CK bands 
were observed which were interpreted as tetrameric, hexameric and/or 
aggregated Mi-CK. However, in the light of the uncertainties inherent in the 
methods employed and the overwhelming body of evidence demonstrating 
no intermediate forms between dimers and octamers, these findings have to 
be seriously questioned. 
Once it was realized that the two distinct oligomeric forms of Mi-CK 
might be of physiological importance, several groups searched for factors 
influencing the dimer to octamer ratio in vitro. This ratio is not influenced by 
the temperature (5-20oC) and the nature of the monovalent anions (chloride, 
nitrate or acetate) or cations (Na+ or K+) in the buffer used at ionic strengths 
between 0.02 and 0.25 M [280,281 ]. In contrast, it is strongly dependent on the 
Mi-CK concentration itself. The proportion of octamers rises as the Mi-CK 
concentrationisincreased[26,100,123,166,167,287,396,397,516].Thedimerto 
octamer ratio also depends on the pH value of the medium, with dissociation 
into dimers being more pronounced at alkaline pH values [280-
282,296,396,483]. Furthermore, partial or complete dissociation of octamers 
into dimers can be achieved by exceedingly high concentrations of 
2-mercaptoethanol [100,166,167,448,502,504], freezing and thawing [281,396], 
low ionic strength conditions [281,282], 1 M KCl [296], p-hydroxy-
mercuribenzoate (Wyss, M. and Wallimann, T., unpublished data) and 1-8 M 
urea [26,123,156,231,296,403]. The mode of action of 2-mercaptoethanol is 
unclear since several weak and strong oxidizing agents did not reverse its 
effect [502]. Upon incubation of Mi-CK octamers with urea, dimers are first 
formed and only on a much slower time-scale, or at higher urea concen­
trations, monomers also appear [26,403], indicating that the intersubunit 
interactions are much stronger within a dimer than between adjacent dimers 
within an octamer (see also II-C.). 
Single CK substrates and "unproductive" substrate combinations on one 
hand were reported not to influence the dimer to octamer ratio 
[280,281,296,396,483]. On the other hand, 4 mM MgADP or MgATP led to 
partial dissociation of octameric chicken ubiquitous Mi
a
-CK into dimers 
[398], suggesting that the stability of octamers differs between Mi-CK 
isoenzymes. In contrast, equilibrium substrate combinations (MgADP + 
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MgATP + Cr + PCr) and formation of a transition state-analogue complex of 
Mi-CK (Mi-CK + MgADP + Cr + nitrate) in all instances resulted in fast 
dissociation of the octamers [280-282,287,296,396,399,483,516]. However, 
even in the presence of MgADP, Cr and nitrate, the dimer to octamer ratio still 
depended on the Mi-CK concentration, but at any given concentration, the 
proportion of octamers was lower than in the absence of substrates [516]. At 
last, Lipskaya and co-workers [280,281 ] concluded from a limited set of data 
that at physiological concentrations of ATP and ADP, the dimer to octamer 
ratio of bovine heart and pigeon breast muscle Mi-CK correlates with the Cr/ 
PCr ratio. This finding may be explained by the fact that with changes in the 
Cr/PCr ratio, the probability that Mi-CK simultaneously binds two comple­
mentary substrates (ADP + PCr or ATP + Cr) also varies. Simultaneous 
binding of two complementary substrates in its turn is expected to have the 
same effect as formation of a transition state-analogue complex of Mi-CK, 
namely to dissociate octamers into dimers. 
As far as the kinetic aspect is concerned, the new equilibrium state 
between dimers and octamers after formation of a transition state-analogue 
complex of Mi-CK is already reached after 15 minutes [296,396,483], whereas 
it is approached very slowly in the absence of substrates [281,396]. Such a 
minute time-scale is clearly sufficient to envisage a physiological role for the 
dimer to octamer interconversions of Mi-CK (see ІП-С. and Fig. 2; page 38). 
Compared to all these findings, virtually no factors stabilizing octamers are 
known. p-Aminobenzamidine was reported to inhibit octamer dissociation 
induced by formation of a transition state-analogue complex of Mi-CK [296]. 
Furthermore, p-aminobenzamidine as well as benzamidine result in partial 
reassociation of dimers into octamers [396]. Finally, inorganic phosphate 
leads to an increased proportion of octamers as well, but only in the presence 
of CK substrates [280]. 
Now that in vitro some factors influencing the dimer to octamer ratio are 
known, the questions of whether changes in the oligomeric state of Mi-CK 
also occur in vivo and if they have any physiological bearing have yet to be 
answered. Radiation inactivation [353,483] and crosslinking experiments 
[284] revealed that the Mi-CK octamer very likely is the only oligomeric form 
bound to intact bovine and rabbit heart mitochondria. This was further 
corroborated with antibodies against purified pig and rabbit heart Mi-CK 
which allowed the discrimination between dimeric and octameric Mi-CK 
[355,483]. In extraction experiments, the vast majority of Mi-CK was released 
from the mitochondrial membranes in its octameric form, independently of 
the releasing agent used [284,296,399,483]. Dissociation into dimers, if it 
happened, only occurred in solution and on a slower time-scale than the 
release of Mi-CK from the membranes. Whereas exclusively octameric 
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Mi-CK could be rebound to pig and rabbit heart mitoplasts [296,483], both 
dimers and octamers rebound to chicken heart mitoplasts [399]. The rebinding 
of both oligomeric forms was strongly pH-dependent, and sharply decreased 
between pH 7.5 and 8.1 for dimeric Mi-CK, but only above pH 8.1 for 
octameric Mi-CK. Therefore, Mi-CK octamers rebound preferentially over 
dimers to mitoplasts at intermediate pH values around 8.0. Since octamers 
have a higher isoelectric point than dimers (see Π-D.) and since the interaction 
of Mi-CK with membranes seems to be mostly ionic in nature (see Ш-В.), 
octameric rather than dimeric Mi-CK is indeed expected to bind more 
strongly to negatively charged groups of the membranes [354,399]. Finally, 
Mi-CK dimers, once bound to the mitochondrial membranes, partially 
reassociate into octamers [399], thus emphasizing that octameric Mi-CK may 
be favoured even more so under in vivo conditions. 
The above findings were further extended by differential digitonin 
extraction of Mi-CK from rat brain mitochondria [257]. Mostly octameric 
Mi-CK was present in intact mitochondria, and dimeric Mi-CK could be 
released from the membranes more easily than octameric. Most importantly, 
exclusively octameric Mi-CK seems to be enriched in CS between 
mitochondrial inner and outer membranes where it is thought to play an 
essential role in mitochondrial PCr production (see ПІ-С). Octamers, in 
contrast to dimers, appear to be ideally suited for a CS localization. Due to 
their identical top and bottom faces, they can simultaneously interact with 
two opposing membranes, as was directly shown in in vitro experiments 
where octameric proved to be much more potent than dimeric Mi-CK in 
inducing close contacts between a spread membrane monolayer and large 
unilamellar membrane vesicles [370]. To conclude, the octameric form of 
Mi-CK seems to be an indispensable prerequisite for the efficient functional 
coupling between Mi-CK and oxidative phosphorylation (see also Ш-С.). 
The existence and physiological importance of dimeric Mi-CK in vivo 
may be questioned by the fact that the Mi-CK concentration in the 
intermembrane space was estimated to be in the range of 3.5-17.2 mg/ml 
[280,396]. At these same concentrations in vitro, Mi-CK is predominantly 
octameric, even under conditions most strongly favouring dissociation into 
dimers, namely formation of a transition state-analogue complex [516]. Thus, 
one is inevitably led to the question of whether dimeric Mi-CK represents 
only a test-tube "artifact" or not. The possibility of its involvement in the 
regulation of mitochondrial energy metabolism should, however, not yet be 
dismissed since (i) interaction of Mi-CK octamers and dimers with 
mitochondrial membranes as well as the octamer to dimer ratio are sensitive 
to physiologically important parameters like pH and the concentration of 
Mi-CK substrates; (ii) a small, but significant fraction of Mi-CK is always 
released in its dimeric form from intact mitochondria; and (iii) Mi-CK 
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isoenzymes from different species and tissues form octamers varying in 
stability. E. g., pig heart and chicken ubiquitous Mi-CK dissociate much more 
readily into dimers than rabbit heart and chicken sarcomeric Mi-CK, respec-
tively [296,397,483,516]. 
Alternatively, different conformations of Mi-CK rather than two 
oligomeric forms may be envisaged as a decisive factor for the regulation of 
mitochondrial energy metabolism. Changes in the octamer to dimer ratio 
may simply reflect changes in conformation, with octamers being more stable 
in one conformation rather than the other(s) [281,296,398]. This view is 
supported by a variety of experiments (fluorescence and EPR spectroscopy, 
inhibition and crystallization experiments, etc.) suggesting thatCK isoenzymes 
undergo conformational changes upon substrate binding [39,238,405,506]. 
Furthermore, conformational changes might also explain why the effects of 
some agents on the dimer to octamer ratio and on the release of Mi-CK from 
the mitochondrial membranes parallel each other. In fact, MgADP, formation 
of a transition state-analogue complex, high chloride concentrations as well 
as p-hydroxymercuribenzoate all efficiently release Mi-CK from the inner 
mitochondrial membrane and, in addition, dissociate octamers into dimers 
[281,296; Wyss, M., Schlegel, J. and Wallimann, T., unpublished data] (see 
also II-A.). However, this parallelism may not be that strict since in the case 
of rabbit heart Mi-CK, p-aminobenzamidine only inhibited the dissociation 
of Mi-CK octamers into dimers, bul not its release from the mitochondrial 
membranes [296]. 
In dimeric bovine heart Mi-CK, the "essential" sulphydryl groups of 
both subunits react readily and with the same rate with alkylating agents 
[123]. Additionally, both subunits of rabbit MM-CK bind substrates [124]. 
Conversely, only half of the subunits of octameric bovine heart Mi-CK bind 
substrates and are readily accessible to sulphydryl group reagents [123,124]. 
Clearly, also in this case, conformational changes may be the underlying basis 
for the observed phenomena. 
Finally, bovine heart Mi-CK octamers were found to have a more than 
two-fold higher specific enzymatic activity than dimers [123], whereas others 
observed no significant difference in this parameter for dimeric and octameric 
chicken and bovine heart Mi-CK [100,396]. To conclude, the question of 
whether changes in the dimer to octamer ratio or simply in the conformation 
of Mi-CK are essential for the regulation of mitochondrial oxidative 
phosphorylation and PCr production deserves full attention in the future. 
Recombinant techniques are likely to be a powerful tool for the direct 
comparison of properties between native (octameric) Mi-CK and dimeric 
cytosolic CK, to which by genetic engineering a mitochondrial target peptide 
is attached, thus allowing its import into the interpiembrane space. 
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Ш-Е. Developmental changes 
Studies on the developmental changes of the CK isoenzyme system were 
conducted mainly with heart and skeletal muscle as well as with brain and 
retina of a variety of species including man [18,107,108,115,165, 
199,200,292,335,435,455,496,500,530]. In all cases, these studies revealed a 
complex pattern of isoenzymes appearing and disappearing during develop­
mental maturation. Total CK activity considerably increases during the last 
stages of fetal development of cardiac and skeletal muscle of mouse, rat, 
rabbit, sheep and man [199,200,202,435]. Whereas total CK activity continues 
to rise postnatally in the mammalian heart [18,107,108,199,335,473], the 
specific CK activity was either found to increase [107,108,473] or to remain 
constant [192]. During postnatal brain development, total CK activity in­
creases markedly at a time when a greater coordination of complex nervous 
activity is becoming apparent. Furthermore, the similar developmental 
patterns of CK and hexokinase suggest that CK is involved in the overall 
coordination of energy metabolism and neuro transmission in the fully active 
adult brain [53,335]. 
The CK isoenzyme distribution is both tissue-dependent and develop­
mental stage-specific. In mammalian brain as well as in heart and brain of 
birds, BB-CK is the major CK isoenzyme at all stages of development. In 
contrast, in skeletal muscle of birds and mammals as well as in mammalian 
myocardium, a developmental transition from B-CK to M-CK mRNA and 
therefore also from BB-CK over MB-CK to MM-CK protein dimers takes place 
prenatally [115,292,466]. In mouse heart, the transition from BB-CK to 
MM-CK happens during the last trimester of fetal development, whereas 
after birth, comparatively small changes in the proportion of the cy tosolic CK 
isoenzymes are observed [165,199]. In human skeletal muscle, the BB- to 
MM-CK transition takes place around week 8 of fetal development, in 
contrast to human heart where MM-CK predominates from the earliest stage 
examined onward, i.e. 4 1/2 weeks of embryonic development [500]. 
Similarly, the developmental transition from B-CK to M-CK expression 
occurs earlier in heart compared to skeletal muscle of the rat [466]. Finally, 
stage-dependent regional differences in the expression of cytosolic CK 
isoenzymes were observed in the prenatal de velopmen t of the rat heart [176]. 
For example, MM-CK was first observed in the outflow tract and the 
trabeculae of the right ventricle at embryonic days 12-14 and only at later 
developmental stages in other parts of the heart. 
As far as Mi-CK is concerned, developmental studies stress its impor­
tance for energy metabolism. In all tissues and species examined, the Mi-CK 
isoenzymes are accumulated at later stages than M- and B-CK, indicating that 
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су tosolic and Mi-CK isoenzymes are subject to different regulatory programs 
[195,202,345]. In contrast, M- and Mi-CK mRNA were coordinately induced 
during differentiation of mouse muscle cells in culture [163]. 
In myocardial tissue of altricious animals like mouse, rat, rabbit and 
chicken, very low amounts of Mi-CK and Mi-CK mRNA are found before 
birth [165,192,195,199,335,418]. Cardiac Mi-CK activity rises sharply be­
tween 6 and 25 days of neonatal life in the mouse [165,199], up to about 3-9 
weeks of age in the rat [107,108,199,202,418],andbetweenaboutland20 days 
in the rabbit [192,510], thereby reaching adult values. However, during these 
periods of time, no changes in a variety of mitochondrial parameters (e.g. 
mitochondrial ATPase activity) were observed [107,108]. In contrast to these 
altricious animals, Mi-CK is already present in fetal heart and/or skeletal 
muscle of precocious animals such as sheep and guinea pig, but astonishingly 
also in man [199,200,435, 479], and accumulation of Mi-CK to the adult 
concentrations occurs mostly before birth. In quadriceps muscle of preterm 
born infants, for example, Mi-CK activity as well as protein content increased 
significantly with gestational age [435]. Adult concentrations of Mi-CK were 
reached soon after birth in both sheep and man. 
Most interestingly, Mi-CK in cardiac muscle appears at a time when, 
during postnatal development, incorporation of MM-CK into the myofibrillar 
M-band of the mammalian heart muscles begins [71,72,192]. During the same 
period of time, a general maturation of the heart muscle towards its full 
contractile potential takes place [18,192,194]. The coordinate postnatal ap­
pearance of Mi-CK on the PCr production side and of M-line-bound MM-CK 
on the PCr consumption side of the PCr "circuit" emphasizes the need for a 
functional coupling of the two systems for optimal muscle function [492]. In 
addition, the developmental accumulation of "total Cr" (Cr + PCr) in the 
mouse, rat and possibly also sheep heart occurs in two consecutive steps 
[199]. First, total Cr concentration increases prenatally, almost in parallel 
with the accumulation of MM-CK, thereby reaching a plateau which is 
maintained for a certain period of time. Then, a further severalfold increase 
in total Cr pool size parallels the accumulation of Mi-CK, indicating that the 
two processes are linked in some way. This assumption is fully in line with 
experiments on cell cultures derived from neonatal rat hearts showing that 
addition of 20 mM Cr to the culture medium stimulates the synthesis of 
Mi-CK [418,473]. Besides, the relative proportion of Mi-CK increases with age 
in culture and with age of animal from which the culture is derived. 
In chicken leg muscle, but not in chicken heart, amounts of Mi-CK mRNA 
similar to those in adult heart were already found at embryonic day 19 [195]. 
In rat brain, Mi-CK is undetectable at birth and increases also postnatally to 
the adult proportion of 15 % of total CK activity [335]. In chicken retina, 
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BB-CK content was high in late stages of embryonic development, decreased 
slightly around hatching and remained high during adulthood [496]. Mi-CK 
content, however, was low during development in ovo, rose just before 
hatching, at a time when visual functions have to become operational in 
autophagous birds to enable them to find food, and remained high through-
out the following developmental periods. Mi-CK was accumulated pre-
dominantly within the ellipsoid portion of the inner photoreceptor cell 
segments. 
31P-NMR measurements were performed to test the functional conse-
quences of the development of the CK system. In neonatal rat brain lacking 
Mi-CK, ischemia led to an almost parallel decrease in the concentrations of 
ATP and PCr [335]. In the adult brain, however, first PCr and, after a delay, 
ATP concentration also decreased, indicating that Mi-CK might be essential 
for efficient rephosphorylation of ADP. This conclusion is corroborated by 
the finding that the capacity of the rodent brain to modulate the rates of 
glycolysis and tissue respiration in response to sudden changes in energy 
demand increases in the narrow time-window between days 12 and 15 of 
postnatal development when also the CK-catalysed reaction rate increases 
[193]. To monitor the developmental changes of fluxes through the CK 
reaction, 3,P-NMR saturation transfer experiments were performed with 
hearts of 3-18 day-old neonatal rabbits at different levels of cardiac perfor-
mance [300,346]. Parallel biochemical experiments demonstrated that during 
this developmental period, total CK activity and adenine nucleotide pool size 
in the heart remained constant, the proportions of MM-CK and Mi-CK as well 
as the Cr pool size increased [see also Ref. 199], and the proportions of 
MB-CK and BB-CK decreased [346]. The 31P-NMR measurements revealed 
that the CK reaction flux in the direction of ATP production was positively 
correlated with the relative proportion of Mi-CK, with the Cr pool size, and 
with cardiac performance [300,346]. Furthermore, the fluxes in both direc-
tions of the CK reaction were identical under all conditions tested [300]. 
In conclusion, the expression of the four known CK subunit isoforms is 
differentially regulated during development on the transcriptional and 
possibly also on the translational level. The reasons for these developmental 
changes and the functions of the different isoenzymes at the various stages 
of development are not fully understood. However, the transition in muscle 
from B- to M-CK has to do with the isoenzyme-specific subcellular localiza-
tion of CK isoenzymes. In sharp contrast to MB- or BB-CK, homodimeric 
MM-CK is capable of binding to the myofibrillar M-band where it fulfils its 
specialized function as an intramyofibrillar ATP regenerator and as a 
structural component of the M-band [488]. The level of expression of M- as 
well as Mi-CK strongly depends on the physiological requirements and is 
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therefore developmental stage-specific. In addition, maturation of the CK 
system differs qui te dramatically between altricious and precocious animals. 
Since Mi-CK appears only after birth in a variety of small animals, it 
seems not to be essential for life per se or for basic muscle function at a low 
work-load. Strikingly, however, the flux through the CK reaction, the 
mechanical performance of the heart, the fraction of M-line-bound M-CK as 
well as the proportion of Mi-CK increase concomitantly, in spite of a constant 
total CK activity [192,346]. These latter results strongly suggest that Mi-CK 
is crucial for energy supply at high work-loads where ADP diffusion may 
become a limiting factor [525]. 
III-F. Adaptive changes 
Two main primary functions were ascribed to the CK /PCr system (see IV-B.). 
First, it is involved in buffering of [ATP] and especially [ADP] during abrupt 
changes in workload, with this function certainly being most crucial for 
fast-twitch skeletal muscles. Second, the CK/PCr system is involved in the 
transport of high-energy phosphates from sites of ATP production 
(mitochondria, glycolysis) to sites of ATP consumption. This function is more 
pronounced in "endurance" tissues like myocardium and slow-twitch 
skeletal muscles, and, in contrast to the "buffer" function, is thought to be 
facilitated by the presence of Mi-CK. 
In accordance with these ideas, training for long-distance running and 
even a marathon race itself increased the proportion of Mi-CK relative to total 
CK activity in human gastrocnemius muscle, with the increase being larger 
in female than in male runners [9]. Total CK activity, however, remained 
unchanged. In addition, activity and relative proportion of Mi-CK were 
found to increase almost linearly with the duration of chronic stimulation of 
fast-twitch rabbit muscle (type II, white fibers) [400], whereas they decreased 
in human quadriceps femoris muscle during 6 weeks of leg immobilization 
after knee surgery [224]. In contrast to these results, endurance training was 
reported not to influence total activity and relative proportion of Mi-CK in rat 
gastrocnemius muscle [342]. 
In most instances, the changes in Mi-CK activity were either directly 
paralleled or even surpassed by changes in the mitochondrial protein content 
or in the activities of mitochondrial marker enzymes like citrate synthase 
[224,400]. Incidentally, chronic stimulation of fast-twitch rabbit muscle was 
found to increase the activities of citric acid cycle enzymes as well as of total 
mitochondrial volume [361]. Furthermore, several mitochondrial enzymes 
were shown to increase after exercise [358]. Finally, Mi-CK as well as MB-CK 
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activity were found to be positively correlated with the oxidative capacity of 
a muscle [457,459]. All these findings strongly indicate that the changes in 
Mi-CK activity induced by training or chronic stimulation are not specific 
events, but are due to general changes in mitochondrial content, thus 
reflecting a transition from a more glycolytic to a more oxidative, fatigue-
resistant energy metabolism. 
In vivo and in vitro ischemia affects a variety of functional as well as 
structural properties of heart and skeletal muscles, some being reversible and 
others not [see for instance Ref. 388]. In rabbit heart, for example, total 
ischemia resulted in a progressive loss of Mi-CK activity, which was closely 
paralleled by a decline in left ventricular pressure [43,215,462]. Within 60 
minutes of ischemia, the ratio of Mi-CK to mitochondrial malate 
dehydrogenase decreased by more than 70 %, indicating that the loss is not 
due to a general decrease in mitochondrial content, but to a specific release 
or selective inactivation of Mi-CK. In addition, the functional coupling 
between Mi-CK and ANT was depressed [462], and Mi-CK was detected in 
blood after ischemia (see III-G.). Inorganic phosphate was suggested to cause 
a selective release of Mi-CK from the inner mitochondrial membrane [462]. 
During prolonged, severe ischemia, intracellular [Pj] may approach 50 mM 
[260], a concentration that is in the range used for in vitro solubilization of 
Mi-CK from the mitochondrial inner membrane [169]. However, since the 
loss of Mi-CK appeared to be irreversible, and since Mi-CK could not be 
detected in the post-ischemic supernatant, Bittl et al. [43] concluded that 
Mi-CK is not just released from the mitochondrial inner membrane, but is 
irreversibly inhibited during ischemia. Again in contrast to these results, 
Saks et al. [388] in ischemic rat hearts found only a transient, reversible 
decrease in Cr-stimulated respiration and thus in Mi-CK activity. In addition, 
even though ventricular performance and metabolite contents of isolated 
perfused rat hearts were permanently depressed, a variety of respiratory 
parameters proved to be highly tolerant to ischemia, thus suggesting that, at 
least under the experimental conditions used, mitochondrial injury is not a 
major component of ischemic damage [388]. Clearly, more experiments are 
needed to unravel the apparent discrepancies. 
Compared to heart muscle, more pronounced mitochondrial changes 
were noticed in ischemic skeletal muscles [172]. For example, ischemia 
resulted in the appearance of giant mitochondria containing paracrystalline 
inclusions. These intramitochondrial inclusions had the appearance either of 
accumulations of finely granular material distending the intracristae space, 
or of plate-like structures sandwiched between the outer and the inner 
mitochondrial membranes or between two leaflets of the inner membrane. 
The inclusions were suggested to derive from aggregation of enzymes 
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present in the intermembrane space of muscle mitochondria such as Mi-CK 
(see below). 
To evaluate whether or not Cr is essential for normal muscle function and 
structure, animal models have been developed to test the effect of Cr 
depletion. An almost complete Cr depletion can be achieved by feeding 
animals with Cr analogues like cyclocreatine (cCr; l-carboxymethyl-2-
iminoimidazolodine) [513], ß-guanidinobutyric acid (GBA) [269] and 
ß-guanidinopropionic acid (GPA) [127], which act as competitive inhibitors 
of Cr uptake into the cell and are in general poor substrates for the CK 
isoenzymes [6,129]. Instead of PCr, large amounts of phosphorylated cCr 
(PcCr) and GPA (GPAP) are accumulated inside the cells. In contrast, GBA 
is not phosphorylated by the CK isoenzymes [531]. As a result of Cr depletion, 
important biochemical, functional as well as morphological alterations occur, 
as will be discussed now in more detail. 
The effects of cCr on brain, heart and skeletal muscle metabolism were 
mainly investigated in relation to ischemia [7,366,469,470,513]. Most impor-
tantly, and also very surprisingly, ATP levels during total ischemia were 
found to be sustained substantially longer in several tissues of cCr-fed 
animals as compared to controls [366,469,470], even though the Vmax value of 
CK with PcCr as substrate is about 160-fold lower than that wi th PCr [6]. Upon 
cCr-feeding, delayed ATP depletion was observed for mouse brain [513] as 
well as for chicken breast muscle [470], chicken heart [469], and rat heart [366], 
these muscles displaying a relatively homogeneous fiber population. On the 
other hand, mixed-fiber leg muscles of cCr-fed mice [7] or chicken [470] for 
unknown reasons did not exhibit a directly measurable ATP-sustaining 
activity during ischemia. The capacity of dietary cCr to sustain [ATP] may be 
attributed to the unique thermodynamic properties of the accumulated PcCr. 
Because its free energy of hydrolysis is roughly 2 kcal /mol lower than that 
of PCr [6], PcCr may continue to buffer the adenine nucleotide concentrations 
and to transport high-energy phosphates throughout the muscle fibers even 
at cytosolic pH values and phosphorylation potentials well below the range 
where the CK/PCr system can function effectively. In contrast to cCr, 
homocyclocreatine and GPA feeding did not delay ATP depletion [366,469]. 
GPA-fed animals also seem a suitable model to study the consequences 
of Cr depletion, although the possibility that GPA or GPAP are toxic for 
muscle has to be considered [349]. GPA feeding results in a variety of 
adaptive changes similar to those observed in transitions from a more 
glycolytic to a more oxidative energy metabolism, as occurs for example 
during endurance training (see above). In rat skeletal muscle, GPA feeding 
decreased the concentrations of total Cr, PCr and ATP by up to 75, 90 and 
50%,respectively [127,154,313,422,427,428], whereas [Pj] remained unchanged 
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[428]. The glycogen content as well as the activities of aerobic enzymes such 
as citrate synthase, 2-oxoglutarate dehydrogenase and 2-hydroxyacyl-CoA 
dehydrogenase were found to be increased in all fast-twitch (plantaris and 
gastrocnemius) muscle regions except the superficial gastrocnemius, but not 
in the slow-twitch soleus muscle [427]. In contrast, the activities of CK, 
phosphofructokinase, and glycogen Phosphorylase decreased in all skeletal 
muscle regions except the deep gastrocnemius [427]. As far as contractile 
characteristics are concerned, plantaris muscles of GPA-fed animals 
exhibited no abnormalities, except for a slight decrease in initial strength 
[349]. Surprisingly, the endurance of soleus muscle was prolonged. In 
addition, the isometric twitch characteristics in this latter muscle were 
altered, and the maximum velocity of shortening was decreased [346]. 
31P-NMR experiments revealed that in resting gastrocnemius muscle of 
GPA-fed rats, the flux through the CK reaction is reduced in the direction of 
ATP synthesis [424], and that there is no measurable phosphate exchange 
between GPAP and ATP [313]. In addition, the rate of GPAP hydrolysis in 
stimulated GPAP-loaded muscle was much less than that of PCr in control 
muscles [313]. Intracellular pH decreased more rapidly during stimulation 
and recovered more rapidly afterwards in GPAP-loaded muscles compared 
with controls. However, despite buffering by PCr hydrolysis, the pH 
ul timately decreased more in control muscles. This finding is very likely due 
to the two-fold greater lactate accumulation in stimulated control 
gastrocnemius muscles as compared to GPAP-loaded muscles. These results 
were taken as an argument that in skeletal muscle, PCr is not essential for 
steady-state energy production,but that phosphate releaseby PCr hydrolysis 
is essential for maximum activation of glycogenolysis and/or glycolysis 
[313]. However, recent evidence suggests that GPAP in workingheartmuscle 
may be used quite efficiently as a CK substrate [88]. 
Heart muscle of GPA- and GBA-fed rats exhibited contractile failure, as 
evidenced by cardiac hypertrophy [305] or by a rise in the left ventricular 
diastolic pressure (LVDP) [235,236,531]. The latter, probably by impairing 
left ventricular filling, may be responsible for the diminished cardiac per-
formance observed in GPA- and GBA-fcd animals [235,531]. The extent of 
contractile failure was found to depend on the functional load and on the 
degree of Cr depletion. However, 3,P-NMR saturation transfer experiments 
revealed that a 80-90 % depletion of PCr results in only a two- to four-fold 
reduced flux through the CK reaction [235,531 ], thus rendering final conclu-
sions about the involvement of the CK/PCr system in contractile failure 
difficult. Finally, the expression of myosin isoenzymes in the left ventride of 
the heart was recently shown to change from the fast form V1 to the slower 
forms V2 and V3 during GPA feeding for several weeks [305], thus reflecting 
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changes in contractile properties similar to those observed in skeletal muscles 
(see above). Taken together, the available data strongly suggest that, at least 
in the heart, the CK/PCr system is essential for proper muscle function. 
In addition to the biochemical and functional alterations discussed so far, 
Cr depletion in muscle also caused several morphological changes, thus 
suggesting that Cr metabolism is important for sustaining normal muscular 
structure. GPA feeding caused an increase in the relative proportion of 
type I muscle fibers (red, slow-twitch), in soleus muscle, for example, from 
81 % in control rats to 100 % in GPA-fed rats [427]. In addition, GPA-feeding 
in general decreased type II fibres (white, fast-twitch) in size and weight, 
while type I fibres were unaffected [349,422,427]. Accordingly, the largest 
change in relative muscle size was observed for the gastrocnemius muscle 
displaying the greatest proportion of type IIb fibres (62 %) [427]. Selected 
fibres of the pectoralis and gastrocnemius muscles of chicken fed GBA 
exhibited loss of thick and thin filaments, disruption of the Z-band, dilated 
mitochondria, as well as dilated and displaced sarcoplasmic reticulum [269]. 
These ultrastructural changes are attributable to an abnormality of Cr 
metabolism, since GBA by itself seems not to be toxic. Accordingly, when 
chicken were given extra dietary Cr in addition to GBA, muscle [PCr] was 
found to be normal, and no significant ultrastructural alterations occurred. 
As a result of Cr depletion, abnormal mitochondria were observed in 
slow-twitch skeletal muscles of rats [154,339]. These mitochondria often were 
enlarged and contained crystal-like inclusions like those frequently observed 
in human mitochondrial myopathies [121,429,444], ischemia [172,180], as 
well as in muscles exposed to mitochondrial poisons [307,373] (see also ΠΙ­
Ο . When adult rat cardiomyocy tes were cultured in a medium devoid of Cr 
or in a medium supplemented with GPA, two populations of mitochondria 
could be distinguished [116]. Giant, cylindrically-shaped mitochondria were 
randomly distributed over the cell and contained inclusions highly enriched 
in Mi-CK, as shown by immuno-gold labelling. In contrast, small, "normal"-
sized mitochondria without inclusions were localized between the myofibrils 
and contained much lower amounts of Mi-CK. Addition of Cr to the culture 
medium caused the disappearance of the giant mitochondria as well as of the 
crystal-like inclusions, accompanied by an increase in the intracellular 
concentration of total Cr. It is not readily understood why only part of the 
mitochondria are affected by Cr depletion and form inclusions. One possi­
bility is that subsarcolemmal mitochondria are more susceptible to metabolic 
alterations and react to a Cr defici t firs t by fusion to form giant mitochondria 
and second by a compensatory accumulation of Mi-CK, the latter resulting in 
the formation of Mi-CK containing crystal-like inclusions [116]. Taken 
together, these results corroborate the sugges tion that changes in Cr metabo-
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lism in mitochondrial myopathies play an important role in the formation of 
abnormal mitochondria as well as mitochondrial inclusions. However, in a 
preliminary study among six patients, no correlation was found between the 
occurrence of abnormal mitochondria and total [Cr] [436]. 
Phosphate depletion in rats produced by dietary phosphorus restriction 
resulted in a decreased concentration of inorganic phosphate in skeletal 
muscle, in an elevated phosphorylation potential, and in reduced oxygen 
uptake [57]. Furthermore, the specific activities of Mi-CK and of myofibrillar 
MM-CK were reduced. Accordingly, addition of Cr to state 4-respiring 
mitochondria did not increase the rate of oxygen consumption. The mecha­
nism by which phosphate depletion may induce the observed alterations is 
unknown. Since Mi-CK is of prime importance in regulation of cellular 
energy production and transport, and since these steps are impaired in 
skeletal muscle during phosphate depletion, the reduction in the activity of 
Mi-CK may be the key biochemical disturbance in the myopathy of phos­
phate depletion [57]. 
Ш-G. Mi-CK in pathology 
III-G1. Neuromuscular diseases 
In recent years, a variety of studies focussed on the possible involvement of 
Mi-CK in the pathology of several neuromuscular disorders such as muscular 
dystrophies and mitochondrial myopathies [31,293]. Muscular dystrophy is a 
heterogeneous group of disorders of which the Duchenne muscular dystro­
phy is most frequently observed in humans. However, to our best 
knowledge, no extensive studies on Mi-CK were performed in human 
muscular dystrophy. In skeletal muscle of dystrophic chicken, compared to 
normal age-matched controls, Mi-CK activity progressively decreased during 
the course of the disease, with the pectoralis muscle being more affected than 
the gastrocnemius [31,293]. Furthermore, Cr-stimulated mitochondrial 
respiration in dystrophic chicken breast muscle was found to be decreased 
[31]. Consequently, a decrease in Mi-CK activity may ultimately cause the 
functional loss in breast muscle fibers by decreasing the efficiency of trapping 
available mitochondrial ATP as PCr. An inborn error of metabolism compris­
ing Mi-CK deficiency would dearly be very helpful in testing this hypothesis. 
A mitochondrial myopathy can be defined as a muscle disease characte­
rized by structurally or numerically abnormal mitochondria and/or abnor­
mally functioning mitochondria. In about 30 % of the patients with an in vitro 
observed disturbed pyruvate oxidation rate, no single enzyme deficiency of 
the mitochondrial respiratory chain is found in the skeletal muscle 
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mitochondria. As an alternative, Mi-CK activity may be affected in these 
patients. However, quantitative measurement of Mi-CK activity by a newly 
developed method [434] revealed no deficiency of Mi-CK in skeletal muscle 
specimens of 11 patients with disturbances in the pyruvate oxidation rate in 
whom no defect in the pyruvate dehydrogenase complex or in complexes of 
the respiratory chain could be established [437]. In two patients with an 
established single enzyme deficiency of the mitochondrial respiratory chain, 
the specific activity of Mi-CK was clearly enhanced. A possible explanation 
is that this increase in the specific activity of Mi-CK reflects some kind of 
adaptation. A similar compensatory increase was also observed for cytochrome 
с oxidase and citrate synthase activities in patients with single enzyme 
deficiencies of the respiratory chain [372]. 
Electron microscopical inspection of muscle samples revealed that ab­
normal mitochondria and intramitochondrial inclusions are a typical feature 
of neuromuscular diseases in general and of mitochondrial myopathies in 
particular [121]. These crystal-like mitochondrial inclusions were frequently 
found in the "ragged red" muscle fibers of patients suffering from ocular 
myopathies with clinical manifestation of progressive involvement of the 
external ocular muscles (chronic progressive external ophthalmoplegia; 
CPEO). In patients with mitochondrial myopathies, two distinct types of 
crystals are observed, which can be distinguished by shape, size, pattern, 
unit-cell dimension, specific localization in the intermembrane space, and 
their occurrence in different muscle fiber types (Fig. 3; page 56 and 57). So-
called type I crystals (Fig. ЗА) are usually present in the intracristae space, 
between two folds of the mitochondrial inner membrane, whereas type Π 
crystals (Fig. 3B) are preferentially located in the intermembrane space 
between outer and inner mitochondrial membranes. Type I crystals occur 
only in type I muscle fibers (slow twitch type with high oxidative capacity) 
and type II crystals in type II muscle fibers (weak or intermediate staining for 
mitochondrial enzymes) [121,444]. Only recently, it was shown that these 
crystals are labelled by antibodies directed against Mi-CK (Fig. 3C; see also 
UI-F.) [445,446]. The Mi-CK immunolabelling of these crystals was uniform 
and irrespective of the orientation of the crystals to the plane of sectioning. 
However, type Π crystals were always more heavily labelled than type I 
crystals [445,446]. In a preliminary study among six CPEO patients, no 
relationship was found so far between the concentration of total Cr, free Cr 
or PCr and the occurrence of mitochondrial crystals in the muscle [436]. This 
holds true especially for one CPEO patient with an extremely low free Cr 
content in muscle, in whom despite thorough electron microscopical inspec­
tion, no crystals were observed. In two patients with CPEO in which Mi-CK 
containing crystals were found in the quadriceps muscle, Mi-CK activity was 
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Fig. 3. Accumulation ofMi-CK in intramitochondrial inclusions. 
Mitochondrial crystals in human skeletal muscle biopsies (m. quadriceps). 
(A) Transversely sectioned Type I crystals in mitochondria of "ragged red" fibers 
from a patient suffering from chronic progressive external ophthalmoplegia (CPEO). 
Note the presence of the crystals in the intracristae spaces. (B) Type II crystals in 
muscle fibers of a patient suffering from unclassified mitochondrial myopathy. 
(C) Strong anti-Mi-CK immunogold labelling of longitudinally sectioned Type I 
crystals from a patient with CPEO. Magnification: (A) 32 400x; (B) 46 OOOx; 
(C) 35 200x. For further details see the text. 
significantly enhanced despite a normal pyruvate oxidation rate [436]. 
Recently, it was realized that long-term zidovudine therapy, used for the 
treatment of patients with the acquired immuno-deficiency syndrome (AIDS), 
can cause a toxic mitochondrial myopathy with depletion of muscle 
mitochondrial DNA [11,93]. Besides inflammatory changes, crystal-like 
mitochondrial inclusions were observed in muscle biopsies of zidovudine-
treated patients. It would be worthwhile to further study these inclusions in 
relation to the CK/PCr system. In addition, further studies are necessary to 
elucidate the mechanism of crystal formation and to clarify if crystal forma-
tion is causative to or only a consequence of mitochondrial myopathies. 
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III-G2. Cardiomyopathies 
A cardiomyopathy may be defined as a dysfunction of the myocardium caused 
by a primary disorder within the myocardium or by secondary disorders, 
like for example hypertension. In experiments on rat hearts, where arterial 
hypertension was induced by suprarenal aortic banding, total CK activity in 
the left ventricle rose within 4 days by about 70 % [133]. In this model of a 
short-term cardiomyopathy, the expression of M-, B- and Mi-CK was con-
comitantly increased, and therefore no significant change in the relative 
proportion of the different CK isoenzymes occurred. Seemingly, the in-
creased energy requirements in acute pressure overload are met by a 
generalized induction of expression and synthesis of all CK isoenzymes. 
In contrast, long-term cardiomyopathies (left ventricular hypertrophy 
due to aortic stenosis, volume overload, or hypertension; coronary artery 
disease; hereditary and diabetic cardiomyopathies) are characterized by an 
unchanged or decreased total CK activity, by a decreased in vivo flux through 
the CK reaction, by an increase in the relative proportions of MB- and BB-CK, 
and by a decrease in the total Cr content [202-205,243,390]. With the single 
exception of Bio 14.6 Syrian hamsters [12], cardiac Mi-CK activity was 
considerably decreased in all sorts of long-term cardiomyopathies in both 
animals and humans [12,45,202,205,243,390,393]. Accordingly, Cr-stimu-
lated mitochondrial respiration was also found to be decreased 
[237,390,476,477]. 
Most interestingly, total CK and Mi-CK activity as well as the flux 
through the CK reaction were normal in spontaneously hypertensive rats 
during the first 12 months of life, this period being characterized by a stable 
compensated hypertrophy of the myocardium [45,202,205]. However, be-
tween the 12th and 18th month of life, a transition from compensated 
hypertrophy to failure occurred, whereby in parallel with the functional 
capacity of the heart muscle, also total CK and especially Mi-CK activity 
drastically decreased. Finally, in various hereditary and experimental 
cardiomyopathies (induced by autoimmunization or by treatment of rats 
with adriamycin, norepinephrine, GPA, or streptozotocin), [ATP + PCr] was 
decreased [237]. With the exception of GPA-treated animals, cardiac output 
at standard load conditions was also substantially lowered, probably due to 
mild bradycardia, elevated left ventricular (LV) diastolic pressure, and 
stiffness that limited cardiac contractile adaptation to volume or resistance 
overloads. The LV diastolic stiffness at maximal functional load was in-
versely correlated with the high-energy phosphate content. Its increase in 
cardiomyopathic hearts may be explained by the increased myofibrillar 
sensitivity to Ca2+ and by the loss of functional coupling of Mi-CK to 
oxidative phosphorylation. Since in another study, the myofibrillar MM-CK 
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activity of the cardiomyopathic heart was found to be normal [477], these 
results clearly indicate that loss of Mi-CK activity may be of prime importance 
for the development of cardiac failure. 
III-G3. Tumor tissues 
Mi-CK was detected in several types of human [101,190,233,340,368,467] and 
animal tumors [275], in the human carcinoma cell line HeLa [473], as well as 
in murine Ehrlich ascites tumor cells [25]. In these tissues or cells, Mi-CK is 
frequently coexpressed with BB-CK, indicating a de-differentiation of trans-
formed cells, which is reflected in the appearance of an embryonic isoenzyme 
pattern. In Ehrlich ascites tumor cells, however, CK activity was found to be 
exclusively associated with mitochondria. The authors therefore suggested 
that the "transport" function of the CK/PCr system (see IV-B.) is not crucial 
for tumor cells [25]. To our knowledge, there are no reports on the Mi-CK 
content of brain tumors. 
No differences in the molecular mass, the electrophoretic mobility, or the 
kinetic characteristics were observed between Mi-CK in tumors of the 
digestive tract and Mi-CK in adjacent normal tissue [340]. Accordingly, 
Mi-CK of malignant and normal liver displayed the same Mr of 320 000-
350 000, similar heat stability, and a similar behaviour in 2 M urea, whereas 
the electrophoretic mobility, for unknown reasons, differed dearly [233]. 
Interestingly, tumors of the digestive tract were shown to contain signifi-
cantly higher amounts of Mi-CK than surrounding normal tissue [340]. This 
may reflect that a higher expression of Mi-CK is required to meet the 
increased energy demands of the tumor cells. However, the facts that (i) 
stomach adenocarcinomas displayed lower Mi-CK activity than the sur-
rounding normal tissue [190], and that (ii) tumors depend more on anaerobic 
rather than aerobic energy metabolism, make this latter interpretation un-
likely. 
III-G4. Body fluids 
Normally, no Mi-CK is detectable in normal human serum [234,288,352] or 
cerebrospinal fluid (CSF). This holds true for most species, although sheep 
may be an exception [24]. Under certain pathological conditions, however, 
Mi-CK is released into the blood or CSF in man. This may cause diagnostic 
confusion, as Mi-CK interferes in many of the methods that are routinely used 
in clinical chemistry for the determination of MB-CK as an indicator of 
myocardial damage. Serum Mi-CK is generally thought to originate from the 
mitochondrial compartment. Therefore, the finding of Mi-CK in a patient's 
serum forms an index of mitochondrial damage. It should be kept in mind, 
however, that the cell nucleus of heart and skeletal muscle has been suggested 
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to contain Mi-CK forms as well [228]. Clinically, the presence of Mi-CK in 
serum should not be ignored, for it may be of help in finding the proper 
diagnosis. 
Serum CK isoforms with a Mr of >80 000 are called macro CK's [527]. 
According to the nomenclature of Stein and co-workers [52,448], macro CK 
type 1 represents an autoantibody complex of BB-CK. In contrast, macro CK 
type 2 is generally assumed to be Mi-CK [449] because of similarities in 
electrophoretic mobility [52,232,449], molecular mass [232,449], activation 
energy [448,449], enzyme kinetics [232,448] and antibody studies [232]. The 
Mr of the principal form of macro CK type 2 was estimated as 287 000-350 000, 
which is similar to the Mr of Mi-CK isolated from tissues [231,449]. In 
addition, smaller quantities of a 80 kD form [231,449] and surprisingly also 
of a >750 kD form of CK were found in serum [449], whereby for the latter, 
nothing is known about the number and stoichiometry of its constituents. To 
avoid confusing terminology in the following section, macro CK type 2 is 
referred to as Mi-CK whenever possible. 
The occurrence in serum of a CK isoenzyme of mitochondrial origin was 
first described for one out of two patients examined with Reye's syndrome 
[367]. The occurrence of Mi-CK in serum was later confirmed [22,222] and 
considered an ominous sign, since 10 out of 14 positive cases died shortly after 
Mi-CK was detected in the serum [222; see also Ref s. 234,352]. In a prospective 
study among 2954 consecutive patients in a hospital for internal diseases, the 
prevalence of Mi-CK in serum was found to be 3.7 % among hospitalized 
patients and 1.1 % among outpatients [450]. In this study, Mi-CK was found 
predominantly in severely ill patients of all ages, mainly with malignancies 
(41 %) and liver diseases (25 %). In a study of 5000 random patient sera, 
malignancies were found in 25 of the 26 adult patients that were positive for 
Mi-CK in serum [514,515]. Of course, the prevalence figure depends both on 
the sensitivity of the test procedure for Mi-CK and on the patient group that 
is screened. 
The occurrence of Mi-CK in serum has been studied extensively in 
neoplastic diseases [183,317]. Serum of patients with malignancies may 
contain Mi-CK, sometimes in combination with mitochondrial aspartate 
aminotransferase, thus indicating mitochondrial damage in the tumor. 
Serum Mi-CK has been found in patients with primary tumors in liver 
[73,158,232-234,515],pancreas[515],lung[158,234,258,274303,452,515],breast 
[73,158,234,258,288,352,450,453,515], gastro-intestinal tract [158,190,234,258, 
289,303,308,317,340,352,368,452,515], prostate [158,234,452,453,515], 
gallbladder [225,234,452], ovaries, and uterine cervix [234]. However, Mi-CK 
was not found in serum of 120 leukemia or lymphoma patients [73]. In 
addition, Mi-CK has never been described in patients with renal tumors. In 
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some cases, the tumor and its metastases were shown to contain the same 
macromolecular Mi-CK as the patient's serum [232,450], thus suggesting that 
tumor tissue itself can release Mi-CK and sometimes also BB-CK into the 
serum. Histological typing of tumors probably releasing Mi-CK into the 
blood has been performed by Kanemitsu et al. [234]. However, a patient can 
have a tumor expressing Mi-CK without displaying measurable quantities of 
Mi-CK in the serum. This was evidenced by two patients with liver metastases, 
in which Mi-CK was released in measurable quantities into the serum only 
after embolization of the hepatic artery [432]. Although hypoxia may play a 
role, the exact mechanism for the pathological release of Mi-CK from tumors 
is unknown. Xenograf ting tumor lines into a thymic mice may be a rewarding 
model for studying Mi-CK release from tumors into the blood [101]. 
Several authors have suggested the use of Mi-CK in serum as a tumor 
marker [234,275,288,303,308,368,450,468], or more specifically as a marker 
for gastrointestinal cancer [258,308,368], metastatic prostatic carcinoma [453] 
and adenocarcinoma [340,352]. Serum Mi-CK activity roughly seemed to 
reflect the tumor burden [232,275,450,452,453], so that in individual cases, 
serum Mi-CK may be used to monitor the initial response to therapy [303]. 
However, the appearance of Mi-CK in serum alone is not a specific signal for 
neoplastic disease (see below). Accordingly, the diagnostic sensitivity of 
serum Mi-CK activity for neoplastic disease in general seems rather poor [73]. 
The presence of Mi-CK in seru m was shown to be related to the clinical stage 
of neoplastic disease for some tumors [308], while it was not so for others [73]. 
Apart from a few patients with various chronic and acute diseases 
[367,450], Mi-CK was frequently found in serum of patients with liver 
diseases, more in particular liver cirrhosis [73,450]. In these patients, serum 
Mi-CK apparently originated directly from liver cells, which in this special 
case were found to contain Mi-CK [232]. Normal liver cells, in contrast, do not 
contain measurable amounts of Mi-CK (see III-A.). 
Myocardial damage was early recognized as an additional potential 
cause of Mi-CK efflux into the blood [22,222]. Mi-CK was found in sera of 
children with myocarditis [362,515], congestive heart failure, and 
cardiomyopathy after aortic valve surgery [515]. Mi-CK appeared to be 
present in serum of patients who have experienced periods of poor tissue 
perfusion [22], myocardial ischemia [158], and cardiorespiratory arrest [92]. 
These findings are in line with the observation that in rats during hypoxia, 
Mi-CK activity in the blood increased in parallel with a decrease in the heart 
[178]. Furthermore, Mi-CK was found in serum of individual cases after acute 
myocardial infarction (AMI) [158,222,289,448,458]. Peak values for serum 
Mi-CK were observed 24 hours after AMI [458]. The activity of Mi-CK 
approximated 20 % of that of MB-CK, the traditional and established 
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indicator of myocardial damage [458]. In larger series, however, serum 
Mi-CK could not be detected at all after AMI or was only found in sporadic 
cases [73,122,352,362,367,441,450,503]. Therefore, release of Mi-CK into the 
blood circulation after AMI seems to be the exception rather than the rule. 
Besides, it remains principally unclear why Mi-CK is released into the blood 
in some patients with AMI and not in others. Interestingly, the drug 
theophylline was suggested to induce Mi-CK release into the serum in vivo 
[99]. As this drug is often given to patients suffering from cardiac diseases, 
it can not be decided yet whether in fact theophylline or simply myocardial 
damage is the actual cause resulting in Mi-CK release into the serum. 
In CSF, Mi-CK was found under several pathological conditions 
[75,76,503,505] : hypoxic-ischemic brain damage [76]; after surgery in relation 
with various central nervous system tumors [503]; apoplexia caused by a 
hypophysis tumor [505]; and meningitis [503]. Due to its presence in human 
brain [75,277,504], Mi-CK in CSF seems to derive directly from the central 
nervous system. Rather surprisingly, Mi-CK in CSF is not necessarily accom-
panied by BB-CK [503]. As of yet the diagnostic potential of determining 
Mi-CK in CSF remains an open question and may be a topic of further 
research. 
As far as clinical chemistry is concerned, electrophoresis was often used 
for the detection and quantitation of Mi-CK. However, interpretation of the 
serum CK zymograms is complicated for several reasons: (i) The human 
Mi-CK isoenzymes either migrate cathodally to or comigrate with MM-CK 
[52,289,502]. Incubation of Mi-CK in normal human serum results in modi-
fication of the most cathodal human heart Mi-CK band [231,502], with the 
modified Mi-CK comigrating with MM-CK [502]. In contrast, human liver 
Mi-CK is not influenced by serum incubation [231]. (ii) Various authors have 
observed one to three Mi-CK bands in serum upon electrophoresis 
[52,183,231,289, 329,432,449,453,502] or even more in isoelectric focussing 
experiments [433,449]. This multiplicity is poorly understood. Blockingofall 
M-CK activity in a zymogram with inhibiting antibodies generally is very 
informative to discriminate between MM-CK and Mi-CK [52] (see below). 
(iii) Comigration of adenylate kinase isoforms [241] and in single cases of a 
macro CK type 1 complex [52,528] with Mi-CK may further complicate the 
zymograms. 
There are several reports in the literature where the authors relied 
exclusively on the electrophoretic mobility to classify a cathodally migrating 
form as Mi-CK. However, in any publication on Mi-CK, it should adequately 
be shown that there is no interference with alternative enzymatic activity at 
stake. Since the mere presence of the inhibitors AMP and diadenosine 
pentaphosphate does not always guarantee full inhibition of adenylate 
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kinase [241 ], a control zymogram of the electrophoresed samples without PCi 
in the reaction mixture is required to exclude the presence of adenylate 
kinase. Proper discrimination between macro CK type 1 and Mi-CK, on the 
other hand, can be achieved by published methods [52,448]. 
Mi-CK in serum was often found just by chance, because (i), it interferes 
with most methods that are commonly used for the detection of MB-CK, and 
(ii), most patients with Mi-CK in serum (81-88 %) have a normal total serum 
CK activity [73,234,450]. As the Mi-CK activity in serum often is below 10 
IU/1 [450], the sensitivity of the assay used is a crucial point. Improvement 
of sensitivity may be achieved by using bioluminescence in combination with 
immuno-inhibition of MM-CK [303,505]. Unfortunately, anti-Mi-CK anti-
bodies for a direct determination of this isoenzyme in serum have been raised 
on a limited scale and have been available for research purposes only. 
Since Mi-CK is not inhibited by antibodies against M-CK, a clinical 
chemist may be alerted for the possible presence of Mi-CK in serum by the 
often abnormally high ratio (residual CK activity after immuno-inhibition of 
M-CK)/(total CK activity) [450]. Accordingly, many researchers have used 
immuno-inhibition of M-CK, thus measuring all the non-M-CK activity 
[303,450,505,514], as a reliable first step in establishing the presence in serum 
or CSF of abnormal CK isoenzymes in general and of Mi-CK in particular. A 
good methodological alternative is the commercially available reagent kit 
that combines immuno-inhibition with precipitation of the immune-com-
plexes by a second antibody [514]. This set-up allows direct discrimination 
between MB-CK on one hand and macro CK forms on the other. In all 
techniques mentioned, however, further tests are necessary to definitely 
confirm the presence of Mi-CK. Among these, determination of the apparent 
activation energy [448,449], the molecular mass [431,448,449], the isoelectric 
focussing pattern [433,449] and the electrophoretic behaviour [52] would 
seem to be most convincing. 
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IV. Integration of Mi-CK in cellular energy metabolism 
ÍV-A. Advantages of the CK/PCr system 
Some of the aspects mentioned below have been discussed in the recent 
review of Wallimann et al. [492], but are reinforced here in order to be able 
to fully understand the new arguments and to get a comprehensive picture 
of the physiological importance of Mi-CK. First, the potential advantages of 
the CK/PCr system shall be elucidated. Clearly, the most evident advantage 
of this system is that PCr and Cr allow a much higher flux of "high-energy 
phosphates" from sites of ATP production to sites of ATP utilization than 
ADP and ATP, since (i) within tissues with high and fluctuating energy 
demands, Cr and PCr are accumulated to much higher concentrations than 
the adenine nucleotides, and (ii) Cr and PCr are smaller-sized and less 
negatively charged than ADP and ATP. Accordingly, in model solutions as 
well as in frog muscle, the diffusion coefficients of PCr and Cr were found to 
be 1.3-2.3 times higher than those of ATP and ADP [219,328,524,525]. 
Diffusion of ATP is unlikely to be hindered by binding to subcellular 
structures, since in the cytosol, its diffusion was restricted to the same extent 
as that of other small molecules. The diffusion coefficients of ATP and PCr 
were both about 60 % lower in frog muscle than in model solutions [525] 
which is in perfect agreement with the observations that the diffusion 
coefficients of several molecules with Mr 170-24 000 are 2-5-fold lower in the 
cytoplasm of mammalian cells than in water [297] and that living cells have 
a fluid phase viscosity 3-4 times greater than water [290]. In contrast to ATP, 
the diffusion of ADP in the cytosol seems to be severely hindered [389,390]. 
As much as 97 % of the ADP may be tightly bound and non-diffusable in 
skeletal muscle and heart [see Refs. 74,219], a finding that may also explain 
the apparent discrepancy between biochemically measured [ADP] (-100-500 
μΜ) and effective in vivo [ADP] of 1-50 μΜ calculated from 31P-NMR spectra 
[42,141,143,312]. 
Assuming appropriate diffusion coefficients, substrate concentrations 
and concentration gradients of 5 %, Jacobus [219] calculated the maximal flux 
rates of the respective substrates to be (in μπιοΐ/ιηίη/π^ cardiac tissue): 
35 for MgATP, 0.112 for MgADP, 57 for P,, 103 for Cr and 123 for PCr. 
Evidently, MgADP is the most diffusion-restricted of all substrates, a fact that 
is also reflected by 31P-pulsed gradient NMR experiments yielding mean-
square lengths of diffusion of 1.8 μιη for ADP, 22 μιη for ATP, 57 μπα for PCr 
and 37 μτη for Cr [525]. However, the values obtained for ADP are still in the 
same range as the maximum measured rate of ATP utilization in the heart 
(0.135 mmol/min/mg tissue) [219] and the diameter of a single myofibril of 
approximately 1 mm [525]. 
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Since the free energy of PCr hydrolysis (AG
obs= -45 kj/mol) [270] is consist­
ently higher than that of ATP hydrolysis (AG^ = -30.5 kj/mol) [157], the CK/ 
PCr system efficiently "buffers" [ADP] and [ATP] and therefore also the 
ATP/ADP ratio as well as the phosphorylation potential in the cytosol 
[230,454]. This is especially important for tissues with abrupt changes in 
energy demand like cardiac and skeletal muscle as well as brain. During 
work or anoxia, first [PCr] decreases at relatively constant levels of ATP and 
ADP, and only when a large part of the PCr is depleted, [ATP] decreases as 
well [141,159,226,330,381,417]. Since ATP and ADP are key regulators of 
many fundamental metabolic pathways, whereas Cr and PCr are likely not 
to be involved in allosteric regulation of intermediary metabolism [128], the 
CK/PCr system, by damping fluctuations of [ATP] and [ADP] upon abrupt 
changes of energy demand, allows a better fine-tuning of whole cellular 
metabolism and therefore protects the cell from energy dissipation (see also 
IV-B.). 
By keeping [ADP] low, theCK/PCr system further protects the cells from 
a net loss of adenine nucleotides [144,209,226,492]. Accumulation of ADP 
activates adenylate kinase (myokinase) which catalyzes the transfer of a 
phosphate group between two molecules of ADP to give ATP and AMP. 
Especially in white and red fast-twitch muscles, AMP is degraded into 
inosine monophosphate (IMP) and ammonia by AMP deaminase [309] which 
is bound to the myofibrils at both ends of the A-band [91]. Cytosolic or 
sarcolemma-bound 5'-nucleotidase dephosphorylates both AMP and IMP 
into adenosine and inosine, respectively. These latter substances ultimately 
leave the cell since the sarcolemma is permeable to the latter two compounds 
[see Ref. 226]. 
As can be directly seen from the chemical equation of the CK reaction, 
PCr2'+ MgADP'+(x).H+ « » MgATP2"+Cr 
the CK/PCr system also avoids acidification of the cytosol during periods of 
high workload [110]. As long as PCr is present in significant amounts, [ATP] 
remains almost constant and thus PCr2'-» Cr + Ρ,*· is the net reaction 
supporting work. Since P, at a pH around 7.0 has a mean charge between -1 
and -2, PCr hydrolysis may at least in part be responsible for the tissue 
alkalinization observed during the first stages of muscular work 
[89,191,264310]. Only when almost all PCr is exhausted, lactate production 
by glycolysis as well as net ATP hydrolysis lead to a considerable acidifica­
tion of the cytosol. Acidification has three main consequences: (i) it decreases 
the maximal force of a muscle, either by itself or in combination with 
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diprotonated inorganic phosphate, H 2 P0 4 ' , which itself is favoured over 
HP0 4
2
" at low pH values [336]; (ii) it reduces the glycolytic flux by inhibiting 
phosphofructokinase [see Ref. 77], thereby also avoiding further acidifica­
tion, exhaustion of high-energy phosphates, and thus irreversible damage of 
the cell; and (iii) it shifts the CK equilibrium towards ATP synthesis, as can 
also be seen directly from the chemical equation. Thus, the CK/PCr system 
ensures an almost constant ATP/ ADP ratio over quite a wide rangeof energy 
demands and pH values which is essential for the proper functioning of all 
cellular ATPases. 
In tissues with high and fluctuating energy demands, at least two 
potential sites of regulation are introduced by the CK/PCr system. Whereas 
the Cr + PCr pool size is likely to be only important for long-term regulation 
and adaptation, the cytosolic and Mi-CK isoenzymes are attractive candi­
dates for short-term regulation of the overall flux through the CK reaction. 
Since the cytosolic CK activity can cope easily with the maximal rates of ATP 
production or ATP consumption and thus the cytosolic CK system is likely 
to be in a near-equilibrium state [205,262,298,310], regulation of cytosolic CK 
activity was suggested to have no influence on energy metabolism. 
In contrast to the cytosolic CK isoenzymes, Mi-CK is thought to be 
involved in metabolic channelling of high-energy phosphates from the 
mitochondrial matrix to the cytosol and is therefore likely to be displaced 
from thermodynamic equilibrium [262]. Accordingly, regulation of Mi-CK 
activity would directly reduce the export of PCr out of the mitochondria. The 
potential implications of regulation of CK isoenzymes can only fully be 
appreciated if one considers that it allows very specific and efficient regula­
tion of whole cellular energy metabolism. Though there have been no 
convincing reports up to now proving regulation of CK activity in vivo, the 
recent findings that phosphorylation of BB-CK reduces the K
m
 for PCr by 
about a factor of two [84,356], that BB-CK is a possible substrate of protein 
kinase С [85] and that a variety of CK isoenzymes are subject to 
autophosphorylation [184] suggest that CK regulation may be of physiologi­
cal relevance. 
As a last point, PCr shall be compared with other Phosphagens. In all 
vertebrate and some invertebrate species, PCr is the sole phosphagen. In 
contrast, a variety of different Phosphagens like phosphoarginine (PAr), 
phospholombricine (PL), phosphotaurocyamine (PTc), phospho-
hypotaurocyamine (PHTc) and phosphoglycocyamine (PGc) were found in 
lower phyla, either alone or in combination with each other or with PCr 
[112,322,493]. Interestingly, exclusively PCr is found in spermatozoa of a 
large number of "lower" species having other Phosphagens in other tissues. 
Determination of the apparent equilibrium constants of the phosphagen 
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kinase reactions by biochemical and 3,P-NMR methods revealed that at pH 
7.25,theapparentequilibriumconstantofCK(K'CK=[Cr][ATP]/[PCr][ADP]) 
is 3-8 times higher than the respective K' values for arginine kinase (AK), 
glycocyamine kinase (GK), taurocyamine kinase (TK) and lombridne kinase 
(LK) [112]. In other words, the free energies of hydrolysis of PAr, PGc, PTc 
and PL are 2.9-5.2 kj/mol lower than that of PCr. This property can be 
explained by the methyl group attached to the guanidine moiety of PCr which 
eliminates almost all resonance states and thus decreases the thermodynamic 
stability of PCr [112,114]. Due to the higher AGobs value of PCr hydrolysis, the 
ATP/ADP ratio can be buffered at a higher value which seems especially 
relevant in the light of experiments on vertebrate skeletal muscle, showing 
that the reciprocal of the relaxation rate constant is directly proportional to 
the cytosolic phosphorylation potential and thus also to the ATP/ADP ratio 
[97,112]. In addition, maintaining a high affinity (free energy change) for ATP 
hydrolysis has been shown to be essential for a variety of cellular ATPases 
[229] (see also IV-B.). On the other hand, when the cellular pH is lowered, 
Phosphagen kinase reactions with a lower K' value will show a smaller 
degree of net hydrolysis of the respective phosphagen [112]. Consequently, 
a pool of the highly labile phosphagen PCr would be rapidly dissipated 
under conditions of intracellular acidosis which especially in molluscs is a 
commonly observed phenomenon. In contrast, AK/PAr may act as an 
effective buffer system under these circumstances. 
These latter reflections shed some light on the functions and evolution-
ary relationships of the different phosphagens. It has been suggested that PAr 
is the most primitive of the phosphagens, representing an evolutionary 
precursor. PCr, present mostly in vertebrates, was thought to represent a 
functional improvement over PAr, because PAr/Ar interfere with amino 
add metabolism, whereas Cr represents an end-product of a distinct meta-
bolic pathway not interfering with amino acid metabolism [495]. No satisfac-
tory explanations for the occurrence of a variety of different phosphagens in 
lower phyla have been presented so far. However, the differential distribu-
tion in the animal kingdom of PCr on one hand and PAr, PL, PTc, etc. on the 
other hand may also be explained as follows. PCr is predominantly found in 
vertebrates, which almost perfectly maintain intracellular homeostasis. In 
contrast, intracellular homeostasis is less pronounced in lower phyla, causing 
larger fluctuations of pH, temperature, substrate concentrations, etc. upon 
changes in the actual environment. Changes in intracellular conditions might 
lead to hydrolysis of the highly labile PCr pool and thus to energy dissipation. 
Consequently, under conditions of poor intracellular homeostasis, more 
stable phosphagens might be better suited than PCr. 
In conclusion, the CK/PCr system has the following major advantages 
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over a system based exclusively on ATP/ADP diffusion: (i) it allows a larger 
flux ofhigh-energyphosphates between sites of ATP production (mitochondria 
and glycolysis) and ATP utilization (all sorts of ATPases), (ii) it allows the 
maintenance of a higher ATP/ADP ratio throughout the cell, (iii) it avoids a 
net loss of adenine nucleotides, (iv) it keeps the pH almost constant during 
the first stages of cellular work, and (v) provides two additional potential 
sites for the very specific regulation of energy metabolism. Most of the models 
of CK function discussed in the next chapter are based primarily on only one 
or just a few of these advantages. Consideration of all advantages, of various 
models and of changes in metabolic demand specific for different develop-
mental stages and metabolic adaptations will lead to a more thorough 
understanding of CK function in whole cellular energy metabolism. 
IV-B. Models of CK function 
Since the discovery of PCr in 1927 [111], the ideas and models about the 
involvement of the CK/PCr system in energy metabolism have changed 
several times. The fact that it is not possible to explain all physiological 
findings with one single of these models may explain why confusion about 
the "real" function of the CK/PCr system still exists in the literature and why 
in most textbooks, energy metabolism is simplified by omitting the CK/PCr 
system and by assuming exclusive diffusion of ATP and ADP between sites 
of ATP production and ATP consumption (Fig. 4A; page 70). This model may 
be correct for cells and tissues lacking CK like liver, but it is clearly incomplete 
for tissues with high and fluctuating energy demands like heart and skeletal 
muscle, brain, spermatozoa, retina, kidney, etc. [see Ref. 492]. For a historical 
overview on the development of alternative models, the reader is referred to 
Refs. 35,37,214. In this chapter, the various models will be discussed only for 
ATP production by oxidative phosphorylation within mitochondria. How-
ever, no differences in the qualitative aspects of the models and in conclusions 
result from a replacement of mitochondrial oxidative phosphorylation by 
glycogenolysis or glycolysis, because functional coupling, like that of Mi-CK 
to oxidative phosphorylation (see III-C), has also been observed between 
cytosolic CK isoenzymes and glycolysis [for reviews see Refs. 381,492]. 
Since during work, [PCr] decreases whereas [ATP] remains relatively 
constant, it was long believed that PCr is the direct source of energy for 
muscular contraction, with ATP being responsible for the regeneration of 
PCr. Thirty years ago, however, rather specific inhibition of CK in frog 
skeletal muscle by l-fluoro-2,4-dinitrobenzene caused a contraction-
dependent decrease in [ATP] at constant [PCr] and therefore proved that ATP 
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hydrolysis directly supports muscular contraction [70]. Because CK inhibi­
tion lowered the number of normal contractions of a muscle fiber from >30 
to approximately 3, it was hypothesized that the CK/PCr system represents 
a back-up system for very efficient "buffering" of [ATP] and especially [ ADP] 
[70,302,485] (Fig. 4B; page 70). However, a large body of evidence challenged 
the validity of the "buffer model" [149,159,160,414] so that instead an 
(exclusive) "transport" function was proposed for the CK system 
[35,37,38,213,301,328, 379,415,416,463,486,488]. According to this model, 
which was also termed "PCr shuttle hypothesis", Mi-CK bound to the outer 
face of the inner mitochondrial membrane catalyzes the transfer of the 
γ-phosphate group of ATP, synthesized by mitochondrial oxidative 
phosphorylation, to Cr. PCr then diffuses out of the mitochondria to sites 
within the cell where energy is consumed and PCr continuously regenerates 
ATP. Diffusion of Cr back to the mitochondria closes the cycle (Fig. 4C; page 
70). In other words, the CK/PCr/Cr system is shunted in between sites of 
ATP production and ATP consumption. 
Many experiments were interpreted as favouring one of the two models 
and dismissing the other. However, within a cell, both "buffer" and "trans­
port" functions of the CK/PCr system may be operational at the same time, 
with the relative contributions of these two aspects depending on the 
metabolic demands of a tissue. For example, the buffer function is likely to 
be more pronounced in fast-twitch muscles where bursts of ATP breakdown 
have to be buffered immediately and very efficiently to allow short periods 
of maximal work. These muscles fatigue rapidly because regeneration of 
high-energy phosphates is achieved on a much slower time-scale mostly by 
glycolysis. In slow-twitch muscles and especially in heart, however, the 
transport function seems more important, since in these muscles, high rates 
of ATP consumption and therefore also of ATP production and transport 
have to be ensured for longer periods of time. For each workload, a steady-
state is attained where ATP production and consumption are efficiently 
regulated and balanced [17]. 
The "buffer" function of the CK/PCr system is supported by the follow­
ing facts: (i) Non-excitable cells and organs like liver with a relatively high, 
but continuous flux of high-energy phosphates contain only small amounts 
of CK and PCr or even none at all [41,518]. This might indicate that the CK/ 
PCr system is not essential for maintaining high flux rates of high-energy 
phosphates, but rather for buffering of sudden changes in energy demand 
(see below), (ii) For a transport function, comparable amounts of Mi-CK and 
cytosolic CK activities are expected within a cell. However, the proportion of 
Mi-CK was found to be only 0-2 % of total CK ас ti vity in some skeletal muscles 
and brain [8,9,48,245,294,434]. In addition, no mitochondrial isoenzymes of 
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Flg. 4. Models of CK function. 
(A) Classical "textbook" model of energy transportbetween sites of ATP production 
(mitochondria, glycolysis) and ATP consumption (all sorts of ATPases). This model 
may roughly reflect the situation in tissues devoid of CK, PCr and Cr like liver, but 
is clearly inappropriate to describe the situation in CK-containing tissues like 
skeletal or cardiac muscle, brain, retina and spermatozoa. (B) "Buffer" (storage) 
function of the CK/PCr system. A large pool of PCr is available for immediate 
regeneration of ATP hydrolyzed during short periods of intense work. Due to the 
high cytosolicCKacti vi ties, theCK reaction remains in a near-equilibrium stateand 
thus keeps [ADP] and [ATP] almost constant. In other words, the CK/PCr system 
efficiently "buffers" theconcentrationsof ATPand especially of ADP. (C) "Transport" 
function of the CK/PCr system. The CK/PCr system fulfils the function of a 
"transport device" shunted in between sites of ATP production and ATP 
consumption. Note that for the "buffer" function no Mi-CK isoenzyme is needed, 
whereas for the "transport" function, Mi-CK may be an essential prerequisite, 
especially if there were diffusion limitations for adenine nucleotides across the 
outer mitochondrial membrane [3233,147,148]. In addition, it should be kept in 
mind that the two models (B) and (C) represent extremes, with the actual situation 
in a cell or tissue being somewhere in between. Accordingly, the physiological 
requirements of a tissue determine the relative importance of the "buffer" and 
"transport" function of theCK/PCrsystemand therefore also the relative proportion 
of Mi-CK. For further details see the text. Φ, sites of ATP hydrolysis, e. g. myosin 
ATPase or ion pumps; Η , Mi-CK; • , cytosolic CK. 
arginine kinase have so far been found in a variety of arthropod flight and 
squidmantle muscles [113,402,451], suggesting that in all these tissues, the 
CK/PCr and AK/PAr systems are not important for energy "transport". 
However, though insect flight muscles are capable of extremely high aerobic 
energy fluxes without the participation of a mitochondrial arginine kinase 
isoenzyme, these results do not exclude a transport function of phosphagen 
kinase systems, since first, rows of densely packed mitochondria are lined up 
in dose apposition to individual myofibrils of insect flight musdes in such a 
way that diffusion distances from mitochondria to myofibrils are minimized 
[438], and second, a mitochondrial isoenzyme is less important for a transport 
function of an AK/PAr than for a CK/PCr system. Theoretical considerations 
have shown that due to the lower equilibrium constant of AK compared to 
CK, the proportion of high-energy phosphate flux carried by Ρ Ar at the same 
ATP/ADP ratio is higher than that carried by PCr [311]. (iii) PCr content, total 
CK and soluble MM-CK activity were found to correlate with the glycolytic 
potential of a muscle [332; for a review see Ref. 492]. Consequently, they were 
highest in fast-twitch musdes with high glycolytic, but low oxidative potentials 
where ATP breakdown due to muscular work occurs on a much faster time-
scale than regeneration by glycolysis [264], indicating that the transport 
72 CHAPTER 2 
function of the CK/PCr system is nearly irrelevant for fast-twitch glycolytic 
muscles, (iv) Biochemical and 31P-NMR experiments demonstrated that in 
brain, heart and skeletal muscle, the cy tosolic CK activity as well as the overall 
flux through the CK reaction are much higher than the maximal rates of ATP 
synthesis and ATP consumption, suggesting that the CK system in the cytosol 
is in a near-equilibrium state [42,88,205,262,299,310,346,381,423,475]. Under 
near-equilibrium conditions, [ATP] and [ADP] are efficiently buffered, as is 
corroborated by physiological experiments revealing that during muscular 
and nervous work, [ATP] remains almost constant, whereas [PCr] decreases 
[381], for a review see Ref. 417]. (ν) No functional coupling was detected 
between Mi-AK and mitochondrial oxidative phosphorylation in the heart of 
the horseshoe crab Limulus polyphemus, meaning that this isoenzyme is in free 
equilibrium with the cytosolic substrate concentrations [106]. Thus, the 
function of this Mi-AK isoenzyme is likely to ensure near-equilibrium 
conditions of the phosphagen kinase reaction in the intermembrane space 
rather than to participate in a "shuttle mechanism" for high-energy phos­
phates. 
A "transport" function for the CK/PCr system is favoured by the 
following arguments: (i) The presence of Mi-CK as well as of cytosolic CK 
isoenzymes within the same cells suggests that they have different functions. 
Most attractively, Mi-CK is responsible for PCr synthesis, and significant 
fractions of cytosolic CK for ATP regeneration (Fig. 4C; page 70). (ii) The 
proportion of Mi-CK increases wi th theoxidative potential and therefore also 
with the expected relevance of the transport function for the proper function­
ing of a tissue (see also III-E. and III-F.). It is higher in slow-twitch than in fast-
twitch muscles and highest in heart (up to 50 %; see Ш-А.). In brain, 
depending mostly on glycolysis, the relative proportion of Mi-CK is low 
[48391,423]. Furthermore, during development, the proportion of Mi-CK 
and muscle performance rose in parallel (see III-E.). Finally, chronic stimu­
lation [400] and endurance training [9] increased the relative proportion of 
Mi-CK, while Mi-CK activity decreased in the immobilized human leg after 
surgery [224]. (iii) In the neonatal rabbit heart, the flux through the CK 
reaction directly correlated with the relative proportion of Mi-CK [346]. 
Furthermore, model calculations suggested that upon heart stimulation, the 
flux through Mi-CK increases severalfold [251,529]. (iv) Whereas the overall 
flux through the CK reaction is probably independent of the metabolic state 
in skeletal muscle [529], it increases with workload in the heart [42,44,46,47, 
262,300,346,386,529] suggesting that the CK/PCr system in working heart is 
no longer in a near-equilibrium state. This conclusion was also corroborated 
for several tissues suffering or recovering from hypoxia or ischemia 
[19,21,141,159,160,206,334] indicating that merely buffering the concentra-
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tions of adenine nucleotides is not the sole function of the CK/PCr system. 
(v) Jacobus [218] calculated that the total ATP pool would only suffice for 10 
s of cardiac work at normal rates of energy utilization. Even with PCr present, 
the "resting" heart turns over the total high-energy phosphate pool between 
two and four times per minute. Similarly, ATP plus PAr would only suffice 
for 1.5 s of flight of Locusta migratoria L. [402]. Assuming concentration 
gradients of 5 %, maximal flux rates (in μιηοίεβ/πυη/π^ heart) of 35 for 
MgATP, 57 for P;, 123 for PCr and 103 for Cr were calculated. However, the 
flux of ADP (0.112 цтоіез/тіп/пг^), primarily due to its very low concen­
tration, is in the same range as the maximum measured rate of ATP utilization 
(0.135 цто1е8/тіп/т§), indicating that especially at higher workloads, 
ATP-ADP flux alone might be insufficient to maintain appropriate 
ATP/ADP ratios throughout the cell [219]. (vi) In an elegant series of 
experiments it was shown that in sea urchin spermatozoa, very specific 
inhibition of the mitochondrial and flagellar CK isoenzymes by l-fluoro-2,4-
dinitrobenzene (FDNB) attenuated flagellar movement in the two distal 
thirds of the sperm tail, indicating that ATP and ADP diffusion alone are only 
sufficient to ensure dynein ATPase activity in the proximal third of the tail. 
Indeed, when ATP was added externally to permeabilized, FDNB-treated 
sperms, they were able to swim again normally [463], indicating that the 
CK/PCr system is essential for energy supply in these highly polar cells. 
Evolutionary studies support this conclusion since high CK activities were 
found in sperms of the primitive type, whereas 10-100-fold lower CK 
activities were observed in sperms with a modified morphology [465]. 
"Primitive" sperms have long flagellae, depend on aerobic energy metabo­
lism, are typical for external fertilization, and the mitochondria are localized 
exclusively within the head. "Modified" sperms are typical for internal 
fertilization, depend also on glycolytic energy flux, and the mitochondria are 
localized in head and tail. That the CK/PCr system is essential for highly 
polarized cells is also supported by the finding of high CK activities in 
chicken and frog photoreceptor cells [465,496] as well as in ciliated cells from 
rabbit oviduct epithelium [465]. (vii) The finding of intracellular 
compartmentation of adenine nucleotides and Cr (see IV-C.) has the direct 
consequences that communication between the various compartments 
(mitochondria, myofibrils, etc.) and thus transport of CK substrates must 
happen, (viii) If only the buffer function were important for the CK/PCr 
system, a homogeneous dis tribution of CK isoenzymes would be expected in 
the cytosol. However, different proportions of cytosolic CK isoenzymes were 
found to be tightly bound to the myofibrillar M-band, the plasma membrane 
and the sarcoplasmic reticulum membrane where CK is thought to locally 
regenerate ATP as well as to be functionally coupled to myosin ATPase, 
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Na+/K+-ATPase and Ca2+-ATPase; respectively [51,120,301,357,383,386,455; 
for reviews see Refs. 38,379,488,492]. Co-localization of CK with ATP-
requiring enzymes together with the likely potential that CK itself is a 
regulated enzyme might be an effective means of high-energy phosphate 
channelling, (ix) Theoretical considerations have shown that even under 
near-equilibrium conditions, most of the high-energy phosphate will be 
transported in the form of PCr at physiological ATP/ADP ratios [311]. 
Accordingly, Meyer et al. [311 ] hypothesize that the binding of CK near sites 
of ATP production or utilization "serves to raise the local enzyme activity 
where the flux is greatest, thus ensuring overall near-equilibrium with less 
total enzyme activity than would be necessary with uniformly distributed 
enzyme". 
Clearly, there were also some arguments raised against a transport 
function of the CK/PCr or AK/PAr systems. First, the AK activities in flight 
muscles of four insect species as well as in squid mantle muscle were found 
to be considerably smaller than the maximal ATP turnover rate [332,451]. 
However, comparison with mammalian tissues is difficult due to profound 
morphological differences (see above). And second, feeding of rats with the 
creatine analogue ß-guanidinopropionic acid (GPA) for 6-10 weeks resulted 
in the heart in a nine-fold decrease in [PCr] as well as in a four-fold decrease 
in the flux through the CK reaction, while GPA and GPAP were accumulated 
and [P,], [ATP], intracellular pH, oxygen consumption and cardiac perfor-
mance remained unchanged [424,426]. Since in GPA-fed rats, the measured 
rates of ATP turnover were 1.5-3 times greater than the flux through the CK 
reaction, it was concluded that PCr cannot be an obligate intermediate of 
energy transduction in the heart [426]. However, it has to be stressed that 
during the rather long feeding periods, compensatory metabolic adaptations 
take place [427] and that GPAP can serve as a CK substrate to buffer [ATP] 
quite efficiently during transitions between work states [88]. Furthermore, 
the left ventricular developed pressure was significantly lower in rats fed 
GPA or ß-guanidinobutyric acid compared to controls [531]. 
Many studies in the past aimed to proof that the CK/PCr system in some 
way is essential for energy metabolism. However, the GPA experiments 
suggest that vital mammalian tissues (except spermatozoa and retina?) still 
function reasonably well at greatly reduced concentrations of Cr and PCr (see 
Ш-F.), this fact simply reflecting the overcapacity of the CK/PCr system 
under normal conditions. Nevertheless, the CK/PCr system in all likelihood 
has both a transport and buffer function and thereby increases the thermo­
dynamic efficiency of energy metabolism, as will be discussed below. A 
second misleading aim was the attempt to demonstrate that a "sufficient" 
flux of high-energy phosphates can not be attained by ADP and ATP alone. 
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Evidently, with sufficiently steep concentration gradients, adenine nucleotide 
turnover and ADP-ATP flux might be balanced as well [219]. Therefore, the 
function of the CK/PCr system may not simply be to guarantee a sufficient 
flux of high-energy phosphates from sites of ATP production to sites of ATP 
consumption, but rather to ensure a sufficient flux of high-energy phosphates 
to maintain appropriate ATP/ADP ratios throughout the cell in order to ensure 
a proper functioning of all ATPases in tissues with rapidly changing energy 
demands [96,97,143,157,229,230]. High ATP/ADP ratios point to high 
phosphorylation potentials and thus to high affinities for ATP hydrolysis. In 
resting skeletal muscle as well as in heart at a basal metabolic rate, the affinity 
for ATP hydrolysis was found to be in the range of 55-64 kj/mol [143,229; for 
a review see Ref. 230], while in other tissues, it amounts to only 45-51 kj/mol 
[230,440]. The facts that a variety of cellular ATPases require energies of 
41-44 kj/mol [96,97,229], that the affinity for ATP hydrolysis seems tobe very 
efficiently buffered between 45 and 50 kj/mol [229] and that the mechanical 
performanceof the heart drastically decreases below 48 kj/mol [229] strongly 
corroborate that the ATP/ADP ratio is of prime importance for energy 
metabolism. Most important in this respect is the finding that the 
Ca2+-ATPase of the sarcoplasmic reticulum depends on a very high affinity 
for ATP hydrolysis to be able to reduce the cytoplasmic [Ca2+] to 100 nM and 
thus to ensure muscle relaxation [229]. Cessation of proper Ca2+ sequestration 
mayevenbe thebiochemical basis for muscular fatigue [97,157]. Kammermeier 
[230] further hypothesized that the affinity for ATP hydrolysis provides an 
explanation why CK is presen t in heart and skeletal muscle as well as in brain, 
but not in liver. In tissues with affinities of 55-64 kj/mol, [ADP] would have 
to be kept very low. Under these conditions, the diffusion gradients of ADP 
and ATP required to maintain the desired high-energy phosphate flux would 
cause an affinity gradient of 2-3 k j /mo l^m. In tissues with affinities below 
51 kj/mol, [ADP] would be higher and the affinity gradients much smaller. 
Thus, the CK/PCr system may have the additional function of flattening 
affinity gradients for ATP hydrolysis and thus avoiding energy dissipation 
[311]. However, this interpretation raises some additional questions: Why do 
brain, heart and skeletal muscle depend on a higher affinity for ATP 
hydrolysis? What are the processes or chemical reactions requiring affinities 
of 55-64 kj / mol? And how is the affinity for ATP hydrolysis regulated wi thin 
a cell? Answering these questions may provide some deeper insight into the 
"real" functions of the CK/PCr system. 
Doubts about the real functions of the CK/PCr system might also be 
raised by the finding of cytosolic as well as Mi-CK isoenzymes in smooth 
muscle tissues [207] displaying much lower maximal performances than 
striated muscles. However, in analogy to striated muscles, "fast" and "slow" 
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smooth muscles may be discriminated. Most visceral and vascular smooth 
muscles are characterized by long-lasting tonic contractions, contain cy tosolic 
and Mi-CK isoenzymes and consequently can be compared with slow-twitch 
skeletal muscles. In contrast, chicken gizzard displays only phasic contrac-
tions without a tonic component, where maximal force is developed after 
10-15 s of stimulation [126]. Since chicken gizzard, in addition, has no Mi-CK, 
but considerable amounts of BB-CK [207], it may be compared with fast-
twitch skeletal muscles. The obvious difference between slow- and fast-
twitch skeletal muscles and "slow" and "fast" smooth muscles is the time-
scale of metabolic changes. An attractive explanation to investigate is that 
diffusion of CK substrates is much more hindered in smooth than in striated 
muscles, but that the CK/PCr system in both muscle types has the same 
functions. 
The last function of the CK/PCr system to be discussed is to "accelerate" 
and "smooth" transitions between different work states. If ADP liberated by 
muscular contraction or by all sorts of cellular ATPases were the signal for 
ATP production by mitochondrial oxidative phosphorylation (see IV-D.), 
and if the system under these conditions were non-linear, then oscillations 
around the new steady-state level would be expected following changes in 
workload. These oscillations would be paralleled by fluctuations in [ADP], 
[ATP] and in the ATP/ADP ratio. Since ATP and ADP are key regulators of 
many of the fundamental metabolic pathways, the net result might be a 
destabilization of whole cellular metabolism. Because near-equilibrium 
conditions only allow for a linear system, where oscillations do not occur, the 
CK/PCr system may dampen the oscillations mentioned above and conse-
quently stabilize whole cellular metabolism. It has to be stressed that the 
oscillations discussed here are completely different from those described in 
several practical and theoretical studies [21,134,139]. The former are due to 
an approach to a new steady-state level, whereas the latter result from 
regularly fluctuating energy demands characteristic of cardiac muscle, or 
from alternating perfusion with 0 2 and N2. 
By accelerating "communication" between sites of ATP production and 
ATP consumption, theCK/PCr system may, in addition, reduce the transient 
times for reaching a new steady-state. Transient times can be shortened in two 
different ways, either by elevating enzyme activities in such a way as to 
guarantee near-equilibrium conditions [109,182] or by metabolite channel-
ling [343]. Both of these mechanisms are probably operational in the CK/PCr 
system, thus indicating as well that reducing transient times is important for 
energy metabolism in tissues with rapidly changing energy demands. The 
cytosolic CK isoenzymes are likely to be in a near-equilibrium state (see 
above), and Mi-CK is apparently involved in metabolic channelling of high-
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energy phosphates out of the mitochondria (see ПІ-С). All of these latter 
interpretations are strongly favoured by the fact that the CK/PCr system is 
predominantly found in tissues with high and fluctuating energy demands 
like brain, cardiac and skeletal muscle, but not in tissues with high but more 
or less constant energy demand like liver. 
In conclusion, the CK/PCr system has two main primary functions: (i) it 
buffers the concentrations of ADP and ATP, and (ii) accelerates the transport of 
high-energy phosphates between sites of ATP production and ATP con­
sumption, thereby accelerating also communication and feedback regulation 
between the two complementary parts of the CK isoenzyme system. The 
remaining functions of the CK/PCr system are direct consequences of the 
"buffer" and "transport" functions. Besides buffering [H+] and preventing 
loss of adenine nucleotides (see IV-A.), (iii) the CK/PCr system, due to 
keeping [ADP] low, maintains a high affinity for ATP hydrolysis which 
seems to be crucial for various ATPases. (iv) Furthermore, transient times 
between different workloads are shortened by the CK/PCr system due to 
metabolite channelling by Mi-CK and near-equilibrium conditions of the 
cytosolic CK isoenzymes, (v) Finally, due to the CK reaction being in a near-
equilibrium state in the cytosol, oscillations in the concentrations of high-
energy phosphates may be avoided upon abrupt changes in workload. 
ÍV-C. Subcellular compartmentatton of CK substrates 
The function of the CK/PCr system to accelerate the "communication" 
between sites of ATP production and ATP consumption, as it was proposed 
in the preceding chapter, would be even more crucial if discrete subcellular 
pools of CK substrates (ADP, ATP, PCr, Cr, H+) occurred. In fact, much 
evidence for microcompartmentation of CK substrates has been accumulated 
over the last thirty years [for reviews see Refs. 38,492]. Incubation of striated 
muscle of the frog with tritium-labelled adenine or Cr, followed by fixation 
of the tissue (in the absence or presence of a lanthanum salt to "precipitate" 
the high-energy phosphates) and autoradiography of thin sections, revealed 
an accumulation of adenine nucleotides and PCr at discrete locations within 
the myofibrils [186-189]. Depending on the conditions of fixation, adenine 
nucleotides were found in a narrow disk either in the I-band or the A-band, 
but in both instances close to the A-I boundary [187,188]. PCr was concen-
trated in a narrow disk within the I-band, approximately half way between 
the A-I boundary and the Z-line [189]. For this latter region, the local [PCr] 
was calculated to be 166 mmol/kg muscle. MM-CK in chicken pectoralis or 
rat muscles was also found to be loosely bound to the I-band, together with 
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glycolytic enzymes, in addition to its localization within the M-band of the 
sarcomeres [491,497]. Even though serious reservations have to be made 
about the method employed by Hill [186-189], the colocalization of MM-CK 
and its substrates nevertheless points to an important role of 
microcompartmentation of the CK/PCr system within the I-band of the 
myofibrils. 
After incubation or perfusion of rabbit or rat heart with 14C-labelled Cr, the 
specific radioactivity of PCr (SAp^), surprisingly, was significantly higher 
than the 5 Α
α
( 5 Α
ρ α
/ 5 Α
α
 1.24-1.87) [272,392]. Subsequent washoutof excess 
Cr or anoxia even increased the SAp^/SA,^ ratio to 5-11, which is a dear 
indication for microcompartmentation. Savabi [392] from her data concluded 
that 55 % of the total Cr (Cr + PCr) in spontaneously beating rat heart atria is 
PCr, 9 % constitute theCr-pool 1 which is readily accessible to phosphorylation 
by (Mi-) CK, and 36 % constitute the Cr-pool 2. Cr in this latter pool is rather 
inaccessible to phosphorylation and may be bound to subcellular structures. 
Incubation of the atria with 14C-Cr causes a selective uptake of radioactive Cr 
into pool 1. PCr hydrolysis due to anoxia also leads to an accumulation of Cr 
in pool 1, suggesting that only a small proportion of the total Cr is metabolically 
"active". If these findings were true, the validity of the conclusions from the 
GPA experiments would have to be seriously questioned. For example, only 
about 80 % of PCr and 60 % of total Cr were depleted by feeding animals with 
GPA for 8 weeks [531]. If GPA-feeding selectively diminished only the Cr-
pool 2, pool 1 and therefore also energy metabolism in general might remain 
almost unaffected. 
Besides sequestration of ATP and ADP in membrane-enclosed dense 
granules of blood platelets [471] and accumulation of ATP in the nucleus of 
frog oocytes [315], as much as -30 % of the intracellular ATP was found to be 
"trapped" in cardiac and liver mitochondria [144; for reviews see Refs. 
177,247,430]. Furthermore, subcellular fractionation of rat heart and liver in 
non-aqueous media revealed the mitochondrial matrix [ATP] / [ADP] ratio to 
be much lower than the cytosolic [ATP] / [free ADP] ratio [177,430]. Together 
wi th the findings of separate mitochondrial and cytosolic CK isoenzymes and 
of diffusion limitations of adenine nucleotides across the outer mitochondrial 
membrane [147,148], these results clearly point to distinct adenine nucleotide 
pools within the mitochondria and in the cytosol. 
The terms "functional coupling" and "metabolite channelling" auto­
matically imply microcompartmentation. Since much evidence has been 
accumulated for functional coupling between Mi-CK, ANT and porin as well 
as between cytosolic CK isoenzymes and myosin-ATPase of the myofibrils, 
Ca2+-ATPase of the sarcoplasmic reticulum and Na+/K+-ATPase of the 
sarcolemma, and since the different CK isoenzymes are in part bound to these 
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subcellular structures in an isoenzyme-specif ic manner (see Ш-С. and IV-B.), 
it seems very likely that not only between mitochondrial matrix, 
intermembrane space and cytosol, but also in the cytosol itself, different 
microcompartments for CK substrates exist, at least at high work-loads. The 
latter suggestion is strengthened by experiments on hypoxic or ischemic 
heart and smooth muscle, indicating that in spite of the high cytosolic CK 
activities, theCK substrates are not in a near-equilibrium sta te [21,159,160,206]. 
The most likely explanation is microcompartmentation of adenine nucleotides 
at the myofibrils [160,301,379,478,488] where ADP was supposed tobe tightly 
bound to actin [144,501]. 
31P-NMR data were also interpreted in favour of subcellular compart-
mentation of CK substrates. In conventional saturation transfer experiments 
under steady state conditions, the apparent high-energy phosphate flux in the 
forward direction of the CK reaction (PCr synthesis) was in most cases 
considerably higher than that in the reverse direction (ATP synthesis) 
[42,44,48,141,252,299,310,337,423]. Two alternative explanations were given 
for this difference: (i) microcompartmentation of CK substrates [251,252, 
337,529]. Two models accounting for microcompartmentation were de­
veloped. According to the model of Koretsky et al. [251], differences in flux 
rates between the forward and reverse direction of the CK reaction are 
observed in conventional saturation transfer, but not in 2D or inversion 
transfer NMR experiments, with these differences being a direct measure of 
microcompartmentation. In fact, the forward and reverse fluxes through the 
CK reaction were found to be equal in 2D-NMR experiments [15]. On the 
other hand, the model of Zahler et al. [529] is based on the assumption that 
some pools of cellular adenine nucleotides are NMR-invisible and conse­
quently not saturable in conventional saturation transfer experiments. This 
model correctly predicts that the flux PCr -> ATP increases with workload in 
the heart [42,44,46,47,262,300,346, 386], but not in skeletal muscle 
[67,141,360,425]. Furthermore, this model was shown to be consistent with a 
NMR-invisible ATP pool at the mitochondria, but not with localization of 
NMR-invisible ATP exclusively within the myofibrils. The notion that 
mitochondrial adenine nucleotides, probably due to the extremely high 
viscosity of the mitochondrial matrix [394], are restricted in rotational 
diffusion and are therefore NMR-invisible, is in support of the second model 
[529]. (ii) Alternatively, the participation of ATP in various side-reactions has 
been proposed as basis for the unequal forward and reverse fluxes through 
the CK reaction [141,299]. This interpretation is favoured by the finding that 
under steady state conditions, the difference between both fluxes vanished 
in multiple saturation transfer experiments, when for the determination of 
the ATP -» PCr flux, the P, as well as PCr resonances were concomitantly 
80 CHAPTER 2 
saturated [472]. Nevertheless, more work is needed to define clearly which 
of the two interpretations or which of the two models of micro-
compartmentation is correct. Finally, 31P-NMR experiments on intact cells 
and tissues as well as anoxic muscle revealed different pH environments for 
P, [412; for a review see Ref. 201] which may be explained by pH gradients 
of up to 0.5-1.0 pH units between the cytoplasmic and mitochondrial 
compartments. 
In conclusion, telling arguments for distinct mitochondrial and cytosolic 
CK substrate pools have been accumulated over the years. In contrast, only 
indirect evidence is currently available for microcompartmentation of CK 
substrates in the cytosol itself. Even though it is difficult to achieve, 
unequivocal corroboration of this latter type of microcompartmentation will 
be an important task for future research, since it critically determines the 
functionsoftheCK/PCr system and likely alsoa variety of cellular processes. 
ÍV-D. Regulation of mitochondrial oxidative phosphorylation 
Since the CK/PCr system in some tissues seems to be an essential part of the 
energy metabolism, its possible involvement in the regulation of mi tochondrial 
oxidative phosphorylation shall briefly be discussed. Up to now, 
mitochondrial respiration was proposed to correlate with (and therefore to 
be regulated by) [ADP], the [ATP] / [ADP] ratio, the phosphorylation poten-
tial, the "adenylatereaction pressure", the [NADH]/[NAD+] ratio, [Ca2+] or 
0 2 supply [152,217,263; for reviews see Refs. 17,56,102,150,171,177,181,218, 
253,294,306]. Whereas experiments on isolated mitochondria as well as on 
liver, skeletal muscle and newborn sheep hearts revealed a good correlation 
between the respiration rate and the concentration of ATP hydrolysis pro-
ducts [17,181,351], these findings were challenged by experiments on in vivo 
or perfused adult heart, brain and kidney, which indicated a poor correlation 
between these parameters [16,17,74,138,181 ]. Ins lead, especially for the heart, 
the [NADH]/[NAD+] ratio and [Ca2+] were favoured as primary regulators 
of oxidative phosphorylation, since Ca2+ at physiological concentrations was 
found to stimulate efficiently a variety of mitochondrial dehydrogenases 
[17,181]. 
At this point, a serious problem emerges. If reduction of transient times 
is an important function of the CK/PCr system (see IV-B.), then the ATP 
hydrolysis products must be primary determinants of the respiration rate in 
adult heart and brain as well. How can the apparent discrepancy be ex-
plained? Let us consider the possible consequences of introducing the 
CK/PCr system in a cell. If, for example, [ADP] (or [ATP]/[ADP] or the 
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phosphorylation potential) determined the mitochondrial respiration rate 
[217,218], and if the diffusion of ADP were restricted, ADP concentration 
gradients would exist between sites of ATP consumption and ATP produc-
tion, with the steepness of the gradient increasing with workload. The larger 
the diffusion restrictions for ADP, the higher the apparent Km of oxidative 
phosphorylation for ADP will be. Introduction of the CK/PCr system would 
drastically reduce the concentration gradient of ADP and therefore decrease 
the apparent Km of oxidative phosphorylation for ADP. This latter effect 
would be even more pronounced in the case of diffusion restrictions for 
adenine nucleotides across the outer mitochondrial membrane [32,33,147,148]. 
In other words, when [ADP] is plotted against the respiration rate or the rate-
pressure product, a much flatter line will be obtained in the presence of the 
CK/PCr system than in its absence, with this flatter dependency probably 
being barely detectable by 31P-NMR techniques [74]. 
These considerations may explain (i) why a clear correlation between the 
respiration rate and the concentration of ATP hydrolysis products was found 
in liver and isolated mitochondria, but not in adult heart exhibiting a fully 
developed CK system; (ii) why the regulation of oxidative phosphorylation 
by ATP hydrolysis products is apparently lost during postnatal development 
of the sheep heart [351 ], at about the same time when the CK system develops 
to its full maturity [199] and (iii) why training or chronic stimulation, known 
to increase the proportion of Mi-CK (see III-F.), also resulted in an apparent 
loss of respiratory control by the phosphorylation potential [86]. 
These reflections suggest that the ATP hydrolysis products ADP, P, and 
H+ are more important for respiratory control in the heart than currently 
believed, and that [Cr], [PCr] or the [Cr]/[PCr] ratio represent some sort of 
intermediate feedback signal for oxidative phosphorylation [42,221,314, 
376,379,414,415]. Since Mi-CK is likely to be displaced from equilibrium, a 
prerequisite for metabolic control, it may even be envisaged that oxidative 
phosphorylation is rate-limited by the Mi-CK reaction [294]. Nevertheless, 
the ATP hydrolysis products are clearly not the sole determinants of the 
respiratory rate [17,177,181]. They may be regarded as primary regulators of 
oxidative phosphorylation, with the [NADH]/[NAD+] ratio or [Ca2+] play-
ing a more modulatory role, or vice versa. For further investigation of 
respiratory control in the heart, it will be essential to determine the diffusion 
limitations for ADP, be it in the cytosol or across the outer mitochondrial 
membrane. 
82 CHAPTER 2 
V. Perspectives 
The aim of this review was to summarize the current knowledge about the 
biochemistry, physiology and pathology of mitochondrial creatine kinase 
and to present working hypotheses for future research. In addition to the 
"buffer" and "transport" function of the CK/PCr system, a third main 
function is proposed here, namely to reduce the transient times of the system 
to reach a new steady state upon abrupt changes in workload (see IV-B.). 
Transient times can be reduced in two different ways: (i) by increasing the 
enzymatic activities in such a way as to guarantee near-equilibrium condi-
tions. The cytosolicCK activity in heart and skeletal muscle was shown tobe 
severalfold higher than the maximal rates of ATP production or ATP 
consumption so that the cytosolic CK system is in a near-equilibrium state; 
(ii) by metabolic channelling of substrates. Many recent findings support the 
notion that octameric Mi-CK within mitochondrial contact sites (CS) is 
involved in metabolic channelling of high-energy phosphates across both 
mitochondrial membranes (see III-C). First, kinetic and thermodynamic 
exfjeriments revealed microcompartmentation of CK substrates within the 
mitochondrial intermembrane space which was either explained by enzyme-
enzyme proximity of Mi-CK and ANT or by diffusion limitations for adenine 
nucleotides across the outer mitochondrial membrane. Second, it was rea-
lized that CS may play an important role in the export of high-energy 
phosphates out of the mitochondria. The ex tent of CS is variable and increases 
with mitochondrial stimulation. Third, Mi-CK was found to be enriched in 
mitochondrial CS. And finally, the highly symmetrical 3D structure of the 
Mi-CK octamer, with two identical top and bottom faces, seems to be ideally 
suited for a CS localization, since the top and bottom faces are likely to have 
the same potency to interact with membranes (see II-C). Together with the 
apparent channel through the octameric molecule, it may be proposed that 
octameric Mi-CK within CS simultaneously binds to both the inner and outer 
mitochondrial membrane and is functionally (and physically?) coupled to 
ANT of the inner and porin of the outer membrane (see Fig. 2.B; page 38). This 
highly ordered multienzy me complex could be an effective means of displac-
ing the CK reaction in the intermembrane space from equilibrium and thus 
of allowing PCr synthesis even at high cytosolic ATP/ADP ratios. In addi-
tion, functional coupling was also demonstrated for cytosolic CK with 
myosin ATPase of the myofibrils, Ca2+-ATPase of the sarcoplasmic reticulum 
and Na+/K+-ATPase of the plasma membrane. 
A further function of the CK/PCr system may be to dampen oscillations 
of [ATP] and [ADP] upon abrupt changes in workload (see IV-B.). Inherent 
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to the latter two ideas is the assumption that Cr acts as some sort of "signal 
transducer" for the feedback regulation of mitochondrial oxidative 
phosphorylation by ATP hydrolysis products (see IV-D.). Whereas the 
"transport" and "transient time reduction" functions of the CK/PCr system 
are thought to predominate in tissues with a high proportion of Mi-CK like 
heart and slow-twitch skeletal muscles, the "buffer" function is dearly more 
important in fast-twitch skeletal muscles with low amounts of Mi-CK. To 
dampen oscillations of [ATP] and [ADP] may be a crucial function of the CK/ 
PCr system in all CK-containing tissues. 
In order to scrutinize these ideas and to get a deeper insight into the 
"real" functions of the CK/PCr system, it will be indispensable to define 
dearly (i) the diffusion limitations for ADP, ATP, PCr and Cr in the cytosol 
of heart, brain, skeletal and smooth muscle, retina and spermatozoa in 
comparison to liver; (ii) the permeability properties of the outer mitochondrial 
membrane for all CK substrates and P^ (iii) the functional and/or physical 
coupling of Mi-CK to ANT and porin as well as the stoichiometries of the 
three proteins within and beyond the CS; (iv) the three-dimensional structure 
of the Mi-CK octamer at atomic resolution in order to see if a channel through 
the molecule really exists and if the active sites of the subunits are directed 
towards this channel, and (v) whether changes in the dimer to octamer ratio 
of Mi-CK as well as dissociation and reassociation of dimeric and octameric 
Mi-CK from and to mitochondrial membranes (see Ш-D.) also occur under 
in vivo conditions and how they influence mitochondrial PCr synthesis or 
feedback regulation of oxidative phosphorylation. These experiments may 
then serve as basis for mathematical modelling of the CK/PCr system which 
is an essential prerequisite for asking further questions. 
From the point of view of comparative biochemistry and physiology, it 
will be intriguing to investigate at which stage of evolution two distinct 
Mi-CK isoenzymes in different tissues of the same species appeared, and how 
widespread the octameric structure of the Mi-CK isoenzymes is. In this 
respect, the human Mi-CK isoenzymes are of particular interest, since up to 
now, no detailed characterization of the higher M
r
 forms of the purified 
isoenzymes has been published. In addition, ubiquitous and sarcomeric 
Mi-CK may serve as valuable tools to clarify whether heart and brain have 
different mitochondrial import machineries for precursor proteins. 
A variety of recent studies suggest that the significance of the CK system 
in human pathology is currently underestimated. Culturing adult rat 
cardiomyocy tes in a medium devoid of Cr or supplemented with GPA led to 
the formation of large cylindrical mitochondria with crystal-like indusions 
enriched in Mi-CK (see III-F.). Similar abnormal mitochondria containing 
crystal-like inclusions enriched in Mi-CK were also observed in human 
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mitochondrial myopathies (see Ш-G. and Fig. 4; page 70). In this case, 
however, formation of mitochondrial inclusions did not seem to correlate 
with [Cr] in the tissue. Therefore, it will be an important task for future studies 
to determine the conditions causing the formation of abnormal mitochondria 
in myopathic tissues. Furthermore, animals fed with GPA or GBA may serve 
as models for the investigation of mitochondrial myopathies. Since the CK/ 
PCr system appears to be very important for spermatozoa, the relevance of 
defects within this system for male infertility will also be a promising subject 
for further research [198]. Finally, studies of patients with decreased levels 
of Mi-CK or with decreased tissue [PCr] may provide new views on the 
"real" functions of the CK/PCr system. 
In addition to all these challenges, the combination of established 
biochemical, biophysical and physiological methods with new, investigative 
techniques like 31P-NMR, overexpression of cloned CK genes in E. coiior yeast 
[14,62,79,140,254], site-directed mutagenesis, or generation of transgenic 
animals [66,255] will open the doors to new playing-fields for CK research. 
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Summary 
Defects in the mitochondrial energy generating system in patients with a 
mitochondrial myopathy are known to be localized in various enzyme 
complexes involved in energy production. Such a defect may exist at the level 
of mitochondrial creatine kinase (Mi-CK). On that account we have deve-
loped a method for measurement of the enzyme activity in human skeletal 
muscle biopsy material (>10 mg). Interfering creatine kinase isoenzymes are 
removed by anion exchange and affinity chromatography. The activity of 
Mi-CK in reference skeletal muscle homogenates amounts to 240 ± 88 mU/ 
mg protein (30 ± 8.0 mU/mg wet weight). 
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Introduction 
Creatine kinase (CK, EC 2.7.3.2) occurs as five isoenzymes in human skeletal 
muscle. Three of them, MM-, MB- and BB-CK, are found within the cytoplasm 
and two are strictly mitochondrial. MM-CK is the predominant cytoplasmic 
form in muscle. The existence of mitochondrial CK (Mi-CK), was first 
described in 1964 by Jacobs et al. [1]. It is located within the mitochondrial 
intermembrane space in tissues with a high energy demand such as muscle, 
brain, photoreceptor cells and spermatozoa. Mi-CK is restricted to 
mitochondria and seems to be well adapted to generate phosphocreatine 
(PCr) from ATP produced within the mitochondrial matrix by forming a 
functionally coupled micro compartment with the ATP/ADP-translocator 
[2]. PCr is then made available by a PCr-shuttle or by facilitated diffusion to 
those fractions of CK that are localized at specific intracellular sites of high 
energy demand [3]. Recently, based on mRNA studies, evidence was ob-
tained for more than one gene encoding for Mi-CK[4]. 
Since the discovery in 1964 of Mi-CK in isolated mitochondria from rat 
brain, skeletal and heart muscle [1], there have been only a few studies on 
human skeletal muscle Mi-CK. Quantitative data were presented by Apple 
and Rogers who showed an obvious training effect on the activity of the 
enzyme in gastrocnemius muscle from long-distance runners [5]. As yet 
there are no clinical studies on the relevance of Mi-CK in neuro-muscular 
diseases. 
Determination of Mi-CK in skeletal muscle is complicated by the pre-
sence of large quantities of cytoplasmic CK isoenzymes, mainly MM-CK. The 
similar isoelectric points of both isoenzymes in humans do not enable a 
quantitative assay based solely on differences in charge. 
Various mitochondrial myopathies are caused by defects in complexes 
of the mitochondrial energy generating system, but the cause can not be 
pinpointed to a single enzyme defect in all patients [6]. This may also occur 
at the level of Mi-CK. For that reason we have developed a method for 
quantitative measurement of Mi-CK activity in small amounts of human 
skeletal muscle and this is now reported. 
Materials and methods 
Preparation of muscle homogenates 
Muscle tissue samples (m. quadriceps) were obtained from patients (age 
range 22 months-59 years, 10 males and 9 females) clinically suspect for a 
neuromuscular disease. Normal results were found for muscle pyruvate and 
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malate oxidation rates and for single enzymes of the respiratory chain [7], 
thus excluding a defect in the energy-generating system except for fatty add 
oxidation. Muscle tissue was freed from fat and connective tissue and 
homogenized (10% w/v) in a 10 mmol/L Tris/HCl buffer pH 7.4, containing 
250 mmol/L sucrose, 2 mmol/L EDTA, 50 U/mL heparin (SETH-buffer) 
using a teflon-glass Potter-Elvehjem homogenizer and three different teflon 
pestles [7]. 
DEAE-Cellulose 
The anion exchanger DEAE-Cellulose (Whatman DE52) was prepared ac­
cording to Nealon and Henderson [8] and stored at 4 0C as a 50% (v/v) 
suspension in a 30 mmol/L Na 2 HP0 4 / МаН 2 Ю 4 buffer pH 7.4 containing 
0.2 mmol/L phenylmethanesulfonyl fluoride and 0.2 mmol/L dithiothreithol 
(buffer A) with addition of 0.01% NaNj. 
Sepharose immobilized anti-M-CK antibodies 
CNBr-activated Sepharose 4B (Pharmacia, Uppsala, Sweden, No. 17-0430-
01) was used for the coupling of anti-M-CK antibodies (polyclonal goat anti-
M-CK antibody, Boehringer, Mannheim, Germany, No. 418 234). The protein 
concentration of the antibody sample after overnight dialysis against the 
coupling buffer recommended by Pharmacia was 2.5 g/L. The coupling was 
carried out according to the instructions of the manufacturer. Approximately 
5 mg protein was bound per mL of activated Sepharose. Sepharose coupled 
anti M-CK was stored in buffer A (+ 0.01% NaNj) at 4 0C. After use, 
regeneration of the immobilized antibody was achieved with a 1 h incubation 
in 2 mol/L NH4SCN (ammonium thiocyanide), followed by extensive 
washing of the Sepharose with buffer A. 
The assay of mitochondrial CK 
Figure 1 gives a schematic representation of the assay procedure. The first 
step was the extraction of Mi-CK in a hypotonic phosphate buffer. Fifty 
microlitres muscle homogenate was diluted five-fold with buffer A with 
0.05% Triton X-100 (v/v). After incubation under gentle mixing (1 h; room 
temperature), and centrifugation at 40 000 χ g for 30 min at 4 0C, the 
supernatant were used for measurements. One hundred and fifty microlitres 
of the supernatant was added to 50 μL DEAE-Cellulose slurry binding 
MB-CK and BB-CK. After incubation (10 min; room temperature) and 
centrifugation (1 min; 8300 χ g), 100 [iL supernatant and 150 \LL Sepharose 
bound anti M-CK were mixed and incubated (10 min at room temperature). 
The Sepharose immobilized antibodies against the M-CK chain bind most 
(>99%, see Results) of the MM-isoenzyme. After centrifugation (2100 χ g; 
1 min) in an Ultrafree-MC Filter Unit (Millipore, Bedford, MA 01730 USA) to 
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avoid contamination with Sepharose bound MM-CK, CK activity was 
measured in the presence and in the absence of inhibiting antibodies against 
the M-CK chain (polyclonal goa t antì-М-СК antibody, Boehringer, Mannheim, 
Germany, No. 418234). At this stage Mi-CK can be accompanied by a minimal 
amount of MM-CK, which is easily inhibited by the antibody. CK activity was 
measured (CBR-CK NAC-activated kit, Boehringer, Mannheim, Germany, 
No. 475742) at 30 0C on a COBAS-Mira analyzer (Hoffman La Roche, Basel, 
Switzerland). Cytochrome с oxidase, citrate synthase and protein were 
determined as described before [9,10,11]. 
Internal standard 
Approximately 2 mg cytochrome с (horse-heart, Boehringer, Mannheim, 
Germany, No. 103889) were added to 200 μ ι muscle extract as an internal 
standard to calculate the dilution factor during the chromatographic met­
hods. This factor was calculated from the absorbance at 550 run in oxidized 
and reduced form (2 mg of K3Fe(CN)6 and 5 mg of Na 2 S 2 0 4 respectively) 
before and after the chromatographic steps (Fig. 1). 
Electrophoresis 
Cellulose acetate electrophoresis was performed at 20 0C for 35 min at 300 V 
(Boskamp: Kammer F21 Microphor, power supply Pherostat 273 and MTB 
Folien No. 49206-04 / sample volume ΙμΙ with total CK activity >500 U/L) 
using a 73 mmol/L Tris-barbi tal-buffer pH 8.6 containing 21.7 mmol/L 
Cytochrome с 
determination 
A 550 nm 
Mi-CK extraction 
D 
40 000 χ g supernatant + cyt с 
DEAE Cellulose 
(batch wise) 
D 
Sepharose bound 
anti-M-CK (batch wise) 
MB+BB-CK 
MM-CK 
V 
Mi-CK activity measurement 
Fig. 1. Schematic representation of the assay procedure. 
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5,5-diethylbutyric acid and 1 mmol/L dithiothreitol. An agar-overlay nitro 
blue tetrazolium technique was used for specific CK staining [12]. 
Behaviour of purified CK isoenzymes in the Mi-CK assay 
CK isoenzymes were purified from human autopsy material (BB-CK from 
brain, MB-CK and Mi-CK from heart, MM-CK from skeletal muscle) to 
establish their behaviour during the Mi-CK assay. 
The various isoenzymes were separated from contaminating CK-forms 
using anion exchange chromatography on mini-columns [8]. The purity was 
checked electrophoretically. These purified CK isoenzymes were submitted 
to the Mi-CK assay. 
Results 
Mitochondrial CK extraction 
Tissue obtained by muscle biopsy was homogenized in an isotonic sucrose 
containing Tris buffer. Under these conditions Mi-CK remains bound to the 
mitochondrial inner membrane. We have studied the release of the enzyme 
after five-fold dilution of the homogenate in hypotonic phosphate buffers 
with varying molarity (20-200 mM). Maximum extraction was obtained with 
an 1 h incubation at room temperature in buffer A with addition of 0.05% 
Triton X-100 (v/v). The buffer had the additional advantage that the 40 000 
χ g supernatant can be used directly in the subsequent DE AE-Cellulose step. 
With a higher phosphate molarity in the buffer MB-CK and BB-CK would not 
bind to the anion exchanger. The extract contained all CK isoenzymes, the 
amount of BB-CK being very low (Fig. 2, lane 1). 
For optimal extraction of Mi-CK the addition of a detergent showed to 
be obligatory. We tested Triton X-100 (Boehringer, Mannheim, Germany), 
n-dodecyl-ß-D-maltoside (Boehringer, Mannheim, Germany), n-octyl-
glucoside (Boehringer, Mannheim, Germany), sodium dodecyl sulphate 
(Merck, Darmstadt, Germany), deoxycholic acid sodium salt (Fluka, Buchs, 
Switzerland), Brij 35 solution (Sigma, St. Louis, USA), Tween 20 (Sigma, St. 
Louis, USA) and Zwittergent detergent 3-14 (Calbiochem, San Diego, USA) 
in different concentrations. Triton X-100 0.05% produced the most efficient 
release of Mi-CK from the mitochondrial inner membrane. Sonification or 
freeze-thawing yielded 30% extra Mi-CK activity in the absence of Triton Χ­
Ι 00 but there was no additional effect in its presence. Extraction at pH 8.0 and 
8.5 resulted in 25% less Mi-CK than extraction at pH 7.4. Addition of Triton 
X-100 at 0.05% showed no interference with the different steps of the 
procedure or enzyme assay. 
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new * 
MB 
M f 
4 5 6 
Fig. 2. Electrophoretic pattern on cellulose polyacetate strips of CK-isoforms in the various steps 
of the assay procedure. 
(1) Supernatant of Mi-CK extraction; (2) and (4) CK-isotrol (Sigma No. c0153); (3) 
after DEAE-anion exchanger; (5) after Sepharose bound anti-M-CK; (6) ibid after 
addition of inhibiting M-CK antibodies. -» = origin; + = anode; - = cathode. 
Anion exchange and affinity chromatography 
Fig. 2 (lane 3) shows that by batch-wise DEAE-anion exchange-chromato-
graphy MB-CK and BB-CK were quantitatively removed from the sample. 
MM-CK and Mi-CK did not bind to the anion exchanger. The majority of the 
MM-CK was removed from the resulting supernatant by affinity chromato­
graphy with Sepharose bound anti M-CK (Fig. 2, lane 5). Apart from Mi-CK, 
which remained unbound, the supernatant contained a limited amount of 
MM-CK, that was inhibited by the addition of anti-M-CK antibodies (Fig. 2, 
lane 6). 
To calculate the correct dilution factor during the various steps in the 
analysis cytochrome с was used as an internal standard. It does not bind to 
the DEAE-Cellulose or to the Sepharose bound anti-M-CK. Furthermore it 
was shown to have no effect on the activity of Mi-CK and does not interfere 
with the assay system for CK. 
Linearity and reproducibility 
The linearity of the assay was checked by dilution of the 40 000 χ g supernatant 
in 30 mmol/L phosphate buffer. Mi-CK activity in the sample with 10% of the 
original activity could still be measured reliably. The coefficient of corre-
1 2 3 
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lation was 0.9997. Reproducibility was measured with five samples of the 
same muscle homogenate undergoing the complete assay procedure. The 
within-run coefficient of variation was 4%, the day to day variation was 14%. 
Specificity 
The specificity of the assay was tested with purified preparations of MM-CK, 
MB-CK, BB-CK and Mi-CK in buffer A. Total CK activity of these prepara­
tions was 70 000,4200,2820 and 8420 U/ L, respectively. Mi-CK recovery after 
the various steps of the assay procedure was good (Table 1). The table 
furthermore illustrates that MB-CK and BB-CK in this order of magnitude 
were efficiently removed by the anion exchanger while a major percentage 
of MM-CK was removed by the Sepharose bound anti-M-CK. The small 
percentage of MM-CK that failed to bind in this affinity step was inhibited by 
anti-M added in the final CK activity measurement. 
Care must be taken to ensure that the binding capacity in the two 
chromatographic steps is not surpassed, since this would lead to falsely high 
values for Mi-CK. Therefore, total CK activity in the 40 000 χ g supernatant 
after Mi-CK extraction should not exceed 100 000 U/L. Furthermore it is 
recommended that the MM-CK binding efficiency of the Sepharose is 
checked by also measuring total CK activity (without addition of inhibiting 
anti-M-CK antibodies) in the supernatant of the Sepharose. The assay will 
produce reliable results if the inhibiting antibodies in the final measurement 
have enough capacity to inhibit the enzymatic activity of all MM-CK present 
in the supernatant of the Sepharose. 
Reference values 
Reference values for Mi-CK were obtained from skeletal muscle biopsies of 
19 patients (m. quadriceps; 10 male and 9 female; Table 2). Mi-CK was not 
only expressed per mg protein and per mg wet weight, but also on two 
mitochondrial marker enzymes e.g. per cytochrome с oxidase (an inner 
membrane bound one) and per citrate synthase (a mitochondrial matrix 
enzyme). We have experience that the mitochondrial content of human 
skeletal muscle can vary to a considerable extent, especially in pathological 
muscle tissue. In case of a decreased Mi-CK activity it is possibly to distin­
guish between a lowered mitochondrial content and a real deficiency, by 
expressing the Mi-CK per unit activity of mitochondrial reference enzymes. 
Total CK activity was used as a skeletal muscle enzyme marker. Table 3 
shows the means with the standard deviations of these 19 patients. Although 
not statistically significant male patients showed a higher specific activity of 
total CK and Mi-CK compared to the females. Mi-CK as percentage of total 
CK showed no differences between the sexes and amounted to 0.9%. Mean 
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Table 1. Behaviour of various CK isoenzymes in the different steps for the determination of Mi-CK 
Partially purified CK isoenzymes 
MM MB BB Mi 
Extract 100% 100% 100% 100% 
Supernatant after 98% <1.5% <0.5% nd 
DEAE Cellulose 
Supernatant after <1% 0% 0% 113% 
anti-M Sepharose 
After anH-M 0% 0% 0% 113% 
immunoinhibition 
nd= not determined. 
Mi-CK activity of all patients, males and females, was 240 mU/mg protein or 
30 mU/mg wet weight. 
Discussion 
Various authors have used electrophoretic techniques to demonstrate the 
presence of Mi-CK in heart tissue. In an earlier study we have used agarose 
electrophoresis to show the presence of Mi-CK in human skeletal muscle. 
This technique can only be used semiquanti ta lively and is hampered by the 
similar electrophoretic behaviour of MM-CK and Mi-CK. Weselake and 
Jacobs were the first to describe a technique for the separation of heart Mi-CK 
from cytoplasmic CK forms by hydrophobic interaction chromatography 
[13]. This technique has been used by Apple and Rogers [5] for quantitative 
determinations. Wallimann et al. used affinity chromatography with Ciba-
chrome-blue Sepharose for the separation of chicken heart Mi-CK from 
MM-CK and from the quantità lively most important cytoplasmic CK-form in 
chicken heart BB-CK [14]. 
A complication in human skeletal muscle is the considerably higher 
amount of MM-CK present in comparison with heart tissue. This led us to 
develop a technique that effectively and quantitatively removes BB-CK and 
MB-CK from the homogenate in a first step (DEAE anion exchanger) 
followed by a second step that removes almost all MM-CK activity 
(anti-M-CK immobilized on Sepharose). The small percentage of MM-CK 
that is not bound by this immunoabsorben t is inhibited in the final CK activity 
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Table 2. Reference values for Mi-CK in human m. quadriceps (n=19). Specific activity and 
Mi-CK expressed per unit of mitochondrial reference enzymes 
(mU/mg protein) 
(mU/mg wet weight) 
(mU/mg protein) 
(mU/mg wet weight) 
(U/U total CK) 
(U/U СОХ) 
(U/U CS) 
Mean 
28 037 
3568 
240 
30 
0.0086 
1.7 
2.7 
SD 
7524 
773 
88 
8.0 
0.0015 
0.36 
0.80 
Range 
13 707-42468 
1871 - 4751 
131-490 
19-52 
0.0061-0.012 
1.1-2.4 
1.4-4.1 
СОХ = Cytochrome с oxidase. 
CS = Citrate synthase. 
Table 3. Comparison of total CK and Mi-CK activity values of 10 male and 9 female patients 
clinically suspect for a neuromuscular disease. 
Total CK 
Mi-CK 
Mi-CK 
(mU/mg protein) 
(mU/mg protein) 
(% of total CK) 
Male 
Mean 
31798 
273 
0.9 
SD 
7015 
103 
0.2 
Female 
Mean 
23 859 
203 
0.9 
SD 
5889 
48 
0.2 
measurement by M-CK inhibiting antibodies. The resulting enzymatic activ­
ity was shown to be caused solely by Mi-CK (Table 1; page 107). This was also 
confirmed electrophoretically after addition of anti-M-CK to the sample (Fig. 
2, lane 6; page 105). The assay for Mi-CK can be applied on amounts of muscle 
tissue as small as 10 mg and can thus be carried out on needle biopsy material. 
Because of the similar physico-chemical properties of Mi-CK in human heart, 
skeletal muscle and brain tissue the assay described in this paper is expected 
to be useful also for the quantitation of Mi-CK in human heart and brain tissue 
[15,16]. 
Total CK activity per mg wet weight in our patient reference group (3568 
U/g) is comparable with the values found by Apple and Rogers for male 
marathon runners (2985U/g)buthigher than in female runners (pretraining: 
1750 U/g) [5]. 
Mi-CK activity per g wet weight (30 U/ g) is in a similar range of activity 
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as given by Apple and Rogers for females: 27.2 U/g , but lower than they 
reported for males: 104 U/g [5]. Expressed per unit total CK, Mi-CK activity 
in m. quadriceps of our patients (0.9%) is probably in conformity with the 
non-running control muscles investigated by Apple and Rogers although 
they did not present exact data. Our mean Mi-CK percentage is somewhat 
lower than those found in marathon runners (female 1.5%, male 3.5%). This 
finding can be explained satisfactorily by the effect of training shown by 
Apple and Rogers [5]. Furthermore differences, like the homogenization 
buffer, between both studies in CK and Mi-CK extraction from muscle may 
play a role. Apart from the study by Apple and Rogers there are to our 
knowledge no other reports in literature presenting quantitative data on 
human skeletal muscle Mi-CK. 
Recently, two Mi-CK mRNAs have been described [4]. However, as yet 
nothing is known about the relationship between the different Mi-CK genes 
and the relative contribution of the putative isoenzymes to the total Mi-CK 
activity in muscle. 
We present reference values based on measurements in patients sus-
pected clinically to suffer from a neuromuscular disease. It would be 
interesting to compare our data with data on (untrained) healthy volunteers. 
Care should be taken in judging Mi-CK activity levels found in patients with 
extreme muscular disuse, in whom the opposite of the effect of training 
described by Apple and Rogers [5] may be anticipated. We have found no 
statistically firm indications for a sex dependent activity as described pre-
viously [5]. 
Further study will concentrate on a influence of age on the reference 
values of the enzyme. The youngest of our patients was 22 months old. 
Reference values for neonates and young children remain to be established. 
After extensive biochemical and histological examinations of muscle 
tissue a group of patients remains in whom there is evidence for a mitochondrial 
myopathy while the exact localization of the defect at enzyme level remains 
unresolved. The clinical spectrum of such patients is very heterogeneous and 
the age of onset, and the severeness of symptoms, may vary considerably. 
Frequently encountered symptoms in neonates are muscle weakness, 
hypotonia and failure to thrive most often accompanied by respiratory 
insufficiency and central nervous system involvement. In children and adult 
patients either myopathic symptoms alone, i.e. excercise intolerance and 
muscle weakness, or a multisystemic disorder occurs, the latter mostly being 
a combination of myopathic, encephalopathic and or ocular involvement. A 
defect at the level of Mi-CK may explain some of these cases. The determina-
tion of Mi-CK may prove to be a useful biochemical diagnostic tool in patients 
with a mitochondrial myopathy. Studies are underway to screen patients for 
defects in Mi-CK using the methodology described in this paper. 
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Summary 
We studied pre- and postnatal changes in total creatine kinase (CK) activity, 
mitochondrial creatine kinase (Mi-CK) activity and immunochemical reac-
tivity with anti-Mi-CK antibodies in skeletal musde specimens from 12 
infants, 10 of them preterm born, after a pregnancy varying between 28 and 
40 weeks. Our results demonstrate that Mi-CK is present in fetal human 
quadriceps musde and that the spedfic activity of Mi-CK increases during 
prenatal development from week 28 to 40 by a factor of about two. Generally, 
adult levels have not been reached at birth, indicating a further postnatal 
increase of the activity of the enzyme. The Mi-CK protein content also 
increases during prenatal development. These results suggest that in human 
skeletal muscle the expression and accumulation of Mi-CK starts at mid-
gestation, later than is known to occur for cytosolic CK. 
Maturation of mitochondrial creatine kinase 113 
Introduction 
CK (E.C. 2.7.3.2) catalyses the reversible transphosphorylatíon reaction 
between phosphocreatine (PCr) and ATP: 
PCr2" + MgADP"+(x).H+ « » MgATP2'+Cr 
Five different isoenzymes of CK are currently known; MM-CK, MB-CK and 
BB-CK are three non-mitochondrial cytosolic isoenzymes, which are dimers 
comprising a combination of two different enzyme subunits, the M or muscle 
type and the В or brain type subunit [1]. 
Most of these cytosolic isoenzymes are soluble, but a small percentage 
may be compartmentalized subcellularly at sites of high ATP-tumover. In 
muscle, for example, MM-CK has been found both free and in association 
with the myofibrillar M-line [2]. 
In mature human skeletal muscle the relative percentages of the various 
cytoplasmic isoenzymes are: 96-100% MM-CK, 0-3% MB-CK and 0-1% 
BB-CK [3]. Kuby and co-workers [4] showed that skeletal muscle of an 11-12 
week old human female fetus already contained BB-, MB- and MM-CK. 
During skeletal muscle development an isoenzyme transition from BB-CK to 
MM-CK takes place [5]. Immunohistochemically it has been demonstrated 
that in human skeletal muscle a switch from BB-CK to MM-CK takes place 
around week 8 of development [6]. 
To our knowledge no data is available about the prenatal development 
in skeletal muscle of the other type of CK; that is mitochondrial creatine 
kinase (Mi-CK) which in adult human quadriceps muscle amounts to 0.9% of 
total CK [Τ]. 
We studied muscle biopsies of preterm and term bom infants to examine 
if there are changes of Mi-CK expression and accumulation during pre- and 
postnatal development as has been shown for other enzymes involved in 
skeletal muscle energy metabolism [8]. 
Clinical data 
Muscle tissue (m. quadriceps) was removed within 1 h post mortem from ten 
preterm bom infants (four females; six males) and two term bom infants (two 
males) with the informed consent of the parents. The gestational age varied 
between 28 and 36 weeks in the preterm bom infants; their weights at birth 
were 460-3350 g. The infants died within the first 6 days of life. 
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One infant died from septic shock, all others died from cardiorespiratory 
failure. Six infants suffered from a congenital disorder, i.e., triploidy, hemia 
of diaphragm (two infants), congenital heart disease (aorta ascendens 
hypoplasia), hydrops fetalis, and single arteria umbilicalis. Anatomical 
examination of the brain showed signs of intracerebral haemorrhage in four 
infants. Three infants had normal anatomy. The patient with the triploidy 
showed an aplasia of the left n. olfactorius. No examination of the brain was 
performed in the other five patients. 
None of the infants showed clinical signs of a neuromuscular disorder. 
Materials and methods 
Preparation of muscle homogenates 
Muscle samples were either immediately frozen in liquid nitrogen and stored 
at -70 0C or immediately homogenized and stored at -70 0C. Muscle 
homogenates (10% w/v) were prepared according to Fischer et al. [9]. 
Cytochrome с oxidase activity was measured according to Cooperstein 
and Lazarow [10] and citrate synthase activity according to Srere [11]. Protein 
was determined by the method of Lowry et al. [12]. 
Electrophoresis of CK-isoenzymes 
Electrophoresis and detection of the CK isoenzymes, using the agargel 
overlay technique, was performed, with slight modifications, as described by 
Harm et al. [13]. The homogenate was five times diluted with a 30 mmol/L 
sodium phosphate buffer (pH 7.4) containing 0.2 mmol/L phenylmethane-
sulfonyl fluoride, 0.2 mmol/L dithiothreitol and 0.05% Triton X-100 (v/v) to 
extract Mi-CK. After a 1 h incubation (room temperature) and centrifugation 
at40 000xg(30 min;40C) the supernatant (sup. 1) was used forelectrophoresis. 
Six microliters of sup. 1 was applied to a cellulose acetate strip for 
electrophoresis. Detection of the CK isoenzymes with nitro blue tetrazolium 
was performed in the presence of a final concentration of 10 μιηοΙ/L 
diadenosine pentaphosphate to inhibit adenylate kinase activity. 
Measurement of mitochondrial CK 
Mi-CK activity was measured according to Smeitink et al. [7]. In brief, 50 \iL 
muscle homogenate was diluted five times with the above mentioned buffer. 
The 40 000g supernatant was used for measurement of total CK activity and 
further treatments. Total CK specific activity was measured (CBR-CK NAC-
activated kit, Boehringer Mannheim, Germany, No. 475742) at 30 "С. Fifty 
microlitres DEAE-Cellulose slurry (Whatman DE 52) [14] added to 150 pL of 
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the 40 000g supernatant, were used to bind BB-CK and MB-CK. After 
incubation (10 min; room temperature) and centrifugation at 8300xg (Imin), 
100 μΐ, DEAE supernatant and 150 μι Sepharose (CNBr-activated Sepharose 
4B, Pharmacia, Uppsala, Sweden) with anti-M-CK (polyclonal goat anti-M-
CK antibody, Boehringer Mannheim) bound to it were mixed and incubated 
(10 min; room temperature). After centrifugation for 1 min at 2100xg in an 
Ultrafree-MC Filter Unit (Millipore, Bedford) to avoid contamination with 
Sepharose bound MM-CK, CK activity was measured in the presence and 
absence of inhibiting antibodies against the M-CK-chain (CBR-CK NAC-
activated kit, Boehringer Mannheim) at 30 0C. The hexokinase/glucose-6-P 
dehydrogenase coupled production of NADPH was measured at 340 nm 
using a COBAS-Mira analyzer (Hoffmann-La Roche, Basel, Switzerland). 
Analysis of the amounts of Mi-CK protein 
Sup. 1 of the same muscles as used for electrophoresis was analysed by 
immunochemical methods. Sodium dodecyl sulphate (SDS)-polyacrylamide 
gel electrophoresis was performed on a 10% gel in the Mini-protein two 
system (Biorad, Richmond, USA) using the buffer system as described by 
Laemmli [15]. The separated proteins (12.5 μg protein) were transferred to 
nitrocellulose membranes essentially as described by Towbin et al. [16]. 
Proteins were stained with Ponceau S (Sigma Chemical Co., St Louis, 
Missouri, USA). The nitrocellulose membranes were washed and incubated 
with a specific polyclonal rabbit anti-chicken Mi-CK antibody [17]. 
Antigen-antibody complexes were detected using alkaline phosphatase 
labelled porcine anti-rabbit serum as second ligand and nitroblue tetrazolium 
as substrate. Finally, the immunoblots were scanned with a laser densitometer 
(Ultrascan XL, Pharmada/LKB Uppsala, Sweden). 
Statistics 
A multiple and a simple linear regression analysis were performed to 
examine for total CK and Mi-CK the dependency of gestational age and 
postnatal age. 
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Results 
Table 1 contains the various enzyme activities measured in the first six days 
after birth compared with those measured in an older reference group of 19 
persons [7]. 
Using a multiple linear regression analysis with gestational age and 
postnatal age as explanatory variables no dependency of the latter age could 
be established (P>0.10). Therefore we proceeded with simple linear regres­
sion based on gestational age. 
The specific activity of total CK showed a dear developmental increase 
with duration of pregnancy (P=0.001;Fig. 1). Electrophoresis of the CK 
isoenzymes showed that with increasing ges tational age the content of BB-CK 
decreased and that of MM-CK increased (Fig. 2; page 118). Mi-CK activity 
was not detected with this technique before week 29 of gestation. It should 
be noted that only one Mi-CKband could be detected by cellulose polyacetate 
electrophoresis (Fig. 2; page 118). 
The specific activity of Mi-CK also showed a developmental increase 
with increasing gestational age (P=0.002;Fig.l). 
Neither Mi-CK expressed relative to citrate synthase, a mitochondrial matrix 
enzyme, nor Mi-CK expressed relative to cytochrome с oxidase, an inner 
membrane bound mi tochondrial enzyme, showed a developmental increase 
Table 1. Ranges of total CK, Mi-CK, q/lochrome с oxidase (COX) and citrate synthase (CS) 
enzyme activities in m. quadriceps of preterm bom infants and of a reference group 
Total CK 
Mi-CK 
COX 
CS 
(U/mg protein) 
(U/mg wet weight) 
(mU/mg protein) 
(mU/mg wet weight) 
(mU/U total CK) 
(U/U COX) 
(U/U CS) 
(mU/mg protein) 
(mU/mg protein) 
Infants 
(0-6 days) 
(n = 12) 
10.3 -
0.65 -
60.0 -
5.2 -
4.2 -
0.61 -
0.69 -
29 
30 -
33.0* 
4.03' 
191 
20.3 
10.2 
2.87 
3.23 
150 
125 
Reference group 
(2 months-60 years) 
(n = 
13.7 
1.87 
131 
19.2 
6.2 
1.09 
1.36 
65 
45 
19) 
. 
-
. 
-
-
-
-
. 
-
42.5 
4.75 
490 
51.9 
12.4 
2.35 
4.10 
247 
143 
' n = l l 
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with the gestational age (P=0.15 and 0.34, respectively). 
Immunoblot experiments appeared to show an increase in Mi-CK pro­
tein with gestational progress (Fig.3). Despite the low number of measure­
ments linear regression analysis of the densitometric results approached 
statistical significance (P=0.08). 
**KJ~ 
3 0 -
2 0 -
10-
Total CK (π 
О 
\U/m 
-"'о 
g protein) 
^ ^ Ό 
О 
О 
о 
1 
о 
о^. 
2 8 ЗО 3 2 34 36 3 8 4 0 
Gestational age (weeks) 
2 0 0 
Mi-CK (mU/mg protein) 
150-
100 
Gestational age (weeks) 
Fig. 1. LinearregressUmamlysìsofthespeàficacHvityoftotalCKfupperpaneDandMi-CKdower 
panel) as a function of gestational age (weeks) 
118 CHAPTER 4 
. ^ ^ м м ш и - І К ЛЕЧ^^ШЛлтЁт. •JH^f l^^^AA 
BB 
MB 
MM 
Fig. 2. Electrophoresis pattern of CK isoenzymes stained for CK activity. 
Supematants of 10% m. quadriceps homogenates were applied after extraction 
with a hypotonic phosphate buffer in the presence of 0.05% Triton X-100 to release 
the CK isoenzymes. Gestational ages (weeks) in lanes 1-5 are: 26,28,355/7,37, and 
40, respectively. Lane 6: control serum (CBR-NAC-activated kit). -> origin; +anode; 
- cathode. 
8 
Fig.3. ImmunochemicaldetectionofMi-CKproteinafterelectrophoresisofsupermtantlonSDS-
PAGE followed by immunoblotting on nitrocellulose in 6 preterm and two term bom 
infants. 
Gestational ages (weeks) in lanes 1-8 are as follows: 26, 28, 285/7, 294/7, 355/7,37, 
384/7 and 40. Markers of molecular weight (kD) are shown on the left and right side 
of the figure. On the left side from top to bottom:180,116,84,58,48.5 and 36.5. On 
the right side from top to bottom: 205,116,97.4,66,45 and 29. 
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Discussion 
The purpose of this investigation was to study the developmental expression 
and activity of total CK and Mi-CK during pre- and postnatal development 
in human skeletal muscle. A prenatal increase in both activities has been 
reported for sheep heart [18]. Data about the developmental changes of Mi-
CK activity in skeletal muscle are of importance both for understanding the 
physiological role of this enzyme in energy metabolism and also for the 
interpretation of results from infants suspected to suffer from a mitochondrial 
myopathy. Mi-CK deficiency may explain the disturbed pyruvate oxidation 
rate found in a substantial percentage of infants and adults, for the decreased 
substrate oxidation rate can not be ascribed to a defect in the pyruvate 
dehydrogenase complex, tricarboxylic acid cycle or respiratory chain [8]. 
No data on prenatal developmental changes of Mi-CK in human skeletal 
muscle are available at this moment, due in part to difficulties in obtaining 
human muscle samples. The relatively lower contribution of Mi-CK to the 
total CK activity in skeletal muscle (mean ± 0.9%) in comparison with heart 
muscle (mean ± 9%) forms another problem in collecting adequate reference 
values for skeletal muscle. Recently, we developed a technique for measure­
ment of the Mi-CK activity after removal and inhibition of the surplus of other 
CK isoenzyme activity [7]. 
We were unable to evaluate Mi-CK and total CK specific activity related 
to age in days after birth because the postnatal lifespan hardly varied in our 
group of infants. 
To reach average adult levels (mean ± SD = 240 ± 88) the Mi-CK activity 
in mU per mg protein (118 ± 44) has to increase by a factor 2 after birth (Table 
1.). A comparable increase of Mi-CK was found between 28th and 40th week 
of pregnancy (Fig. 1; page 117). Thus, on average, Mi-CK increases in m. 
quadriceps by a factor of about four from the 28th week of pregnancy to 
adulthood. 
Immunoblot studies of Mi-CK with a polyclonal rabbit anti-chicken 
Mi-CK antibody showed a prenatal increase in the Mi-CK protein content 
(Fig. 3). Thus, the increase in Mi-CK activity during gestation appears to be 
paralleled by a rise in Mi-CK protein. Cytochrome с oxidase, a membrane 
bound enzyme like Mi-CK, shows a similar prenatal development to Mi-CK. 
The prenatal increase in total CK activity can not be explained by the 
observed increase in Mi-CK activity since the proportion of Mi-CK relative 
to the total CK activity is small. The major contribution to this increase is due 
to a developmental increase of the MM-CK isoenzyme, the most abundant CK 
isoenzyme in skeletal muscle, as could be shown with the agargel overlay 
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technique after cellulose polyacetate electrophoresis (Fig. 2.; page 118). 
In conclusion, these data provide an insight into the maturation of Mi-CK 
and so extend our knowledge of h u m a n skeletal muscle energy metabolism 
in neonates. They also provide a baseline for the correct interpretation of 
results from patients suspected to suffer from a mitochondrial myopathy. 
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Summary 
Eleven patients with an established disturbance in muscle mitochondria 
energy generation, in whom no defect in the pyruvate dehydrogenase 
complex or in the complexes of the respiratory chain could be detected, were 
investigated for a possible deficiency in the mitochondrial creatine kinase 
(Mi-CK) (EC 2.7.3.2). Moreover, four patients with a defect in one of the 
complexes of the respiratory chain were also investigated as to the Mi-CK 
activity. In none of the investigated patients a Mi-CK deficiency was found. 
Surprisingly enough two of the four patients with a defect in one of the 
respiratory chain complexes showed an enhanced activity of Mi-CK. It can be 
concluded that a Mi-CK deficiency is not frequently found as the primary 
defect in patients with a disturbance in the mitochondrial energy generation 
but more patients should be examined to allow a definite conclusion. 
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Introduction 
A mitochondrial myopathy can be defined as a muscle disease characterized 
by structurally or numerically abnormal mitochondria and/or abnormally 
functioning mitochondria [1 ]. Clinically such disorders should be considered 
in all floppy infants and in those babies with perinatal problems like failure 
to thrive, seizures and cardiomyopathy [2]. The most important symptoms 
in older infants and adults are muscle weakness and exercise intolerance [2]. 
The biochemical approach for diagnostics of mitochondrial myopathies, 
as applied in our department, consists of a metabolic screening in body fluids 
(lactate, amino acids and organic acids), measurement of mitochondrial 
substrate oxidation rates and ATP plus PCr (phosphocreatine) production 
rates by muscle preparations. In this way a defect in the mitochondrial energy 
metabolism can be established [2]. A more exact localization of a defect is 
based on enzymatic procedures [e.g. 3], including measurement of the 
activity of the pyruvate dehydrogenase complex (PDHc) and of the com-
plexes of the respiratory chain. 
Applying the afore mentioned diagnostic approach regularly patients 
have been detected with a defect in the mitochondrial energy production in 
whom no specific enzyme defect could be established in the PDHc or in the 
respiratory chain. 
Clinical symptoms like fatigue, exercise intolerance and muscle weak-
ness with lactic acidosis and/or an increased lactate/pyruvate ratio, found 
in most patients suffering from a mitochondrial myopathy, can theoretically 
be caused by a Mi-CK deficiency. Therefore the diagnostic program was 
extended by measurement of the Mi-CK activity as a possible cause of the 
disturbance in the energy generation. Here the results of these investigations 
are presented. 
Materials and methods 
Substrate oxidation rates, ATP plus PCr production rates, PDHc activity, 
single enzyme activities of the respiratory chain and Mi-CK activity were 
measured in skeletal muscle samples (m. quadriceps) of 15 patients (11 
males/4 females;age range: 1 month - 35 years) who were biopsied after 
informed consent. 
In all patients a muscle biopsy was performed because of the suspicion, 
based on clinical examination and laboratory investigations, that they 
suffered from a mitochondrial myopathy. 
The oxidation rates of the various radiolabelled substrates and production 
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rates of ATP plus PCr were measured in supernatants of fresh musde 
homogenates as described previously [3,4]. Cytochrome с oxidase (COX) and 
dtrate synthase (CS) activities were determined according to Cooperstein 
and Lazarow [5] and Srere [6], respectively. NADH:02 oxidoreductase, 
NADHrQ, oxidoreductase and succinatexytochrome с oxidoreductase ac­
tivities were measured according to Fischer et al. [3]. In the NADH:02 
oxidoreductase assay Mg2* was not added because omission results in higher 
activities in most supernatants. 
Measurement of total PDHc activity in muscle homogenate was per­
formed as described earlier [7]. Mitochondrial and total creatine kinase 
activity was determined according to Smeitink et al. [8]. Protein was deter­
mined by the method of Lowry et al. [9]. 
Results 
Most important dinical data and the highest measured blood ladate concen­
trations are summarized in Table 1. 
All patients investigated showed a disturbance in the mitochondrial 
energy generation. The [l-14C]pyruvate oxidation rate in the presence of 
malate ranged in our patients from 0.27-2.7 nmol. (h. mU CS)"1 (control range: 
3.6 - 7.5; n= 14) (Table 2). The ATP and PCr production rates with pyruvate 
plus malate as substrates ranged from 0-30 nmol.(h. mU CS)"1 (control range: 
42 - 81; n= 16) (Table 2). Four patients exhibited a decreased pyruvate 
oxidation rate caused by a defidency in one of the complexes of the respira­
tory chain (Table 3; page 128). Patients 1, 3 and 4 showed a deficiency of 
complex I, measured as NADHiQj oxidoreductase, being 24,22 and 25 mU/ 
U CS, respectively (control range: 53 - 220; n=l 1). Patient 2 exhibited mainly 
a complex IV defidency, COX activity being 81 mU/U CS (control range: 300 
- 2770; n=ll) (Table 3; page 128), but also the other parts of the respiratory 
chain were reduced. The NADH:02 oxidoreductase activity, reflecting the 
overall capadty of the respiratory chain, was diminished in all 4 patients. In 
the other 11 patients no spedfic defed could be established. 
Measurement of the adivity of Mi-CK expressed on basis of protein, 
dtrate synthase and cytochrome с oxidase, the latter being mitochondrial 
reference enzymes, revealed no dearly decreased activity in 12 patients with 
a decreased pyruvate oxidation rate, although the values in patient 5,6,12 
and 14 were only borderline normal (Table 4; page 129). In 2 of the 4 patients 
with an established deficiency in the respiratory chain the spedfic activity of 
Mi-CK was enhanced (patients 2 and 3, Table 4). Mi-CK expressed per unit 
total CK adivity was markedly high in the two latter patients. 
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Table 1. Some clinical data and highest measured blood lactate concentration (mmol/l) of the imestigated 
patients. 
patient 
muscle weakness 
hypotonia 
exercise intolerance 
motor retardation 
failure to thrive 
mental retardation 
convulsions 
ophthalmoplegia 
cardiomyopathy 
lactate 
1 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
-
3.1 
2 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
-
3.2 
3 
. 
-
+ 
± 
-
-
-
-
-
4 
_ 
-
-
-
-
+ 
+ 
-
-
1.7 4.7 
5 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
3.4 
6 
+ 
+ 
-
+ 
-
+ 
+ 
+ 
-
nm 
7 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
-
8 
+ 
-
+ 
+ 
+ 
+ 
-
-
-
5.0 5.0 
9 
. 
+ 
-
+ 
-
-
-
-
-
1.4 
10 
. 
-
-
-
+ 
• 
-
-
-
4.4 
Π 
_ 
-
-
+ 
+ 
+ 
+ 
-
-
7.1 
12 
+ 
+ 
-
+ 
-
+ 
-
-
+ 
4.8 
13 
+ 
+ 
+ 
-
+ 
• 
-
+ 
-
1.9 
14 
+ 
+ 
-
+ 
-
+ 
-
-
-
3.0 
15 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
-
3.8 
+ = present; ± = mild; - = absent; nm = not measured 
Table 2. Oxidation rates and production rates of ATP plus PCr by intact skeletal muscle mitochondria, 
measured in 600 g supernatant. 
patient [1-14C] pyruvate + malate oxidation* ATP+PCr production from pyruvate+malate* 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Controls 
mean 
SD 
range 
1.59 
0.27 
0.82 
1.61 
1.52 
2.67 
2.65 
2.50 
1.87 
1.62 
1.60 
2.27 
0.75 
1.17 
1.56 
η = 14 
5.52 
0.99 
3.6-7.5 
14.2 
0.97 
6.2 
14.3 
17.1 
11.2 
26.2 
24.0 
12.6 
n.d. 
21.6 
29.7 
11.2 
12.5 
20.1 
n=16 
63.9 
10.1 
42.1 - 81.2 
»Values are expressed in: nmol. (h. mU CS)"1; n.d. = not detectable 
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Table 3. Enzyme activities of skeletal muscle supernatant or homogenate (PDHc) 
patient NADH:02 NADttQ, Succinate: Cytochrome с Citrate PDHc 
oxidoreductase oxidoreductase cytochrome с oxidase Synthase 
oxidoreductase 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Controls 
mean 
SD 
range 
76 
12 
42 
98 
278 
347 
303 
412 
503 
248 
394 
341 
run 
ran 
204 
n = 9 
470 
140 
280-620 
24 
22 
22 
25 
127 
193 
131 
184 
205 
85 
124 
144 
207 
46 
154 
n = ll 
140 
45 
53 - 220 
175 
79 
433 
431 
444 
400 
344 
488 
385 
383 
275 
707 
253 
218 
322 
η = 35 
450 
150 
180-800 
2189 
81 
2143 
1096 
3628 
1911 
1688 
1581 
2385 
1353 
1196 
2390 
2839 
1500 
996 
n = ll 
1490 
680 
300 - 2770 
146 
203 
293 
166 
63 
45 
32 
43 
39 
34 
51 
41 
87 
28 
67 
η = 32 
91 
32 
48-162 
nm 
nm 
nm 
59 
34 
53 
88 
nm 
108 
73 
32 
59 
72 
65 
51 
n = 25 
81 
24 
34-122 
Values are expressed in mU (U CS)"1, except for citrate synthase which is given in mU (mg protein)"1 
nm = not measured 
Discussion 
Mi-CK, located at the outer surface of the inner mitochondrial membrane as 
well as free in the innermembrane space, phosphorylates creatine by 
dephosphorylation of ATP, thereby producing PCr plus ADP [10,11,12]. 
Recently a quantitative method for the measurement of Mi-CK activity in 
small amounts of human skeletal muscle has been reported [8]. This assay has 
now been added to the conventional diagnostic program of patients 
suspected to suffer from a disturbance in the mitochondrial energy genera­
tion because the latter could also be caused by a Mi-CK deficiency. 
A reduced activity of Mi-CK probably leads to a diminished PCr 
concentration and to an elevated intramitochondrial ATP/ ADP ratio which 
in turn inactivates PDHc mediated by a phosphorylation of the El subunit. 
Furthermore, in the presence of a physiological, intact coupling state of 
the oxidative phosphorylation, an ADP lack causes inhibition of the electron 
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Tab le 4. Mitochondrial creatine kinase activities 
patient Mi-CK (mU/mg protein) Mi-CK (U/U COX) Mi-CK(U/UCS) Mi-CK(mU/UCK) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Controls 
mean 
SD 
range 
292 
857 
1341 
302 
189 
101 
139 
173 
378 
138 
184 
102 
366 
95 
150 
η = 19 
240 
88 
131-490 
1.32 
34 
3.26 
??9 
1.07 
0.89 
2.24 
1.93 
2.22 
1.39 
1.56 
1.04 
2.83 
0.95 
2.72 
η = 19 
1.66 
0.36 
1.09-2.35 
1.65 
2.53 
5.55 
2.63 
1.29 
1.17 
1.39 
7 7? 
3.97 
1.89 
1.62 
1.23 
4.42 
1.39 
1.76 
η = 19 
2.70 
0.80 
1.36-4.10 
12.1 
53.3 
50.4 
12.4 
9.4 
3.9 
6.8 
7.0 
6.8 
8.4 
9.7 
6.0 
17.0 
5.2 
6.3 
η = 19 
8.6 
1.5 
6.2 -12.4 
flow through the respiratory chain. The resulting increase of the NADH/ 
NAD+ ratio also produces a feedback inhibition of the PDHc, leading to 
accumulation of pyruvate and lactate. As a result of the increased 
intramitochondrial NADH/NAD+ ratio the cytosolic NADH/NAD+ ratio is 
shifted likewise through the action of the malate-aspartate shuttle. 
The main clinical symptoms of patients with a Mi-CK deficiency are 
probably identical to those which has been observed in patients with 
mitochondrial myopathies, e.g. fatiguability, exercise intolerance and mus­
cle weakness. 
In all investigated patients a disordered pyruvate oxidation rate and 
ATP plus PCr production rate was found pointing to a defect in energy 
generation. Besides, most of them showed lactic acidemia and/or clinical 
symptoms as observed in patients with mitochondrial myopathies. In four of 
them the localization of the enzyme deficiency in the respiratory chain was 
known. The eleven patients with an unexplained decrease in activity of the 
oxidative phosphorylation showed a normal Mi-CK activity. Surprisingly, 
two of the four patients with a localized defect showed a clearly increased 
activity of Mi-CK. The contribution of Mi-CK to total CK activity was 
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enhanced in these patients, too (Table 4; page 129). Such a phenomenon has 
been found earlier for other mitochondrial enzymes, like dtrate synthase in 
complex I or complex IV deficiencies [e.g. 13,14]. This enhancement may be 
caused by a mechanism to compensate for a diminished ATP production by 
the mitochondria. 
From these results it can be concluded that Mi-CK deficiency is not 
frequently the primary defect in patients with a disturbance in the 
mitochondrial energy production but more patients should be investigated 
to allow a definite conclusion in this respect. 
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Summary 
Mitochondrial crystals containing mitochondrial creatine kinase (Mi-CK) 
protein were described recently. From in vitro studies it has been suggested 
that alterations in creatine concentration are connected to the occurrence of 
these crystals. 
In the present study, free, phosphorylated and total creatine concen-
trations as well as Mi-CK activity were determined in muscle samples of six 
patients with chronic progressive external ophthalmoplegia (CPEO). Two of 
them showed Mi-CK containing mitochondrial crystals. 
The activity of Mi-CK was found to be dearly enhanced in those muscle 
samples in which mitochondrial crystals were present. 
No relationship was found between the concentration of total, free or 
phosphorylated creatine and the occurrence of mitochondrial crystals. An up 
to now unknown mechanism seems to cause the formation of Mi-CK contai-
ning crystals in human muscle mitochondria. 
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Introduction 
Mitochondrial disorders can be defined as diseases characterized by struc-
turally or numerically abnormal mitochondria and/or dysfunctioning 
mitochondria. These disorders are clinically heterogeneous in severity and 
organ involvement, ranging from distinct myopathic syndromes to complex 
multisystem disorders. 
Chronic progressive external ophthalmoplegia (CPEO), in which a 
slowly progressive paresis of the muscles that rotate the eyes in the orbit and 
elevate the eyelids is the predominant sign, is an appropiate example of the 
clinical heterogeneity observed in mitochondrial disorders [1]. For instance 
neurological, cardiac and renal impairment can occur in this syndrome [1]. 
Morphological and biochemical studies in CPEO have been performed 
mostly on skeletal muscle mainly based on practical considerations. How-
ever, similar changes as can be found in skeletal muscle have occasionally 
been observed in other tissues [2]. 
A structural skeletal muscle alteration in CPEO, also occurring in other 
mitochondrial disorders, is the occurrence of so-called "ragged red" fibres 
with increased succinate dehydrogenase activity. These fibres possess 
irregularly shaped peripheral aggregates of mitochondria [1]. Electron 
microscopy of these fibres reveals that the numerically increased mito-
chondria are often markedly enlarged and possess aberrant configurations of 
cristae. The mitochondrial matrix sometimes contains electrondense in-
clusions or shows vacuolization. The occurrence of highly ordered inclusions 
in the intermembrane space is probably the most striking structural abnor-
mality in patients with mitochondrial disorders and is regularly observed. 
These inclusions are real crystals, composed of protein material [3,4]. 
By now little is known about the underlying mechanism of mito-
chondrial crystal formation in human mitochondrial myopathies. In particu-
lar, the question whether the appearance of the mitochondrial crystals is 
causative to or a consequence of the disease cannot be answered yet. Recently 
it was observed that intramitochondrial crystals arise, looking similar as 
those in human mitochondrial myopathies, in rats fed with the creatine 
analogue and competitor ß-guanidinopropionic add (ß-GPA) as well as in 
creatine depleted cultured adult rat cardiomyocytes [5,6]. These crystals 
contained mitochondrial creatine kinase (Mi-CK) [6]. 
In this study we investigated the possible relation between the creatine 
content and mitochondrial crystal formation as was shown in cultured adult 
rat cardiomyocytes [6]. Furthermore, we studied whether in patients with 
such crystals, Mi-CK activity was altered compared with those patients in 
which no Mi-CK containing crystals were present. 
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Materials and methods 
Subjects 
From six patients (two females; four males) fulfilling the clinical criteria of 
CPEO [1] a muscle biopsy (m. quadriceps) was obtained, after informed 
consent, for diagnostic purposes: light and electron microscopic investiga­
tions and biochemical studies were also performed. 
The ages at which the biopsy was undertaken in patients 1 to 6 (Table 1) 
were, respectively: 25,15,8,29,20 and 27 yr. 
Patients 1,2,3 and 6 showed besides an ophthalmoplegia also exercise 
intolerance. Patient 1 furthermore showed some pigmentary degeneration of 
the retina and sensoneural hearing loss. The knee jerk and Achilles jerk in 
patient 3 were absent. Patient 6 also presented muscle weakness of the 
proximal shoulder and pelvis. Patien ts 4 and 5 only showed ophthalmoplegia. 
Microscopic studies 
The muscle specimens were submitted for conventional histology, enzyme 
histochemistry and electron microscopy. 
Immuno-electron microscopic studies 
For immuno-electron microscopy the specimens were fixed in 0.1 M phos­
phate-buffered 2% paraformaldehyde/0.1% glutaraldehyde solution (pH 
7.3; 40C) for 1 h and after brief immersion periods in 50% and 70% ethanol, 
subsequently transferred via a mixture of LR Whi te (London Resin Company 
Ltd, Basingstoke, Hampshire, U.K.) - 70% ethanol to pure LR White as the 
embedding medium. Polymerization occurred at 50° С for 24-48 h. 
Thin LR White sections on copper grids were blocked for 30 min in 1% 
BSA in 0.1 M phosphate buffer (pH 7.3) and after three rinses with the same 
buffer incubated with the polyclonal rabbit anti-chicken Mi-CK antibody 
(dilution 1:200). After thorough rinsing the sections were incubated for 30 
min with Protein A -10 nm gold complex (Janssens Pharmaceutica, Beerse, 
Belgium). Thereafter the sections were rinsed three times in the above buffer, 
followed by three rinses in distilled water and air dried. Further treatment 
was as for conventional electron microscopy. 
Biochemical investigations 
Biochemical studies of muscle samples were performed as described by 
Fischer et al. [7]. The muscle specimen was cooled in ice-cold 10% SETH-
medium [7] and transported directly to the laboratory. A 10% (w/v) 
homogenate was prepared in SETH-medium. For determination of free and 
phosphorylated creatine concentrations in skeletal muscle a 300 μΐ portion of 
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Table 1. Concentration of free and phosphorylated creatine, specific activity of Mi-CK and 
Mi-CK expressed per milliunit citrate synthase in muscle of six patients with chronic 
progressive external ophthalmoplegia. 
Patient 
1 
2 
3 
4 
5 
6 
Controls 
mean 
SD 
range 
Free Cr 
(nmol/g ww) 
13.1 
12.0 
23.3 
13.8 
18.0 
0.5 
n=16 
14.9 
3.4 
9.2-21.2 
PCr 
(μιηοΐ/g ww) 
6.2 
8.8 
3.7 
7.0 
7.2 
13.4 
n=16 
8.5 
2.6 
2.3 -13.1 
Mi-CK 
(mU/mg prot.) 
680 
539 
285 
267 
177 
246 
n=19 
240 
88 
131-490 
Mi-CK 
(mU/mU CS) 
5.0 
5.1 
3.0 
3.1 
2.8 
5.1 
n=19 
2.7 
0.8 
1.4-4.1 
Crystals were present in muscle mitochondria of patients 1 and 2. 
ww = wet weight; prot. = protein; CS = citrate synthase 
the total homogenate was denaturated by 3 M HC104 and the supernatant 
neutralized with 1 M KHC03. The assay was performed essentially as 
described in Bergmeyer using pyruvate kinase and hexokinase-mediated 
NAD(P)H coupled reactions [8]. 
Reference values were determined from muscle samples of patients 
suspect to suffer from a mitochondrial disorder in whom, however, despite 
thorough biochemical and microscopic examinations no abnormalities were 
found. 
Protein was determined by the method of Lowry et al. [9]. Mitochondrial 
creatine kinase activity in muscle was determined according to Smeitink et 
al. [10]. 
Results 
Light microscopic studies revealed normal data except for the existence of 
ragged red fibres in two muscle samples (patients 1 and 3). In some fibres of 
patient 2 the sarcolemmal activity was accentuated but no real ragged red 
fibres were seen. Histochemistry of cytochrome с oxidase was performed in 
patients 1 and 2 (normal results) and patient 6, the latter showing many 
cytochrome с oxidase negative fibres. 
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Electron microscopy of a muscle sample of patient 3 showed, especially in the 
ragged red fibres, giant mitochondria, up to 5 mm, with abberant configura­
tions of the cristae (tubular or angular appearance). Mitochondrial crystals 
(type I) were regularly observed by electron microscopy in patient 1. In 
patient 2 initial stages of crystal formation (type I) were frequently observed. 
In both muscle samples the crystals could be heavily labelled with the anti-
Mi-CK antibody. Figures 1A and В show the mitochondrial crystals and 
immunolabelling of the crystals with Mi-CK antibodies of patient 1 and the 
initial stages of crystal formation and immunolabelling as observed in patient 
2, respectively. 
Biochemical studies, i.e. measurement of the oxidation rates of pyruvate 
and malate, and the adenosine triphosphate plus phosphocreatine produc­
tion by intact mitochondria, revealed normal activities of the mitochondrial 
energy metabolism in all six investigated patients. 
Table 1 (page 137) summarizes the concentrations of free (non-phospho-
rylated) and phosphorylated creatine, the activity of Mi-CK is expressed per 
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Fig. 1. (A)Biopsyofm.quadricepsofpatient 1.Mitochondrialtypelcrystalspredominantly 
present in the outer mitochondrial compartment show distinct immunogold 
labelling with Mi-CK antibodies. Magnification; 64 OOOx. 
(B) Biopsy of m. quadriceps of patient 2. Subsarcolemmal accumulation of 
mitochondria showing irregularly arrangement of cristae. Immunogold particles 
can be seen to be present above dilated intracristal compartment with moderate 
electron density. Arrowhead indicating initial stages of crystal formation. 
Magnification: 44 OOOx. 
milligram protein as well as expressed per milliunit of citrate synthase. 
The free creatine content was lowered only in patient 6. Phosphorylated 
creatine was normal in all subjects. The specific activity of Mi-CK as well as 
the activity of Mi-CK expressed per milliunit of citrate synthase, a 
mitochondrial reference enzyme, was enhanced in patients 1 and 2. Patient 
6 also showed an enhancement of the latter ratio but this was due to a low 
normal specific activity of citrate synthase (48; control range: 48-162 mU/mg 
protein)^ 
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Discussion 
Gori et al. [5] described the occurrence of abnormal mitochondria in type 1 
(slow twitch) skeletal muscles of rats after feeding them the creatine analogue 
and competitor ß-guanidinopropionic acid (ß-GPA), a drug known to cause 
total creatine depletion (free Cr + PCr) in muscle tissue. The compound 
inhibits creatine entry into muscle cells from blood plasma [11-13]. These 
abnormal mitochondria often contain, according to the authors, crystal-like 
inclusions which are very similar to those induced by ischemia or poisons and 
to those often observed in patients with a mitochondrial myopathy. They 
proposed that a decrease in the ATP buffering capacity, caused by a PCr 
depletion, could play a role in the pathogenesis of human myopathies. 
Eppenberger-Eberhardt et al. [6] observed that crystal-like mitochon-
drial inclusions were also formed in adult rat cardiomyocytes, when they 
were cultured in a creatine free medium or in a medium which contained 
ß-GPA. Immunolabelling of the crystal-like inclusions with antibodies 
against Mi-CK revealed a strong specific decoration of these mitochondrial 
inclusions [6]. The latter authors speculated that "accumulation of Mi-CK at 
the mitochondrial inclusions could be a compensatory phenomenon to a 
metabolic stress situation of the cultivated cardiomyocytes caused by low 
intracellular total creatine levels". 
Abnormal mitochondria and the occurrence of intramitochondrial crys-
tals are also found in human myopathies [4]. There are two distinct types of 
crystals, which can be distinguished by shape, size, pattern, unit-cell dimen-
sion, specific localization in the intermembrane space and their occurrence in 
different muscle fibre types. So-called type I crystals are usually present in 
the intracristal space, between two folds of the inner mitochondrial mem-
brane, whereas type II crystals are preferentially localized in the 
intermembrane space between outer and inner mitochondrial membrane [4]. 
Recently it has been shown by immunohistochemical studies, using rabbit 
anti-chicken Mi-CK antibodies, that both types of crystals in the mito-
chondria of human myopathic muscle consist mainly of Mi-CK [14,15]. The 
type Π crystals were always more heavily labelled than the type I crystals. 
Image processing of the type Π crystals revealed arrays of regularly ordered 
square-shaped particles with dimensions of 10 χ 10 nm and with a central 
cavity. Thus, the building blocks of the crystals appeared to be very reminis­
cent of isolated Mi-CK octamers [16]. From these observations it was sug­
gested that the mitochondrial inclusions seen under pathological conditions 
consist mainly of Mi-CK octamers [15]. 
On the analogy of the hypothesis for cultured adult cardiomyocytes [6] 
the question arose as to whether a disturbance in creatine metabolism could 
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account for the formation of mitochondrial crystals containing Mi-CK. In our 
patients no relationship was found between either the free, phosphorylated 
or total creatine concentrations of the investigated muscle samples and the 
presence of mitochondrial crystals. Due to in vitro hydrolysis the in situ 
phosphorylated creatine concentration may be underestimated. Comparing 
the total creatine concentration in patients 1 and 2 with that in patients 3,4 and 
5 indicated that crystal formation is not related to total creatine concentration 
because the total creatine concentration is normal in both groups of patients. 
Whether hydrolysis has caused the lowered phosphorylated creatine concen-
tration in patient 3 is not clear. The ATP concentration in this sample was quite 
normal. In patient 6 which showed, for unknown reasons, a clearly dimi-
nished free creatine content in the muscle, no crystals were found despite 
thorough electron microscopic study. So, there is no indication that a low free 
creatine concentration induces Mi-CK containing crystals. 
In two CPEO patients mitochondrial crystals (type I), showing distinct 
labelling with Mi-CK antibodies, were present. Our study shows that, at least 
in patients with CPEO, the free, phosphorylated and total muscle creatine 
concentrations likely do not cause crystal formation. Apparently, the condi-
tions resulting in the formation of Mi-CK containing crystals are different 
from those reported by Eppenberger-Eberhardt et al. [6] who performed their 
experimental work on adult rat cardiomyocytes in vitro. No data are available 
about the occurrence of mitochondrial crystals in the human heart muscle. 
In both patients the specific activities of Mi-CK as well as Mi-CK activities 
expressed per milliunit citrate synthase were dearly enhanced. This high 
activity of Mi-CK in both patients with electron microscopically observed 
Mi-CK labelled crystals is remarkable. Although the number of patients is 
low one can hypothesize about this phenomenon. It may reflect the presence 
of more than the normal number of Mi-CK molecules located at the outer 
surface of the mitochondrial irmermembrane or free in the intermembrane 
space, but can also be a consequence of solubilization of the crystals during 
the homogenization procedure and/ or the subsequent re-activation of the 
Mi-CK protein. 
In conclusion no relationship was found between human skeletal muscle 
creatine content and mitochondrial crystallization in CPEO patients. Mi-CK 
activity was dearly enhanced in those CPEO pa tients who were found to have 
mitochondrial crystals containing Mi-CK. Further studies are necessary to 
eluddate the nature and the mechanism of formation of these crystals. 
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Mitochondrial creatine kinase and mitochondrial myopathies 
In this thesis clinical, biochemical and morphological aspects of mitochon-
drial creatine kinase (Mi-CK) are described. Thus far this enzyme has hardly 
been studied in relation to human pathology and has not been investigated 
in relation to mitochondrial myopathies. 
The study was initiated as a consequence of the observation that, in a 
substantial number of patients with a mitochondrial myopathy, no specific 
enzyme deficiency could be detected despite an observed disturbance in the 
pyruvate oxidation rate. Since a deficiency of Mi-CK might also be respon-
sible for a disturbance in the pyruvate oxidation rate, a method to determine 
Mi-CK activity in human skeletal muscle samples was developed 
(chapter 3). So far, in 80 muscle samples, sent for diagnostic purposes, Mi-CK 
activity has been estimated and has been found normal. Twenty-nine of these 
muscle samples showed decreased substrate oxidation rates e causa ignota. 
Among the remaining specimens were localized enzyme defects of the 
respiratory chain as well as specimens with normal oxidation rates. To allow 
for a definite conclusion as to the occurrence of Mi-CK deficiencies in patients 
with a mitochondrial myopathy, a much larger number of Mi-CK activity 
determinations is required. 
For patients and their relatives a correct diagnosis of the biochemical 
defect responsible for the patient's complaints is important for genetic 
counselling and a therapeutic approach. Moreover, the clinical and bioche-
mical features of patients with a Mi-CK deficiency can extend our knowledge 
about the putative role of Mi-CK in cellular metabolism. 
An interesting feature of Mi-CK is that its activity in skeletal muscle of 
preterm born infants increases during pregnancy (chapter 4). The physio-
logical basis for this increase, which is also observed in animals, is not dear 
at present and needs further study. Regulation by hormones, as suggested for 
ubiquitous Mi-CK mRNA in rat uterus and placenta [1], can serve as a 
possible explanation of the observed developmental increase of Mi-CK in 
skeletal muscle. 
Another important result of the study of Mi-CK in relation to 
mitochondrial myopathies is the observation that crystals, observed in 
mitochondria in skeletal muscle fibers of some patients suffering from 
chronic progressive external ophthalmoplegia or from other mitochondrial 
encephalomyopathies, are highly enriched in Mi-CK [2,3; chapter 6]. At 
present the mechanism of this crystal formation is not clear. In cultured adult 
rat cardiomyocytes a relationship between creatine concentration and the 
occurrence of such crystals was observed [4]. Such a relationship could not 
be confirmed in the investigated patients with chronic progressive external 
ophthalmoplegia. 
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Disturbed pyruvate and malate oxidation rates e causa ignota: 
recommendations for further investigation 
An important step in the diagnostic procedure for the detection of a 
mitochondrial myopathy is the morphological and biochemical investigation 
of a muscle biopsy. Before a muscle biopsy is taken, patients have to meet 
certain clinical criteria. Furthermore, analysis of body fluids, whether after 
a provocative test or not, must be indicative of a disturbance in the pyruvate 
oxidation. Despite such precautions, the cause of an in vitro observed 
disturbed pyruvate oxidation rate remains unknown in a substantial part of 
the investigated muscle samples of carefully selected patients. Probably the 
diagnostic program is still incomplete. Enzymes like Mi-CK, the adenine 
nucleotide translocator and the FQF,-ATPase are not generally included in the 
diagnostic program. Moreover, deficiencies of co-factors involved in energy 
generation as well as transport disturbances across the mitochondrial inner-
membrane could account for the disturbed oxidation rates. Also, the search 
for factors with a secondary influence on the in situ oxidation of pyruvate and 
malate like: (i) the various causes of ischemia and anoxia, (ii) malnutrition, 
(iii) defects at the level of hormones and neurotransmitters, (iv) viral and 
bacterial infections, (v) poisoning by exogenous components and (vi) extra-
mitochondrial or extracellular inborn or acquired errors of metabolism has 
to be performed [5]. Determination of Mi-CK activity in a muscle sample of 
patients with an unexplained lactic acidosis is urged. 
Molecular biology of mitochondrial creatine kinase 
Separate nuclear genes encode two closely related, tissue-specific isoenzymes 
of Mi-CK [6; chap ter 2]. The method described in chapter 3 measures the total 
Mi-CK activity in skeletal muscle. The two Mi-CK isoenzymes (ubiquitous 
and sarcomeric) can be differentiated by using specific antibodies. However, 
thus far no such antibodies are available. A possibility to differentiate 
between ubiquitous and sarcomeric Mi-CK is the use of specific cDNA or 
genomic probes which recently became available [6]. With the use of a human 
ubiquitous Mi-CK cDNA probe the DNA of nine patients with a pyruvate 
oxidation rate e causa ignota was examined using the restriction fragment 
length polymorphism technique. No major rearrangements within the ubi-
quitous Mi-CK gene were observed using Southern blot analysis in these 
patients. Studies with a sarcomeric human Mi-CK cDNA probe are in 
progress. 
A reduced Mi-CK activity has very recently been found in patients with 
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cardiomyopathy [7]. Up till now no structural rearrangements in the ubiqui-
tous Mi-CK gene were detected by us in six patients with a dilated cardio-
myopathy, three patients with a hypertrophic obstructive cardiomyopathy, 
four patients with a hypertrophic non-obstructive cardiomyopathy and two 
patients with a syndrome consisting of hyper-trophic cardiomyopathy, lactic 
acidosis, mitochondrial myopathy and congenital cataract (No. 21235 in the 
McKusick register, 1983; [8,9]). This study will be extended using a sarco-
meric human Mi-CK cDNA probe. 
A recently developed genetic method i.e. gene targeting by homolo-
gous recombination in embryonic stem cells enables study of the conse-
quences of Mi-CK deficiency in an animal model. Such studies are in progress 
now (K. Steeghs, personal communication). Extrapolation of the results 
obtained by such experiments could be of great importance to the under-
standing of Mi-CK deficiencies and related human pathology. 
Mi-CK and pathology 
A review of the literature concerning Mi-CK and pathology is included in 
chapter 2. The existence of Mi-CK was already reported in 1964. The possible 
involvement of the enzyme with respect to human pathology has hardly been 
investigated. Based on the existence of separate Mi-CK genes, two possible 
clinical presentations of Mi-CK deficiency may be anticipated. Disturbances 
in the sarcomeric gene will mainly involve heart and/or skeletal muscle, 
whereas disturbances in the ubiquitous Mi-CK gene consequently will lead 
to a multisystem disorder. However, if a disturbance occurs at the mito-
chondrial membrane level or during protein assemblage, only a single tissue 
or organ may be affected. 
Up till now reduced Mi-CK activities in man are only found in cardio-
myopathic patients. Further investigation into the involvement of a reduced 
Mi-CK activity in mitochondrial myopathies and other, up to now unex-
plained, pathological conditions in man is necessary. 
Most probably the enzyme is also present in other, as yet unexamined 
human cells or tissues like the retina as found in chicken [10]. A complete 
study of the tissue distribution of Mi-CK in man certainly will be helpful with 
respect to the understanding of physiological and patho-physiological 
processes. 
In condusion, the work described in this thesis clarifies some aspects of 
Mi-CK in relation to mitochondrial myopathies and hopefully gives a push 
for further investigation of this enzyme and its putative role in human 
pathology. 
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Summary 
Mitochondrial creatine kinase (Mi-CK; EC 2.7.3.2) plays an important role in 
the processing of high energy phosphates generated by the mitochondrial 
oxidative phosphorylation. The enzyme is localized at the outer surface of the 
inner mitochondrial membrane. Highest enzymatic activities of Mi-CK are 
present in organs with high and fluctuating energy demands like skeletal 
muscle, heart and brain. 
A deficiency of this enzyme can have important consequences as to the 
function of cellular metabolism. 
Up till now data on investigations of Mi-CK in man are rather limited. 
Investigations of Mi-CK in man are of importance to extend our knowledge 
about normal cellular processes as well as for the understanding of patho-
logical processes concerning energy metabolism. For example, investigation 
of Mi-CK in patients with mitochondrial myopathies can possibly contribute 
to the elucidation of a decreased mitochondrial pyruvate oxidation rate e 
causa ignota. A deficiency of Mi-CK may induce a dysfunctioning of the 
respiratory chain and thus a reduced pyruvate oxidation rate occurs. 
In the present study we investigated the activity of Mi-CK in normal and 
diseased human skeletal muscle. 
In chapter 1 a short introduction to the topic and the subsequent chapters is 
given. 
In a subs tantial part of patients, suspected to suffer from a mitochondrial 
myopathy, detailed biochemical examination of skeletal muscle specimen 
shows a decreased pyruvate oxidation rate. Such a decrease may be caused 
by a deficiency of one of the enzymes or enzyme complexes of the pyruvate 
dehydrogenase complex, the dtric acid cycle or the respiratory chain. 
However, in approximately 30% of the patients with a decreased pyruvate 
oxidation rate this decrement can not be explained by a deficiency of one or 
more enzymes of the mitochondrial energy-generating system. This observa-
tion makes it necessary to extend the diagnostic program. A deficiency of 
Mi-CK could account for such a disturbance in the pyruvate oxidation. 
The aim of this study was to develop a method to determine Mi-CK 
activity in human skeletal muscle, to investigate the developmental aspects 
of the enzyme and to study Mi-CK with respect to mitochondrial myopathies. 
Chapter 2 comprises the state of the art of Mi-CK. The aim of this chapter is 
to give a comprehensive overview on what is known about biochemical, 
physiological and pathological aspects of Mi-CK. 
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In chapter 3 a method is described for the measurement of Mi-CK activity in 
human skeletal muscle. The method is based on the removal and specific 
inhibition of interfering CK isoenzymes. Reference values for Mi-CK activity 
are included in this chapter. 
Chapter 4 contains the results of the study concerning the maturation of 
mitochondrial and other isoenzymes of CK in skeletal muscles of preterm 
born infants. This study was performed because earlier observations have 
shown an age-related development of various other enzymes involved in 
mitochondrial energy metabolism. As some of the patients with mito-
chondrial myopathies already show symptoms immediately after birth, 
knowledge about the existence of an age-dependency is necessary for correct 
interpretation of biochemical investigations in skeletal muscles of this age 
group. Evidence has been obtained for a prenatal increase in total CK and 
Mi-CK activity. 
The results of the measurements of Mi-CK activities in patients with un-
known and known causes of defects of the pyruvate oxidation are given in 
chapter 5. Normal results were obtained with regard to the Mi-CK activity in 
the patients investigated so far with an unexplained disturbance of the 
pyruvate oxidation rate. 
In patients with a localized defect in the pyruvate oxidation pathway, 
more specifically patients with an isolated enzyme defect of the respiratory 
chain, no combination of a defect co-existing with Mi-CK was noticed. 
In chapter 6 the results are presented of the study of mitochondrially 
localized crystals in patients with a chronic progressive external 
ophthalmoplegia. In this study we investigated the possible relationship 
between creatine content, Mi-CK activity and the presence of mitochondrial 
crystals. Recently it was shown that these crystals contain Mi-CK protein. 
Furthermore, it was shown that in these cases the Mi-CK activity was 
enhanced. No relationship was observed between the occurrence of such 
crystals and the creatine content of the skeletal muscle. This in contrast to 
animal and cell culture studies. 
Finally, in chapter 7, considerations about the work performed in this thesis 
and recommendations for future investigation are given. In the twenty-nine 
investigated patients with a decreased substrate oxidation rate no Mi-CK 
deficiency was found. Molecular biological investigations concerning Mi-CK 
are in progress. Both, molecular biological and enzymological investigations 
of Mi-CK will extend our insight in the Mi-CK functioning in normal and 
pathological conditions. 
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Samenvatting 
Mitochondriaal creatine kinase (Mi-CK; EC 2.7.3.2) speelt een belangrijke rol 
bij deverwerkingvan het door demitochondriale oxydatievephosphorylering 
gevormde ATP. Het enzym bevindt zich aan de buitenzijde van de mito-
chondriale binnenmembraan. De hoogste Mi-CK activiteit is aanwezig in 
organen met hoge en fluctuerende energie-behoeften zoals skeletspier, hart 
en hersenen. 
Een deficiëntie van het Mi-CK kan belangrijke gevolgen hebben voor het 
functioneren van het celmetabolisme. 
Tot nu toe is er bij de mens nauwelijks onderzoek verricht naar Mi-CK. 
Onderzoek naar de diverse aspecten van dit enzym is echter van belang voor 
het vergroten van onze kennis omtrent het normale verloop van cellulaire 
processen en de consequenties van stoornissen hierin. Resultaten van 
onderzoek betreffende Mi-CK zouden een verklaring kunnen geven voor de 
bij patiënten met een mitochondriale myopathie veelvuldig gevonden, 
onverklaarde, verlaagde mitochondriale pyruvaat oxydatiesnelheid. Een 
deficiëntie van het Mi-CK kan namelijk het functioneren van de 
ademhalingsketen nadelig beïnvloeden waardoor een dergelijke verlaagde 
pyruvaat oxydatiesnelheid ontstaat. 
In dit onderzoek bes tudeerden wij de activiteit van Mi-CK in normale en 
pathologische humane skeletspier. 
In hoofdstuk 1 worden de achtergronden van het onderwerp en het doel van 
de studie weergegeven. 
Een belangrijk aantal van de onderzochte patiënten van wie wordt aan-
genomen dat ze een mitochondriale myopathie hebben, laat bij biochemisch 
onderzoek van de skeletspier in vitro een verlaagde pyruvaat oxydatiesnel-
heid zien. Een dergelijke verlaging doe t een deficiëntie vermoeden in één van 
de enzymen of enzymcomplexen van het pyruvaat dehydrogenase complex, 
de citroenzuurcyclus of de ademhalingsketen. Bij ongeveer 30% van de 
patiënten met een verlaagde pyruvaat oxydatiesnelheid is deze afwijking 
echter niet te verklaren op basis van een defect in een of meer enzymen van 
het mitochondriale energie-producerende systeem. Deze bevinding maakt 
het noodzakelijk het diagnostische pakket uit te breiden. Op theoretische 
gronden kan een Mi-CK deficiëntie een verlaging in de oxydatiesnelheid van 
substraten tot gevolg hebben. 
Het doel van dit onderzoek is het ontwikkelen van een methode voor de 
bepaling van de activiteit van het Mi-CK in de humane skeletspier, studie 
verrichten naar de rijping van dit enzym en het bepalen van de Mi-CK 
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activiteit bij patiënten van wie aangenomen wordt dat ze een mitochondriale 
myopathie hebben. 
Hoofdstuk 2 geeft een overzicht van de huidige kennis over met name de 
biochemische, fysiologische en pathologische aspecten van Mi-CK. 
In hoofdstuk 3 wordt de door ons ontwikkelde methode voor het bepalen 
van de activiteit van Mi-CK in humaan spierweefsel beschreven. De methode 
is gebaseerd op verwijdering en specifieke remming van de storende CK 
isoenzymen. Referentiewaarden worden gegeven. 
Hoofdstuk 4 geeft de resultaten weer van het onderzoek naar de rijping van 
Mi-CK en de andere CK isoenzymen in de skeletspier van prematuur 
geborenen. Deze studie werd verricht naar aanleiding van een eerdere 
observatie waaruit bleek dat enkele daartoe onderzochte enzymen, betrokken 
bij het mitochondriale energie-metabolisme, een aan leeftijd gerelateerde 
ontwikkeling doormaakten. Kennis over de ontwikkeling van deze enzymen 
is in de diagnostiek van patiënten met een mitochondriale aandoening van 
belang, omdat bij patiënten met dergelijke ziekten de symptomen zich al 
direct post partum kunnen manifesteren. Zowel de totale CK activiteit als de 
Mi-CK activiteit nemen toe met de duur van de zwangerschap. 
Hoofdstuk 5 geeft de resultaten weer van de bepaling van de Mi-CK activiteit 
in patiënten met een te lage pyruvaat oxydatiesnelheid, veroorzaakt door een 
onbekend of een bekend defect in het energie-metabolisme. In de tot nu toe 
onderzochte patiënten met een onverklaarde verlaging in de substraat 
oxydatiesnelheid werd een normale activiteit geconstateerd voor Mi-CK. Er 
werd geen combinatie gevonden van een gelocaliseerd defect in de ademha-
lingsketen met een deficiëntie van de Mi-CK activiteit. 
In hoofdstuk 6 worden de resultaten gepresenteerd van onderzoek dat 
verricht werd bij patiënten met een chronische progressieve externe 
Ophthalmoplegie. Bij deze patiënten werd gezocht naar een relatie tussen de 
Mi-CK activiteit, de creatine concentratie van de skeletspier en het al dan niet 
aanwezig zijn van mitochondriaal gelocaliseerde kristallen. 
Onlangs werd aangetoond dat dergelijke kristallen Mi-CK bevatten. Wij 
toonden aan dat de Mi-CK activiteit verhoogd was in de skeletspier van deze 
patiënten zonder dat er sprake was van een gestoorde substraat oxydatie. Er 
werd geen relatie gevonden tussen de aanwezigheid van dergelijke kristallen 
en de creatine concentratie van de skeletspier. Dit laatste in tegenstelling tot 
bevindingen bij dier en celkweek studies. 
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In hoofdstuk 7 wordt een beschouwing gegeven over de uitgevoerde studie 
en worden aanbevelingen gedaan voor verder onderzoek. Bij deonderzochte 
patiënten met een verlaagde pyruvaat oxydatiesnelheid is tot nu toe geen 
deficiëntie van het Mi-CK gevonden. Er is een start gemaakt met moleculair 
biologisch onderzoek van Mi-CK. Zowel moleculair biologisch als enzymo-
logisch onderzoek van Mi-CK zal onze kennis over het functioneren van dit 
enzym onder normale en pathologische condities doen toenemen. 
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ik vanaf nu wat meer tijd voor jullie kan reserveren. 
Willemien, zonder jou had ik dit nooit volbracht. Ik wist mij steeds van jouw 
steun verzekerd. Je hebt me steeds de vrijheid gelaten die nodig was voor het 
schrijven en je voelde perfect aan wanneer het tijd werd om een pauze in te 
lassen. Keer op keer heb je geluisterd naar de inhoudelijke en politieke zaken 
rondom dit onderzoek. Dit alles is vast niet altijd eenvoudig geweest. Het is 
duidelijk dat je een grote invloed hebt gehad op de totstandkoming van dit 
proefschrift. 
Mark, over een aantal jaren zal ik je uitleggen waarom mama in jouw 
eerste levensmaanden zoveel meer aandacht aan je heeft gegeven dan ik. We 
halen dit zeker in. 
Rest mij nog waardering uit te spreken voor het enthousiasme, de belang-
stelling en de hulp van diegenen die ik vergeten ben met name te noemen. 
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Curriculum Vitae 
De auteur van dit proefschrift werd geboren te Arnhem op 21 juni 1956. Vanaf 
1973 volgde hij de opleiding tot klinisch chemisch analist aan de school voor 
laboratorium personeel te Eindhoven, waar hij in 1976 het diploma HBO-A 
klinische chemie behaalde. Na het vervullen van zijn militaire dienstplicht 
begon hij in 1978 zijn studie in de Geneeskunde aan de Katholieke Universiteit 
te Nijmegen. In 1983 slaagde hij voor zijn doctoraal examen, in mei 1985 werd 
het artsexamen met succes afgelegd. Van augustus 1985 tot augustus 1986 
was hij werkzaam als agnio op de Afdeling Kindergeneeskunde van het St. 
Radboudziekenhuis te Nijmegen, waar hij vanaf augustus 1986 tot april 1991 
in opleiding was tot kinderarts (Opleider: Prof. Dr. G.B.A. Stoelinga). Op 1 
mei 1991 werd hij als kinderarts ingeschreven in het specialisten-register. 
Van januari 1988 tot augustus 1991 was hij voorzitter van de Junior 
Afdeling van de Nederlandse Vereniging voor Kindergeneeskunde. Uit 
hoofde van deze functie was hij van januari 1988 tot november 1990 lid van 
het Bestuur, het Concilium Paediatricum en de Plenaire Visitatie Commissie 
van de Nederlandse Vereniging voor Kindergeneeskunde. 
Vanaf april 1991 tot heden is hij verbonden aan de klinische afdeling 
metabole ziekten (Hoofd: Prof. Dr. B.T. Poll-The) van het Wilhelmina 
Kinderziekenhuis te Utrecht. 
De auteur is gehuwd met Willemien E.M. Berkers en samen hebben zij 
een fantastische zoon. Mark. 
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Dit proefschrift werd vormgegeven met behulp van Aldus PageMaker 4.0, 
CorelDRAW2.0 en Microsoft Windows 3.1. Deze programmatuur draaide op 
een personal computer met een 80486 microprocessor. Het document werd 
geprint op een Postscript laserprinter en cameraready aan de drukker 
afgeleverd. Deze heeft een verkleiningsfactor van 80% toegepast. 
De gebruikte lettertypen zijn Palatino, Palatino Bold en Palatino Italie. 
Voor de standaard tekst werd een 12 punts letter, voor tabellen een 10 punts 
letter en voor koppen een 18 of 14 punts letter gebruikt. De interlinie bedroeg 
135% van de puntgrootfë. 
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Stellingen 
Behorend bij het proefschrift 
MITOCHONDRIAL CREATINE KINASE 
some clinical, biochemical and morphological aspects 
Nijmegen, 6 oktober 1992 
Jan A.M. Smeitink 
I 
Bij de interpretatie van de resultaten van onderzoek naar de activiteit van het 
mitochondriaal creatine kinase in de humane skeletspier dient rekening gehouden te 
worden met de leef tijdsafhankelijkeheid van de activiteit van dit enzym. 
Dit proefschrift. 
II 
De aanwezigheid van intramitochondriaal gelocaliseerde kristallen in de Ьхяпапе 
skeletspier bij patiënten met een chronische progressieve externe Ophthalmoplegie lijkt 
niet gerelateerd te zijn aan de creatine concentratie van de skeletspier. 
Dit proefschrift. 
III 
Omdat mitochondriaal creatine kinase gecodeerd wordt door twee verschillende genen 
zal een deficiëntie van dit enzym tot een wisselende klinische expressie aanleiding 
geven. 
Dit proefschrift. 
IV 
Bij een patiënt met spierklachten in combinatie met een sterk verhoogd plasma CK dient 
voor er invasieve diagnostiek plaatsvindt de schildklierfunctie onderzocht te worden. 
Soomers, persoonlijke mededeling. 
V 
Me tabool onderzoek gericht op stoornissen in de mitochondriale ß-oxidatie van vetzuren 
bij kinderen die onverwacht overlijden is een diagnostische uitdaging met vele valkuilen. 
Duran et al. Pediatrics (1986) 78:1052-1057. 
VI 
Een stoornis in de assemblage van peroxisomen, leidend tot het Zellweger syndroom, 
kan meer oorzaken hebben. 
Shimozawa et al. Science (1992) 255:1132-1134. 
Gärtner et al. Nature genetics (1992) 1:16-23. 
VII 
De vorming van peptide-bindingen bij de eiwitsynthese wordt met grote 
waarschijnlijkheid gekatalyseerd door RNA-moleculen in het ribosoom. 
Nolier et al. Science (1992) 256:1416-1419. 
VIH 
De door velen gehanteerde ondergrens vannormoglycaemie dient naar boven bijgesteld 
te worden. 
IX 
Specifiek laboratorium onderzoek ten behoeve van de diagnostiek van erfelijke 
stofwisselingsziekten dient een artikel 18 voorziening te worden. 
X 
Zowel tijdens als na behandeling met ifosfamide dient men bedacht te zijn op het 
ontstaan van een glomerulo-tubulaire stoornis. 
Smeitink et al. Eur. J. Pediatr. (1988) 148:164-166. 
XI 
De recentelijke waarneming van een nieuw syndroom bestaande uit hydrops f oetalis op 
basis van congenitale anemie met afwezige duimen, neu tropenie en immuundef iciëntie 
bevestigt het concept van een ontogenetisch veld dat zowel de radiale straal als het 
hematopoëtisch en immunologisch systeem omvat. 
Semmekrot et al. Am. J. Med. Gen. (1992) 42:736-740. 
XII 
De kwaliteit van de kindergeneeskundige zorg dient onafhankelijk te zijn van de 
assertiviteit van de ouders. 
XIII 
De voorgeschreven afstand van 7 cm tussen de spijlen van een kinderbed is, zeker voor 
zuigelingen, te groot. 
XIV 
Milieubelangen zijn niet altijd tegenstrijdig aan economische belangen getuige de snel 
groeiende markt voor milieu-adviesbureau's. 
XV 
De wens om zelf te bouwen is voor velen een ideaal. Als het ideaal verwezenlijkt kan 
worden ontbreekt het velen de moed om durf te tonen in de vormgeving van dit ideaal. 
XVI 
De door de resultaten van aerodynamisch onderzoek gewijzigde vormgeving van 
moderne automobielen heeft het adequaat anticiperen in het verkeer een stuk moeilijker 
gemaakt. 
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